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Abstract 
Follicular lymphoma (FL) is an incurable human B-cell neoplasm that follows a 
chronic relapsing course requiring multiple treatment episodes and culminating in 
therapy resistance and/or large-cell transformation. The disease is notable for its 
clinical variability but the biological basis for this variability is poorly understood. In 
addition to intrinsic genetic and epigenetic alterations that drive tumour growth, an 
intricate cross-talk between malignant B cells and the immune microenvironment 
have been shown to play a significant role in the pathogenesis of FL. This thesis tests 
the hypothesis that some of the heterogeneity of FL might result from chronic 
infection with cytomegalovirus (CMV). The latter affects ~50% of the adult 
population and has been linked to premature immune senescence and expedited age-
related alterations in the T cell repertoire. I reasoned that CMV infection might have 
two distinct effects in FL: (1) by accelerating immune senescence, it might increase 
the risk of treated-related infection; and (2) by altering the lymphoma 
microenvironment, it might modulate the effect of chemo-immunotherapy.  
To address these questions, I was able to access stored PMBCs, serum and tissue 
samples from patients of known CMV serostatus who were recruited into the 
PACIFICO trial. The trial compared two different chemo-immunotherapy regimens in 
older patients with FL and recruited 360 patients between 2009 and 2015. My 
experimental approach was to compare CMV-positive and CMV-negative patients for 
blood lymphocyte subsets by flow cytometry (Chapter 3), serum cytokines by 
Luminex profiling (Chapter 4), accessory cells in the lymphoma microenvironment by 
immunofluorescence of biopsy material (Chapter 5), and treatment effectiveness and 
toxicity using follow-up information obtained as part of the trial (Chapter 6). Chapters 
3 and 4 employed a cohort of 42 cases (21 of which were CMV- positive) that were 
carefully selected to be well balanced in other respects. Chapter 5 employed a similar 
cohort of 42 cases (20 of which were CMV- positive) including 6 that were also in the 
cohort used for Chapter 4 (it was not possible to use exactly the same cases for 
Chapters 3, 4 and 5 owing to the limited availability of biopsy material). Chapter 6 
related CMV serostatus to clinical outcome in the two cohorts employed for Chapters 
3,4 and 5, and also in a third cohort consisting of all 269 patients of known CMV 
serostatus who were recruited into PACIFICO (109 of which were CMV- positive). 
Finally, Chapter 7 examined the relationship between CMV-dependent biological 
variables and treatment efficacy with the aim of shedding light on the mechanisms 
through which CMV might modulate therapy response in FL. 
Flow cytometric analysis of PBMCs revealed significant accumulation of end-stage 
differentiated (TEMRA) T cell subtypes including pE2-CD4 (P=0.046), E-CD4 
(P=0.029), EM3-CD4 (P=0.018), E-CD8 (P=0.033) and EM3-CD8 (P=0.005) 
phenotypes as well as increased NKT cells (P=0.031) in CMV-positive patients. 
Luminex data showed significantly reduced levels of multiple serum cytokines 
including IL-9 (P=0.006), IL-17A (P=0.020), FGF-basic (P=0.028), MIP-1α 
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(P=0.039), MIP-1β (P=0.029), IL-6 (P=0.029) and IL-8 (P=0.037) in the CMV-
positive group. Taken together, these findings support the hypotheses that CMV 
infection in FL is associated with accelerated immune senescence with the 
accumulation of exhausted T cells and reduced cytokine production. 
Immunofluorescence staining of biopsy material revealed that the CMV-positive 
group expressed significantly higher levels of CD21 (expressed by follicular dendritic 
cells; P=0.043) and tended to express higher levels of FOXP3 (expressed by Tregs; 
P= 0.069) and PD-1 (expressed by exhausted T cells; P=0.097).  
Analysis of therapy response in the two cohorts used for lymphocyte/cytokine 
profiling and tissue staining showed an overall trend for higher complete remission 
(CR) rates in the CMV-positive groups with a significant difference observed in the 
first cohort after 4 cycles of therapy (P=0.020). This finding could not be confirmed 
in the overall trial cohort. However, the CMV-positive group in this cohort contained 
more patients with adverse prognostic features, potentially biasing it towards inferior 
therapy response. Interestingly, a significant association was observed between the 
achievement of CR and the number of circulating E-CD4+ T cells but not serum 
cytokine levels or the tissue accessory cells expressing CD21, FOXP3 or PD-1. 
Analysis of toxicity data by CMV status showed a significant association between 
CMV positivity and heterologous infection of any grade. This association was 
observed in the overall trial cohort (P<0.001) as well as in the cohort used for tissue 
staining (P=0.017).  
Taken together, my findings support the hypothesis underlying this thesis, namely that 
the biology of FL is influenced by chronic CMV infection. Specifically, CMV-
positive patients with FL undergo accelerated immune senescence and experience 
more infections following rituximab-containing chemo-immunotherapy. CMV-
positive patients may also achieve better responses, possibly due to the higher 
numbers of cells expressing Fcγ receptors required for antibody-dependent cell-
mediated cytotoxicity (ADCC).  
Based on my findings, a case could be argued for the routine application of CMV 
screening in FL prior to treatment with chemo-immunotherapy with the 
implementation of enhanced infection surveillance in CMV-positive patients. If 
properly harnessed, these understandings can ultimately improve on the therapeutic 
strategies in FL management toward a combinatorial approach for direct cytotoxic 
and indirect immunomodulatory perspectives. 
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Chapter 1 : General Introduction 
1.1 Introduction  
This section offers an overview of the thesis with a particular emphasis on the main 
components of the study. In this chapter, a detailed review of related literature of key 
areas linked to this study is presented. Such areas include follicular lymphoma (FL) 
and cytomegalovirus (CMV) infection, amongst other pertinent subthemes, with a 
direct relation to the rationale, goals and objectives of the study.  Furthermore, this 
section offers a concise description of the depth and scope of study in addition to the 
research content and niche. 
1.2 Follicular Lymphoma   
Follicular lymphoma (FL) is part of a group of cancers called Non-Hodgkin 
lymphomas  (NHL) which are a highly prevalent group of haematological cancers 
(Song et al., 2013). It is comprised of some closely linked lymphoid proliferative 
disorders emanating from the lymphoid tissues at various phases of differentiation; 
comprising of heterogeneously diverse immunophenotypic, morphologic, clinical and 
genetic properties (Gibson et al., 2013, Morton et al., 2008, Song et al., 2013). NHL is 
characterised by malignant transformation of the lymphoid cells, either mature or 
precursor cells, and it is one of the leading causes of cancer death (Morton et al., 
2008, Nagai et al., 2008). World Health Organization (WHO) has categorised NHL 
into two main groups, based on cells of origin,: those of B-cell origin and those of T-
cell/natural killer (NK)–cell origin (Norris and Stone, 2008).  According to the 15th   
Cochrane Haematological malignancies biannual report, about 85 percent to 90 
percent of NHL cases emanate from B-cells, such as, mantle cell lymphoma, FL,  
Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); while the T-cell 
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involved diseases include  anaplastic large cell lymphoma and precursor T-
lymphoblastic  (Rancea et al., 2013). Although the aetiology of NHL is not clear, a 
growing body of evidence has listed certain viral and bacterial infections such as 
Epstein-Barr (EB), altered immune function and a considerable number of immune-
related gene polymorphisms and alterations as predisposing risk factors (Charbonneau 
et al., 2012, Gibson et al., 2013).  
The second most prevalent NHL is FL, after Diffuse large B-cell lymphoma (DLBCL 
or DLBL) (Taskinen et al., 2007). Literature confirmed the clinical progression of FL 
as being highly indolent but characterised by incredibly diverse clinical outcomes 
(Kiaii et al., 2013). Despite the fact that FL is incurable, it can be managed with about 
11.1 years being the average documented median survival (Staudt, 2007). 
Interestingly, many FL patients live for decades after the initial diagnosis without 
treatment; but in contrast, a proportion develops rapid disease progression with a short 
survival rate (Kiaii et al., 2013). Additionally, it has been estimated that more than 30 
percent of patients suffering from follicular lymphoma undergo histologic 
transformation to DLBCL and elucidating the cause of the heterogeneity in FL would 
better inform the clinical management and treatment approaches thus improving the 
outlook for FL patients.   
1.2.1 The pathology of FL  
From a morphological understanding, FL is described as the proliferation of 
malignant germinal centre B cells (GCBs) that are intermixed with non-malignant 
cells. The common non-malignant cells in the GC include the follicular dendritic cells 
(FDCs), T cells, and macrophages as well as centroblasts and centrocytes that 
represent the predominant cell types of the germinal centre reaction (Campo et al., 
2011). The traditional grading method for FL utilises the relative proportion of 
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centrocytes to centroblasts, as its limits. Thus grade 1 FL has minimal centroblast 
numbers of 0–5 per high-power field while grade 3B FL is comprised of thick sheets 
of these cells (Kridel et al., 2012). However, the FL grading does not offer precise 
prognostic implications of disease as seen in several other malignancies. There is no 
satisfactory consensuson the characteristics of grade 3B FL, considering its similarity 
to de novo DLBCL and to some extent, the expression  of different molecular features 
compared to grades 1–3A FL.  There is also the case that, Grade 3B FL is frequently 
negative for t(14; 18) while inconsistently expressing CD10 (Salaverria and Siebert, 
2011). The characteristic follicular growth pattern of FL can be revealed by staining 
for FDC markers, for instance, CD21 or CD23 (Kridel et al., 2012). Moreover, the 
disease’s molecular hallmark is in the overexpression of anti-apoptotic BCL2. (Kridel 
et al., 2012) due to the translocation of t(14; 18) (q32; q21) identified by fluorescence 
in situ hybridization (FISH) in 85 percentage of all patients. This translocation, 
therefore, is not critical or adequate for diagnosis, since it is missing in 15 percent of 
FLs and also present in approximately 20 to 30 percent of GCB-type DLBCLs  
(Salaverria and Siebert, 2011, Weiss et al., 1987). 
1.2.2 Cell of Origin of FL  
The perceptions that the neoplastic cells are arranged in follicles, display germinal 
centre surface markers, for instance CD10 and BCL6, and have a characteristic gene 
expression profile of centroblasts or centroblasts (Alizadeh et al., 2000) provide that 
FL B-cells are capable of attaining a differentiation phase indicative of GCB cells 
(Küppers, 2005). The initial oncogenic cascade’s hit resulting in FL is commonly 
associated with the t(14; 18), founded on the consistency of the genetic irregularity as 
well as its intended mode of action (Kridel et al., 2012). The occurrence of 
translocation takes place subsequent to a double-strand break within the 
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Immunoglobulin heavy (IGH) locus on chromosome 14 associated with faulty 
recombination-activating gene (RAG) -mediated VDJ recombination and a break at 
the BCL2 locus on chromosome 18 perceived to be connected to an intrinsic frailty at 
CpG sites (Tsai et al., 2008, Tsujimoto et al., 1985). The VDJ recombination takes 
place at an initial B cell growing phase in the bone marrow, and as a primary genetic 
hit, the t(14; 18) is equally likely to happen in the bone marrow but does not hinder 
additional differentiation. Colonization of secondary lymphoid tissue is undertaken by 
the naïve B cells expressing the t(14;18) upon exiting bone marrow, hence 
undertaking the germinal centre reaction although they hold survival benefit because 
of their BCL2 constitutive expression, which is typically not in the germinal centre 
(Roulland et al., 2011). BCL2 is equally capable of rescuing these cells from 
apoptosis because of weak BCR affinity (Roulland et al., 2011). Nevertheless, the 
appearance of a structurally and probably functionally conserved BCR appears critical 
as, regardless of the progressive somatic hypermutation, a discerning selection against 
adverse transformations in BCR is apparent (Bahler and Levy, 1992, Zuckerman et 
al., 2010). BCR signalling may be additionally activated by the interface of 
mannosylated immunoglobulin variable regions with lectins present on non-neoplastic 
immune cells’ surface (Coelho et al., 2010). The primary FL progenitors subsequently 
attain secondary genetic modifications under the impact of activation-induced 
cytidine deaminase (AID ), the value of which has been demonstrated in a mouse 
model whereby genetic deletion of AID prevented BCL6-driven germinal centre–
derived lymphomas (Pasqualucci et al., 2008).  
The present hypothesis that identifies naïve t(14;18)-positive peripheral B cells as 
likely tumour-triggering cells for  FL pathogenesis is questioned by the findings that 
such cells have also been reported in the blood of 50 to 70 percent of healthy people 
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who are not prone to acquiring FL (Dölken et al., 1996, Limpens et al., 1995, Schüler 
et al., 2009). The prevalence of FL plus the occurrence of t(14;18)-positive cells in 
healthy people rises with age (Schüler et al., 2009). Literature confirms that some of 
these cells are not naïve B cells, but rather germinal centre-experienced IgD+CD27+ 
(or IgM+CD27+) memory cells (Hirt et al., 2007, Roulland et al., 2006). Identical to 
true FL tumour cells, these alleged FL-like cells in healthy people demonstrate class-
switch recombination of the translocated IGH allele, while the functional allele 
encodes a surface IgD (or IgM) (Kridel et al., 2012). The contribution of these FL-like 
cells to the pathogenesis of FL remains obscure. Nevertheless, originating lymphoma-
initiating cells ought to exist, as depicted by two FL reports on allogeneic 
hematopoietic stem cell transplantation (Carlotti et al., 2009, Weigert et al., 2012). In 
a retrospective study, the t(14;18) was detected from the donor lymphocyte infusion 
as well as a small number of mutated alleles that correspond to 14 of the 15 gene 
mutations common between the recipient’s and donor’s tumours (Weigert et al., 
2012). This study report suggests proof that the necessary lymphoma progenitor holds 
more intricate genetic variations than initially thought. The understanding of the 
origin of FL is additionally made complicated by the identification  of a loosely 
defined component described as FL in situ, which has been suggested as a valid 
precursor cell on the grounds of relatively rare progression to overt FL (Cong et al., 
2002, Jegalian et al., 2011).  
1.2.3 Genetic Landscape of FL 
The understanding that BCL2 has anti-proliferative activities on top of its anti-
apoptotic characteristics  (Zinkel et al., 2006) and that the t(14;18)  is also present in 
healthy people (Dölken et al., 1996, Limpens et al., 1995, Schüler et al., 2009), 
suggests that BCL2 over-expression alone is not enough to activate 
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lymphomagenesis. Furthermore, over-expression of BCL2 in transgenic mouse 
models does not recapitulate FL pathogenesis.  In the inventive Eμ-BCL2 
reproduction, mice established follicular hyperplasia and, upon prolonged latencies, 
elevated-grade lymphomas that were evidently not indicative of FL (McDonnell and 
Korsmeyer, 1991). Egle et al. established a VavP-BCL2 mouse model whereby BCL2 
was overexpressed and controlled by pan-haematopoietic VavP promoter (Egle et al., 
2004). The mice developed lymphomas that had common morphological 
characteristics with FL, however, the high BCL2 transgene expression present in the T 
cell region illustrated a condition absent in FL (Egle et al., 2004). The consideration 
that clonal cytogenetic eccentricities, copy number variations, as well as uniparental 
disomy, are identified in FL and offers extra support to the idea that further genetic 
alterations add to FL pathogenesis (Kridel et al., 2012).  
In addition to the t(14;18) translocation, other chromosomal abnormalities comprise 
of non-random  1p36 and 6q losses in addition to 7, 18, and X  gains (Cheung et al., 
2009, Horsman et al., 2001, Johnson et al., 2008, Schwaenen et al., 2009). Of late, 
there has been a positive outcome of insight regarding dominant players after a 
thorough assessment of candidate genes within such areas. For instance, considering 
the 1p36 region that is highly targeted by copy-neutral loss of heterozygosity as well 
as heterozygous deletions, the TNFRSF14 gene was found being repeatedly mutated 
(Cheung et al., 2010, Launay et al., 2012). Two studies found that mutations in the 
TNFRSF14 gene (Cheung et al., 2010, Launay et al., 2012) lead to a truncated protein 
in 57% of TNFRSF14 mutations regardless of its transmembrane domain, causing a 
reduction in surface expression. TNFRSF14 mutations offered the initial evidence of 
the connection between FL genetics and the associated microenvironment. Although a 
collection of ligands bind TNFRSF14, the receptor can carry both stimulatory and 
7 
 
inhibitory signals to T cells irrespective of ligand, which warrants further 
investigation to illuminate the functions of these mutations in FL pathogenesis.  
Frequently deleted regions on the long arm of chromosome 6 (6q) (Oricchio et al., 
2011), are increased in FL which is associated with the poor prognosis (Cheung et al., 
2009). It was evident that a negative NF-κB signalling regulator identified as 
TNFAIP3/A20, and a receptor tyrosine kinase EPHA7, were potential tumour 
suppressors in FL (Oricchio et al., 2011). Additionally, the studies illustrated that 
silencing EPHA7 resulted in an increase in lymphomagenesis in VavP-BCL2 
transgenic mice while restoring its suppressor function of the tumour via exogenous 
EPHA7 administration hindered the formation of tumour in xenograft models. A 
model whereby EPHA2 is bound by EPHA7 on the cell surface of lymphoma is 
proposed by these authors, hence avoiding any signalling activation via extracellular 
signal-regulated kinases (ERK) in addition to other proto-oncogene tyrosine-protein 
(SRC) kinases. Furthermore, the researchers revealed that expression of EPHA7 was 
lacking by immunohistochemistry in 72% of FL cases for a tissue microarray and 
hypothesised that any lack of protein expression transpired via genomic deletions plus 
promoter methylation, harmonising with earlier results from Dawson et al. (Dawson 
et al., 2007).  
High-throughput sequencing approaches have elevated the rapidity of cancer research 
to an exceptional level. The mutational landscape of FL has been recently revealed 
using whole-genome or whole-exome sequencing, in a combination of targeted deep 
sequencing (Okosun et al., 2014).  Recurrent mutations in genes involving in linker 
histone, JAK-STAT signalling, NF-κB signalling and B cell developmental, are 
unequivocal evidence for a reservoir ancestral population, enriched in early mutations 
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in driver genes, including CREBBP, EZH2 and KMT2D (MLL2).  Other mutations, 
such as EBF1, MYD88 and TNFAIP3, are acquired subsequently and propagate 
successive disease events. Although no single compelling genetic event has been 
identified to be responsible for FL transformation, the acquisition of distinct genetic 
alterations in ancestral common progenitor clone may prompt the onset of aggressive 
disease and resistance to therapies.  
The mutational environment among nodal lymphomas has hitherto been precisely 
stipulated and described in DLBCL and, to a minor level, in FL (Lohr et al., 2012, 
Morin et al., 2011, Pasqualucci et al., 2011a, Pasqualucci et al., 2011b). 
Unpredictably, it was revealed that germinal centre–derived lymphomas are defined 
by recurrent alterations of histone-modifying genes. Specifically, in FL repeated 
mutations have been revealed in EZH2 (7.2%), histone methyltransferases MLL2 
(89%) , EP300 (8.7%), the histone acetylases CREBBP (32.6%)  and MEF2B (15.3%) 
(Morin et al., 2010, Morin et al., 2011, Pasqualucci et al., 2011a). The increased 
repetitive occurrence of such mutations demonstrates how FL is possibly epigenomic 
in addition to the genomic disorder (Baylin and Jones, 2011). Arguably, the best-
characterised lymphoma histone-modifying gene, EZH2, is the catalytic component of 
the polycomb suppressive complex 2. Tyr641 mutations within EZH2 SET domain 
have been found in 22 percent of GCB-like DLBCLs and 7 percent of FLs, resulting 
to enhanced histone H3 Lys27 trimethylation (H3K27me3) (Morin et al., 2011, 
Sneeringer et al., 2010, Yap et al., 2011). The result regarding the upregulation of 
EZH2 in B cells within germinal centre reaction (van Galen et al., 2004) provides that 
any activation in EZH2 mutations results in a transcriptional outcome supporting 
proliferation. Anti-proliferative genes, EZH2-mediated silencing, was consequently 
highlighted in typical centroblasts (Velichutina et al., 2010), offering additional back 
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up to the concept that FL can subvert the GCB cells’ normal functional gene 
expression program. Regardless of our increased comprehension of genetic 
aberrations in FL within the last few years, there is an urgent need for future studies to 
facilitate a wide mutational database of all genetic variations resulting in 
tumourigenesis. 
1.3 The tumour microenvironment 
The tumour microenvironment (TME) undoubtedly acts as a survival factor, with a 
close and steady relationship between the tumour and its immediate surroundings 
usually infiltrated by inflammatory cells (Balkwill and Mantovani, 2001, Mihm Jr et 
al., 1996, Whiteside and Parmiani, 1994). Paradoxically, tumours can affect the 
microenvironment through the release of extracellular signals that promote tumour 
angiogenesis that compels peripheral immune tolerance; while conversely, the 
accessory immune cells are capable of impacting the development and exacerbation 
of cancer cells. Regardless of the condition, such inflammatory cell infiltrates are 
capable of varying in amount as well as composition from one tumour to another. 
Hitherto, the existence of cellular infiltrates in the cancer environment is indicative of 
endeavours to interfere with the progression of the tumour in a process identified as 
immune surveillance (Zitvogel et al., 2006). Tumour inflammatory infiltrates are 
deemed as the host’s effort to identify the growing tumour cells, attack and remove 
them (Zitvogel et al., 2006). Several reports have associated the existence of 
inflammatory infiltrates in human tumours to enhanced prognosis or improved patient 
survival (Baxevanis et al., 1994, Whiteside, 2007). Multiple analyses of immune 
markers, inclusive of microarrays and heat maps; provide that type, location and 
density of tumour’s immune cells can confer prognostic assessment (Galon et al., 
2006, Galon et al., 2007, Pagès et al., 2005). In contrast, several reports have justified 
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the absence of considerable connections between the intensity of lymphocytic 
infiltrates and enhanced prognosis or associated immune cell infiltrates to an inferior 
prognosis (Nakano et al., 2001, Sheu et al., 1999, Stewart and Tsai, 1993). These 
contradictory reports remained unexplained for years until recently it became possible 
to explore functional properties of tumour-infiltrating lymphocytes (TIL), which often 
represents the major component of immune infiltrates in tumours (Mihm Jr et al., 
1996). In general, TIL in humans demonstrate reduced proliferation following 
antigens or mitogens stimulation, diminished signalling via T cell receptor and 
declined capacity to arbitrate cytotoxicity of tumour targets or to generate Th1-type 
cytokines after tumour antigens simulation (Kiessling et al., 1996, Reichert et al., 
2002, Uzzo et al., 1999), as illustrated in Figure 3-11. TIL’s functional impairments 
occur more frequently in patients that have chronic cancer than in early disease,  
while they seem to differ in the frequency as well as magnitude, depending on the 
kind of tumour or its originating tissue. The functional status of TIL has been argued 
to be an independent and significant correlate of good prognosis and long-term 
survival among cancer patients (Reichert et al., 1998). With the rapid improvements 
in the techniques of studying functions and characteristics of tissue infiltrating 
immune cells, plus the understanding of their local interactions with other cells, the 
part played by the microenvironment in health and disease is better understood. A 
thorough multivariate examination of cellular interrelations in the tumour 
microenvironment founded on the function, nature, location, and density of the 
immune cells present in human colorectal cancers revealed how clinical outcome can 
be affected by immune responses within the tumour (Galon et al., 2006, Galon et al., 
2007, Pagès et al., 2005). From the present understanding, tumour microenvironment 
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is perceived in a manner that it exerts an effecton tumour development and growth 
and that adjusting this attribute could likely present exceptional therapeutic gains. 
1.3.1 Cellular components of the tumour microenvironment 
For a growing tumour, the microenvironment is composed largely of the tumour 
stroma, proliferating tumour cells, infiltrating inflammatory cells, blood vessels and a 
number of related tissue cells (Whiteside, 2008). It is a distinctive environment that 
develops during tumour growth resulting from its relations with the host (Whiteside, 
2008). It is generated by and constantly shaped and overlooked by the tumour, which 
coordinates cellular and molecular events transpiring within the nearby tissues 
(Whiteside, 2008). A range of effector immune cells from the innate arm of the 
immunity; polymorphonuclear leukocytes and macrophages have been identified in 
the tumour, as well as mediators of the adaptive arm including T lymphocytes and 
dendritic cells (DC) and infrequently B cells, (Whiteside, 2007). Natural killer (NK) 
cells are rarely seen in tumours, acting as a critical first line of defence against a wide 
range of pathogens eliciting innate immune responses (Whiteside et al., 1998, Lanier, 
2003, Wang et al., 2013). Tumour cells downregulate the expression of HLA antigens 
in addition to being enriched in MHC class I chain-related genes (MICB and MICA 
molecules) (Chang et al., 2005) which make them vulnerable to NK cell-mediated 
cytotoxicity (Lee et al., 2004); their scarcity in tumour infiltrates may be an example 
of the circumvention technique to avoid NK-cell attraction to the tumour location. 
Normally, TILs comprise of some CD3+CD4+and CD3+CD8+T cell populations and 
are an essential component of the tumour microenvironment (Whiteside, 2007). 
Several of these T cells are particular for tumour-associated antigens, as evident from 
clonal evaluation (Miescher et al., 1987) as well examination of the CD8+T cells 
tetramer staining isolated from human tumours (Albers et al., 2005). In a few types of 
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tumours, e.g. medullary breast carcinomas, lymph node-like structures are formed by 
the infiltrating lymphocytes, implying that there is an immune response in situ 
(Coronella et al., 2002). Additionally, TILs are the basis for specificity of tumour 
lymphocytes employed in adoptive transfers upon expansion in IL-2-containing 
cultures (Zhou et al., 2004). Clones of TILs with the specific characteristics to a high 
multiplicity of the tumour-associated antigen can be expanded from human tumours, 
affirming that immune reactions are not simply directed at ‘specific’ antigens 
expressed by the tumour, but equally at a variety of representative or tissue-specific 
antigens (Romero et al., 2006). Even though the increase in effector T cells in the 
tumour microenvironment would be seen as an indication of immune surveillance by 
the host, they are mostly futile in controling tumour growth. Of the CD4+T cells in 
the tumour microenvironment, a subpopulation of CD4+CD25high Foxp3+cells is 
increased to about 5–15% of CD3+CD4+T cells of tumour-infiltrating lymphocytes 
compared to the small numbers reported in the circulating peripheral blood of cancer 
patients (Woo et al., 2001). These regulatory T cells (Tregs) can suppress the 
proliferation of other T cells within the microenvironment by contact-dependent 
mechanisms or TGF-β and IL-10 secretion. There are different subtypes of Tregs,  for 
instance, the natural Treg (nTreg) and induced Treg (iTreg), and characterised 
microenvironment in human tumours (Bergmann et al., 2007). Macrophages present 
in tumours are known as tumour associated macrophages (TAMs). They are re-
programmed to inhibit lymphocyte functions through release of inhibitory cytokines 
such as IL-10, prostaglandins or reactive oxygen species (ROS) (Mantovani et al., 
2002, Mosser and Edwards, 2008). The myeloid suppressor cells accumulating in 
human tumours are CD34+CD33+CD13+CD15(-) bone marrow-derived undeveloped 
dendritic cells (Serafini et al., 2006).  Mesenchymal stromal stem cells (MSCs) 
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promote tumour development and restrains functions of immune cells via abundant 
generation of an enzyme arginase 1 involved in L-arginine metabolism. Arginase 1 
synergizes with inducible nitric oxide synthase (iNOS) with the intent of enhancing 
the production of superoxide and NO, thus dampening the lymphocyte responses 
(Ochoa et al., 2007). This mechanism will also enhance the induction of inducible 
oxygen species (iNOS) in neighbouring cells  (Tsai et al., 2007). A study illustrates 
the expansion of CD14+HLA-DR-/low myeloid-generated cells adopting immune 
inhibition via TGF-β secretion within the peripheral circulation of patients undergoing 
treatment for metastatic melanoma using GM-CSF-based vaccines (Filipazzi et al., 
2007). The tumour coordinates MSC's recruitment to the tumour location. Some 
factors produced by tumours, which support MSC accumulation as well as preventing 
DC maturation plus lymphocyte functions include VEGF, IL-10, and GM-CSF 
(Serafini et al., 2006). 
Granulocytes are seldom seen in infiltrates of human tumours, with the exception of 
eosinophils that may exist in association with tumour cells in different squamous cell 
tumour (Loukinova et al., 2000). Evasion of the tumour from the host occurs through 
the capacity of human tumours to destabilise antitumour immunity by down-
regulating or entirely supressing local and systemic innate immunity as well as 
adaptive antitumour immunity via a range of methods (Whiteside, 2008).  
1.3.2 The FL microenvironment  
In most instances, the microenvironment in FL is the lymph node (Yang and Ansell, 
2012b). Structurally, the lymph node is compartmentalised into the outer region (the 
cortex), the paracortex, and the inner region (the medulla). It is within the cortex that 
follicles containing germinal centres (GCs) are found. The various immune accessory 
cells in the FL microenvironment live strategically in the different zones within the 
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compartments (Katakai et al., 2004). For instance, T cells are primarily located in the 
medulla and paracortex compartments whereas B cells occupy the follicles of the 
cortex (Yang and Ansell, 2012b). 
Following antigenic challenge, B and T cells migrate to follicles in lymph nodes and 
the T-cell zone where they interact with antigen presenting cells (APCs) and 
experience clonal expansion (von Andrian and Mempel, 2003). To initiate primary 
immune responses, FDCs present antigen to B cells and are only present in follicles of 
primary and secondary lymph organs (von Andrian and Mempel, 2003). However, 
before antigen encounter, the follicle is comprised mainly of naïve B cells with no GC 
for B cell maturation. Following antigenic stimulation, GCs are developed in the 
follicles and drive the differentiation of B cells into plasma cells that secrete 
immunoglobulins (Calame, 2001). Despite the understanding that most T cells live 
outside of the follicle, the follicular T helper (TFH) cells live in the GCs and arean 
essential subcategory of CD4+ T cells for antigen-dependent activation of B cells. 
In FL, the structure and the cellular content of the follicles are different from the 
normal lymph node as a result of the enlargement of GC caused by the expanding 
quantities of B lymphoma cells (Amé-Thomas et al., 2007). An alteration in the 
cellular distribution can be studied in tissue biopsies from FL lymph nodes and relate 
to those of normal lymph nodes. For instance, an elevated number of Treg cells and 
reduced effector T cells, such as TH17 and TH1 cells characterise follicular content in 
FL. A lot of the effector T cells present in the tumour microenvironment of FL have 
an exhausted phenotype and display reduced functional potential, as well as the 
presence of elevated numbers of naïve immune suppressive macrophages. These 
changes have all been shown to possibly influence antitumoral immunity and support 
lymphoma cell survival and development in FL. Intratumoral T cells in Follicular 
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lymphoma is portrayed by the presence of a high number of T cells, up to half of the 
total number of cell content in the tumour microenvironment. These intratumoral 
lymphocytes substantially affect antitumor resistance and patient outcome (Dave et 
al., 2004). T cells are heterogeneous and impact tumour immunity in both a negative 
and positive manner, which is contingent upon the mix of the different T-cell types 
inside the microenvironment. For the most part, high quantities of intratumoral T cells 
are connected with positive prognosis in patients with FL, (Wahlin et al., 2011). 
1.4 T-lymphocytes    
1.4.1 Major histocompatibility complex (MHC)  
MHC molecules are surface peptide receptors of the immune system that permit T 
lymphocytes to recognise antigens (Kindt et al., 2007, Savill and Fadok, 2000, 
Murphy, 2011). Their crystal structures contain a groove which is occupied by a short 
peptide specific to an antigen that allows for immune recognition (Falk et al., 1991). 
For example, after a macrophage engulfs bacteria, it partially digests it and presents 
peptide particles of the microorganism on its surface, attached to MHC molecules 
(Chaplin, 2010, Abbas et al., 2014). The T lymphocytes recognise the foreign particle 
attached to the MHC molecule and binds to it, activating an immune response 
(Benacerraf, 1978). Within healthy cells, the MHC molecule displays peptides from 
its cell (self-peptides) and the T cells do not usually respond to them (Matzinger, 
1994).  
There are two major categories of MHC molecules: The MHC class I molecules are 
ligands for inhibiting or stimulating natural killer (NK) cell receptors displayed on T 
cells and NK cells (Bauer et al., 1999, Karabekian et al., 2015). They are carried on 
the majority of nucleated cells, including cardiac myocytes and fibroblasts. This class 
I molecule contain a heterodimer of a highly polymorphic α heavy chain, non-
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covalently associated with a conserved light chain called β-2 microglobulin. On the 
other hand, MHC class II molecules are a family of molecules mainly expressed by 
professional APCs, such as dendritic cells (DC), mononuclear phagocytes, some 
endothelial cells, thymic epithelial cells, and B cells and composed of two polypeptide 
chains an α and a β chain of approximately equal length (Matzinger, 1994, Rock et al., 
2016).  
To efficiently attack and eradicate foreign bodies including those contained within or 
on bacteria, viruses, other microorganisms, or cancer cells; T-cells have to recognise 
the antigenic peptides presented on the surface of the cells (Larsson et al., 2001, 
Höftberger et al., 2004). Antigens from endogenously manufactured proteins within 
the cytosol are attached to MHC class I molecules and are identified by CD8 positive 
T-cells, while peptides internalised through the process of endocytosis and produced 
within vesicles are attached to MHC class II molecules and identified by CD4 positive 
T-cells (Larsson et al., 2001).  
1.4.2 Activation of Naïve T cells 
The naïve T cells are programmed to recognise antigens only in the T cell zones of the 
secondary lymphoid tissues, and for this reason, initiation of the immune response 
depends upon transport of antigen to these areas from the site of infection (Cyster, 
2005, von Andrian and Mempel, 2003). Naïve T cells leave the thymus and 
continually migrate between secondary lymphoid organs (spleen, lymph nodes, and 
Peyer’s patches) (Gowans and Knight, 1964, Picker and Butcher, 1992, Butcher and 
Picker, 1996) entering the circulation as resting cells in the G0 stage of the cell cycle 
(Tough and Sprent, 1994). However, naïve T cells can only make contact with antigen 
within the secondary lymphoid organs. After the antigen has been taken up by cells it 
is processed into immunogenic peptides as the cells migrate to the secondary 
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lymphoid tissues.  En route the cells may differentiate into mature dendritic cells 
(DC), and localise in the T cell zones expressing  antigen peptides on the MHC 
molecules (Sprent and Surh, 2002) for the naïve T-cells to recognise. 
The first admission of T cells to the spleen is nonspecific; along the splenic artery. 
The cells (and antigens) travel through the splenic trabeculae artery into the trabeculae 
and empties into the  marginal zone at the margin of the white and red pulp (Steiniger 
et al., 2001). After that, the T (and B) cells move selectively to the white pulp in 
which they accumulate around central arterioles; these regions known as the 
periarteriolar lymphocyte sheaths (PALS) are the key T cell area within the spleen 
(Kraal, 1992, Van Ewijk and Nieuwenhuis, 1985, Gunn et al., 1998a). Even though 
the process through which T cells move into PALS from the marginal zone is not 
indistinct, it is noteworthy that activated T cells without the chemokine receptor 
CCR7, enter the red pulp but are barred from the white pulp (Potsch et al., 1999). 
Therefore, T cell entry into the white pulp might be directed by CCR7 recognition of 
distinct chemokines expressed on stromal cells (Cyster, 2005). After around 12 h, 
immature T cells migrate from the PALS into the red pulp and depart the spleen 
through venous blood (Sprent and Surh, 2002). Quite the opposite to the spleen, 
admission of T cells into Peyer’s patches and lymph nodes is extremely precise and 
happens once cells go into high endothelial venules (HEV) (Miyasaka and Tanaka, 
2004, von Andrian and Mempel, 2003, Sprent and Surh, 2002). With respect to lymph 
nodes, the luminal surface of HEV expresses peripheral node addressin (PNAd) (Berg 
et al., 1991)  and CCL21 (SLC), a chemokine (Gunn et al., 1998b). These ligands are 
identified by two lymph node homing receptors on T cells, CD62L and CCR7 
correspondingly (Rosen, 2004, Weninger et al., 2001, Cavanagh and Von Andrian, 
2002). The lymph node homing receptors facilitate T cells to attach to and enter the 
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walls of HEV and arrive at the T cell zone, the paracortex. The T cells then migrate 
out of the paracortex and depart lymph nodes through efferent lymphatic vessels, 
followed by re-admission into the bloodstream through the thoracic vessel (Girard et 
al., 2012, Förster et al., 2012). This course of blood-to-lymph recirculation via lymph 
nodes takes around 12–18 hours (Sprent, 1973). 
The constant migration of T cells via the secondary lymphoid organs is extremely 
significant for permitting T cells to create an active contact with antigens discharged 
from pathogens (Sprent and Tough, 2001). The antigens released are presented to T 
cells in the form of peptide fragments bound to MHC molecules (Berczi and 
Szentivanyi, 2003). For naïve T cells, these immunogenic peptide/MHC complexes 
have to be presented by specialised APCs, primarily by dendritic cells (Steinman, 
1991, Inaba et al., 1990). These cells are strategically located as a compact system in 
the T cell zones and are constantly scrutinized by recirculating T cells for expression 
of foreign peptides (Banchereau and Steinman, 1998). Because naïve T cells are 
mainly tolerant to self-components, they overlook the self-peptide/MHC complexes 
on normal dendritic cells. As a result, T cells are permitted to permeate gradually 
through the T cell area and then re-enter the bloodstream for further recirculation. 
Throughout their usual course of blood-to-lymph recirculation, immature T cells are 
metabolically dormant and have a long life span (von Boehmer and Hafen, 1993, 
Weng et al., 1995). However, the durability of immature T cells is dependent on 
constant contact with at minimum two outer ligands, known as self-peptide/MHC 
compounds on dendritic (Ernst et al., 1999) and IL-7 (Martínez et al., 2015). The 
recognition of these ligands most probably delivers low-level signals that maintain T 
cells to prevent apoptosis. 
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It is well accepted that cessation of the primary response is followed by a broad-scale 
loss of effector cells. The elimination of effector cells following the clearance of 
pathogens makes sense since leaving these cells to remain would overload the 
immune system with non-functional cells, resulting in lymphoid hypertrophy and 
traffic congestion and thus compromise the response of naïve T cells to novel 
pathogens (Sprent and Surh, 2002). 
1.4.3 Memory T cells  
Following exposure to infectious agents or cancerous cells, a state of immunological 
memory is attained. Thus the memory acquired by antigen-specific T and B cells is 
frequently enduring (Sprent and Surh, 2002). Primarily, immune responses to 
antigenic challenge might be categorised into primary or secondary reactions. The 
primary immune response to antigen happens on the initial encounter with a foreign 
body and results in the formation of memory cells with extremely high avidity and 
specificity for the stimulating antigen. After this first experience, antigen-specific 
CD4 T-cells and CD8 T-cells display an improved performance in providing support 
to B cells by producing cytokines and other stimulatory factors and the production of 
a vast number of antigen-specific cells that can directly kill infected cells accordingly. 
This phase of response can be said to be a secondary response which moreover are 
more robust compared to primary responses (Ahmed and Gray, 1996). 
Signals from the T cell receptor (TCR) due to  large doses of peptide antigen attached 
to MHC class II molecules on APCs are critical for the activation of naïve CD4 T 
cells and their transition to memory and effector cells (Swain et al., 1999, Rogers et 
al., 1998). It has been reported that transport of effectors, produced in vitro from 
immature CD4 T cells to adoptive hosts leads to the growth of lifelong memory CD4 
although no additional antigen is added (Swain, 1994). Diverse strengths of TCR 
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interplay with peptide-MHC are required for T cell response at different steps of T 
cell differentiation and can influence different outcomes. It has been demonstrated 
that immature CD8 T-cells within class I– deficient mice (Tanchot et al., 1997) and 
immature CD4 T cells in class II– deficient mice (Takeda et al., 1996, Murali-Krishna 
et al., 1999, Rooke et al., 1997) have abridged life-spans that suggest that interactions 
between  MHC and TCR increase the life span of naïve T cell. Immature CD4 T cells 
need high avidity or intense TCR interactions for the induction of cytokine synthesis 
while effector and memory cells react effectively at lesser avidity/ intensity (Dubey et 
al., 1996). Therefore, memory and effector cells might be expected to overcome this 
MHC dependence. 
Memory CD8 T cells are a significant constituent of long-standing immunity due to 
their prolonged persistence and their unique capability to quickly enlarge their 
numbers and generate cytotoxic molecules and antiviral cytokines following second 
antigen encounter (Kaech et al., 2002). Throughout the majority of infections, most of 
the antigen-specific CD8 T cells produced by clonal unidentified, and particularly the 
process that decides which of the antigen-specific CD8 T cells will remain and 
convert into memory cells and which will die has yet to be clarified (Kaech et al., 
2003). This quest has been stalled mostly due to lack of authoritative markers that 
differentiate among the two cellular fates of survival or death. A classic CD8 T cell 
response comprises of three key developmental phases: increase in effector cell and 
differentiation; reduction in effector cell; and stabilisation and preservation of the 
memory cell numbers (Kaech et al., 2003). 
Memory T cells are quite suitable to fight pathogens since they exist in greater 
numbers compared to naïve cells, they persevere for long periods because of the 
antigen-independent homeostatic turnover, and they react speedily on a reencounter 
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with a pathogen (Kaech et al., 2002). By their anatomical location, two subgroups of 
memory T cells were defined, the composition of cell surface markers and 
consequence of expansion die following antigen removal, and the surviving cells turn 
into the long-lasting memory cell population (Busch et al., 1998, Murali-Krishna et 
al., 1998). Central memory cells (TCM) refer to a class of T cells that express 
molecules such like CCR7 and CD62L, which facilitate effective homing to lymph 
nodes (LNs). On the other hand, memory T-cells that do not express the LN homing 
receptors resident within non-lymphoid organs are called effector memory cells 
(TEM). Nevertheless, both T cell subtypes are available in the spleen and blood. Some 
studies have as well demonstrated that TEM obtains effector roles such like cytokine 
secretion and killing, more rapidly compared to TCM (Sallusto et al., 1999, Masopust 
et al., 2001, Reinhardt et al., 2001). Wherry et al. have been able to demonstrate that 
TCM has a greater capacity to persevere in Vivo than TEM and are more proficient in 
mediating defensive immunity due to their enhanced proliferative potential (Wherry et 
al., 2003b). 
1.4.4 The T cell surface markers  
Cell surface markers are proteins on the surface of cells and act as markers for 
recognition. TLymphocytes separate into numerous cell subtypes, essential for 
biological functions. Throughout lymphocyte differentiation diverse surface receptors 
are expressed that can recognise cellular subtypes and ligands. Improper cellular 
proportions of differentiated leukocytes, such like the comparative quantities of TH1 
and TH2 cells, take place in pathophysiological circumstances such like autoimmunity 
(Pitkänen, 2005). The presence of cell surface markers can likewise figure out 
whether a cell type expresses the particular receptor essential for a biological 
response. Testing for surface marker expression is likewise fundamental in 
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determining whether a trial medication or ligand will be recognised by the cell type of 
interest (Wingender and Kronenberg, 2015). The expression of diverse combinations 
of chemokine receptors can be employed to name specific T helper subsets (Zhu et al., 
2010), and through the secretion of a particular combination of cytokines, the subsets 
of T helper can define the ongoing immunological state  (Wingender and Kronenberg, 
2015). 
Identification of antigen by the immune mechanism elicits a coordinate number of 
variations in lymphocyte and lymphocyte subtypes that enable the system (a) to 
eradicate or neutralise likely dangerous pathogens and (b) to react faster and suitably 
following repeated antigen encounter in a process known as immunological memory. 
Inside the T cell compartment of the lymph node, immature T cells, memory T cells, 
and effector T cells can be discerned. Practically, memory T cells have various 
qualities that differentiate them from naïve T cells. Not just do they react effectively 
to recall antigens; memory T cells likewise have less stringent prerequisites for 
activation and can possibly discharge a broad range of cytokines (Merkenschlager et 
al., 1988, Byrne et al., 1988, Picker et al., 1995). Also, naïve and memory T cells vary 
in the expression of numerous cell surface antigens (Sanders et al., 1988) though it is 
not clear if these markers can be regarded as valid memory markers or if they indicate 
cellular stimulation (Michie et al., 1992). 
 
Studies  have reported phenotypic differences between  effector, naïve, and memory T 
cells that showed that with relation to immature T cells, cytotoxic T lymphocyte 
effectors have downregulated the lymph node homing receptor, CD62L (L-selectin) 
whereas expression of CD44, CD11a/CD18, CD11b, and CD49d are increased in 
expression (Hamann et al., 1997). In contrast to effector T cells, memory T cells have 
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varied levels of CD62L expression and do not possess CD11b on their surface; they 
nevertheless display an intermediate CD49d expression. Studies have demonstrated 
that memory, naïve and effector kind of cells can be differentiated with the 
combination of functional and phenotypic characteristics (Hamann et al., 1997). 
Models have been used to assist in defining populations and subpopulations of CD4 
as well as CD8 T cells sequential progression from naïve to terminally differentiated 
effector memory (TEMRA) populations. For instance, this study adopts a classic 
differentiation system showing cell types: Naïve ˃˃ Central Memory ˃˃ Effector 
Memory-1 ˃˃ Effector Memory- 2 ˃˃ pre-Effector -1 ˃˃ pre-Effector -2 ˃˃ Effector 
Memory-4 ˃˃ Effector Memory-3 ˃˃ Effector end-stage non-proliferative effector 
cells. These phases of cell development have been identified using relevant markers 
and in combination with proliferation and cytokine secretion assays (Koch et al., 
2008b, Mojumdar et al., 2012, Alves et al., 2007). Consequently, the presence of 
specific T cell types and expressions of cell surface markers have been useful as 
prognostic tools, for example, an elevated number of peripheral T cells has often been 
reported in CLL patients, which is largely as a result of  increased frequency of CD8+ 
T cells and lowering the CD4/CD8 ratio (Zaknoen and Kay, 1990). Also, the capacity 
to elicit an effective immune response against novel pathogens depends on the 
availability of circulating naïve T cells, hence shortage of naïve T cells is blamed for 
the increased susceptibility to infectious and malignant diseases, as well as impaired 
vaccine efficacy among the older persons (Briceño et al., 2016).  
Within the peripheral blood, a subpopulation of CD4 TCM cells expressing CXC 
chemokine receptor 5 (CXCR5) is essential for antibody production (Chevalier et al., 
2011, Morita et al., 2011, Vinuesa and Cook, 2011). These cells have been referred to 
as peripheral T follicular helper cells (pTfh) because they share functional features 
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with germinal centre-Tfh and can help B cells to generate antibodies through 
promotion of somatic hypermutation and class-switch recombination (Crotty, 2011, 
Chevalier et al., 2011, Morita et al., 2011, Vinuesa and Cook, 2011). As a standard 
method in numerous laboratories, flow cytometry plays a pivotal role in identifying T-
cell populations in comparison with single-parametric analysis (Chen and Cherian, 
2013). Immunohistochemistry (IHC) and immunofluorescence (IF) give outstanding 
immunophenotyping methods employed to identify the comparative abundance and 
location of protein biomarkers within fixed cells. 
1.4.5 T cell exhaustion 
T cell exhaustion has for a long time been defined as a dysfunction and subsequent 
physical elimination of antigen-specific T cells throughout chronic viral infection in 
mice (Zajac et al., 1998, Gallimore et al., 1998, Jiang et al., 2015). Accordingly, 
exhausted T cells may be described as a condition of T-cell dysfunction in a chronic 
setting leading to reduced cytokine expression and effector function (Jiang et al., 
2015). Typically, exhausted T cells demonstrate high degrees of inhibitory receptors 
such as programmed cell death protein 1 (PD-1), T-cell immunoglobulin domain and 
mucin domain protein 3 (TIM-3), lymphocyte activation gene 3 protein (LAG-3). 
Other markers of exhaustion include T-cell immunoglobulin and immunoreceptor 
tyrosine-founded inhibitory motif domain (TIGIT), band T lymphocyte attenuator 
(BTLA) and cytotoxic T lymphocyte antigen-4 (CTLA-4) (Barber et al., 2006, Jin et 
al., 2010, Crawford and Wherry, 2009, Blackburn et al., 2009, Fourcade et al., 2012, 
Joller et al., 2011). T cell exhaustion has been shown in a broad assortment of animal 
models and humans having chronic bacterial, viral, and parasitic infections, as well as 
in human tumours (Virgin et al., 2009, Baitsch et al., 2011). Exhausted T cells have 
been demonstrated to represent a discrete phase of T cell differentiation.  . Two points 
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are considered to help understand the T cell exhaustion phenomenon. The foremost is 
the perception that both extrinsic negative regulatory pathways, for instance, 
immunoregulatory cytokines and cell-intrinsic negative regulatory courses, such as 
PD-1 play essential functions in exhaustion.  
1.4.6 Effector function during T cell exhaustion 
The exhausted CD8+ T cells were initially discovered during chronic Lymphocytic 
Choriomeningitis Virus (LCMV) infection of virus-specific, tetramer-positive CD8+ 
T cells that do not generate cytokines (Zajac et al., 1998). Functional impairment in 
the course of the T cell exhaustion has been portrayed to adopt a stepwise pattern 
(Virgin et al., 2009, Wherry et al., 2003a, Wherry and Ahmed, 2004, Fuller and Zajac, 
2003), for instance IL-2 generation, high proliferative capability, and ex vivo killing 
aspects of memory T cells are the initial set of functions that are impaired. Other 
qualities, including the capacity to generate Tumour Necrosis Factor (TNF), are 
frequently lost at more intermediate phases of dysfunction (Wherry, 2011). Severe 
exhaustion ultimately results in virus-specific cells that partly or, in some situations, 
fully lacks the capacity to generate good quantities of interferon-γ (IFN-γ), β-
chemokines or the capacity to degranulate. The last phase of exhaustion is physical 
elimination of virus-specific T cells (Moskophldis et al., 1993, Wherry et al., 2003a, 
Zajac et al., 1998). Severe CD8+ T cell exhaustion corresponds with a high viral load 
that implies that the potency of activation has some correlation to T cell exhaustion 
(Jameson and Masopust, 2009).  On top of the antigen load, lengthy time of infection 
or lack of support from CD4+ T cells drives to severe exhaustion (Virgin et al., 2009, 
Wherry et al., 2003a). Likewise, virus-specific CD4+ T cells have as well 
demonstrated loss of effector function during chronic viral infection (Brooks et al., 
2005, Oxenius et al., 1998, Kaufmann et al., 2007, Urbani et al., 2006). Most likely, 
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the persistent viral infection might signify a diverse impact on virus-specific CD4+ T 
cells compared to an effect on CD8+ T cells (Fröhlich et al., 2009, John et al., 2009, 
Elsaesser et al., 2009, Blackburn and Wherry, 2007). 
1.4.7 T cell exhaustion and T cell senescence 
Senescence can simply be described as conditions of terminal differentiation and 
nonresponsiveness, which are significant qualities of numerous biological processes 
like T cell responses. T cells expressing diminished proliferative potentials can be 
detected by the expression of the co-inhibitory receptor killer-cell lectin-like receptor 
G1 (KLRG1) in the mouse and CD57 in humans (Joshi and Kaech, 2008, Brenchley 
et al., 2003). Several latent infections, like EBV or CMV infections, produce virus-
specific T cells that express markers of senescence and terminal differentiation (Van 
Leeuwen et al., 2006, Moss and Khan, 2004). Diverse biological systems might have 
differing reasons for cellular senescence, replicative senescence, and terminal 
differentiation. During the process of T cell reaction to infection, several T cells get 
terminally differentiated and lose the proliferative ability, in line with a simplistic 
description of senescence (Wherry, 2011). However, exhausted CD8+ T cells also 
exhibit defective proliferative capability. Nevertheless, gravely exhausted CD8+ T 
cells have reduced expression of immunological markers of senescence-like KLRG1 
(Wherry et al., 2007). The expression of CD57 is not significantly related to that of 
PD-1 in HIV infection (Day et al., 2006), even though there is a link between PD-1 
and the length of telomere in HIV-infected individuals (Lichterfeld et al., 2008). In 
most cases, CD8+ T cells expressing markers of senescence such as KLRG1 or CD57 
can still actively undertake effector functions, but not exhausted CD8+ T cells (Akbar 
and Henson, 2011). The transcriptional profiles of repeatedly stimulated CD8+ T cells 
that have some features of senescence or terminal differentiation also experience 
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some alterations indicative of T cell exhaustion (Wirth et al., 2010, Hertoghs et al., 
2010). Up to date, most findings infer that exhaustion and senescence are discrete 
mechanistic processes. However, the molecular relationships between exhaustion and 
senescence has still be definitively elusidated (Akbar and Henson, 2011).  
1.5 Cellular components of innate immunity 
Innate immunity prevents the admission of microorganisms and swiftly eradicate 
them if they incidentally gain entry into the host system (Abbas et al., 2012). The key 
constituents of which are soluble mediators competent of instantly inhibiting alien 
microbes and specialised cells enriched with detection receptors and the capacity to 
phagocytize microbes (Coico and Sunshine, 2015). The central cellular mechanisms 
of innate immunity are the phagocytosis of foreign bodies followed by the 
intracellular killing of the ingested microbes. Phagocytes discharge lytic substances 
within the surroundings to mediate intracellular destruction of pathogens (Thompson 
and Wilton, 1992, Lollini et al., 2006). 
Basophils and neutrophils are two cell types termed granulocytes containing 
intracellular granules (Amulic et al., 2012, King and Wills, 2005). Neutrophils serve a 
significant role in providing protection against bacterial infections (Conlan and North, 
1991), whereas basophils possess an antiparasitic function. Basophils express the 
αβγ2 type of the high-affinity receptor for IgE (FcεRI) on their surface and can be 
stimulated to produce different preformed mediators and lipid mediators in addition to 
cytokines, following crosslinking of FcεRI-bound IgE with bivalent or multivalent 
antigen (Wedemeyer et al., 2000).  
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1.5.1 Natural Killer (NK) Cells 
Natural killer (NK) cells are nonphagocytic components that destroy virus-infected 
cells. NK cells constitute part of the innate immune system and possess the capacity 
to destroy target cells and offer an immediate supply of immunoregulatory cytokines 
(Cooper et al., 2001a, Robertson and Ritz, 1990).  
Human NK cells consist of about 10% - 15% of the entire circulating peripheral blood 
lymphocytes (Cooper et al., 2001a, Cooper et al., 2001b) and are phenotypically 
described by the expression of CD56 and absence of CD3 expression (Robertson and 
Ritz, 1990). Over the past three decades, and with the introduction of monoclonal 
antibodies (Abs) for particular NK-cell markers, it was reported that two discrete 
populations of human NK cells could be distinguished by their specific cell-surface 
density of CD56 (Lanier et al., 1986b, Cooper et al., 2001b). Around 90% of human 
NK cells show low-density expression of CD56 (CD56dim) in combination with 
raised levels of CD16 (Fcγ receptor III), expression, whereas about 10% of NK cells 
express CD56
bright
CD16
dim
 or CD56brightCD16
−
 (Cooper et al., 2001a). At first, NK 
cells were functionally identified by their capability to recognise and destroy foreign 
cells in the host, without needing previous exposure (Campbell et al., 2001, Ribas et 
al., 2003). The majority of NK cells express the FcR CD16 that could decide Ab-
dependent cytotoxicity (Eischen et al., 1996), an additionally recognised function of 
NK cells (Campbell et al., 2001). Nevertheless, a tiny subset of NK cells do not 
express CD16 but express higher levels of CD56 and CD94, an attribute that made 
this group distinct from the majority of NK cells (Campbell et al., 2001). There is 
evidence to suggest that discrete immunoregulatory functions can be attributed to the 
CD56bright and CD56dim NK-cell subsets (De Maria et al., 2011). Studies have 
demonstrated that CD56bright NK cells are the main population accountable for NK 
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cell cytokine production in response to monokines (Cooper et al., 2001b). These 
findings endorse a model in which CD56bright and CD56dim NK cells symbolise 
functionally different subsets of fully developed human NK cells. NK cells are inborn 
immune effectors that generate immunoregulatory cytokines, for instance, interferon γ 
(IFN-γ) and granulocyte macrophage–colony-activating factor (GMCSF), crucial to 
immediate host protection against a diversity of bacterial, viral, and parasitic 
pathogens (Robertson and Ritz, 1990, Biron et al., 1999, Bancroft, 1993, Scharton-
Kersten and Sher, 1997). CD56bright NK cells constitutively express the high to 
intermediate affinity IL-2 receptors and enlarge in vitro and in vivo in response to 
picomolar doses of IL-2 (Caligiuri et al., 1990, Baume et al., 1992, Caligiuri et al., 
1993). This category of NK cells as well displays the c-kit receptor tyrosine kinase 
whose ligand improves IL-2–induced proliferation (Matos et al., 1993, Carson et al., 
1997). On the contrary, resting CD56dim NK cells convey simply the intermediate 
affinity IL-2 receptor, and proliferate feebly in response to elevated doses of IL-2 in 
vitro, still after the introduction of the high-affinity IL-2 receptor (Baume et al., 
1992). Resting CD56dim NK cells are severely cytotoxic towards NK-sensitive 
targets compared to CD56bright NK cells (Nagler et al., 1989). Nevertheless, after 
stimulation with IL-2 or IL-12, CD56bright cells show comparable or improved 
cytotoxicity toward NK targets matched with CD56dim cells (Nagler et al., 1989, 
Ellis and Fisher, 1989, Robertson et al., 1992). NK cell subtypes have distinct natural 
killer receptor (NKR) repertory. The entire resting CD56bright NK cells display high 
expression of CD94/NKG2 C-type lectin receptors (Voss et al., 1998). A minor 
proportion expresses killer cell immunoglobulin-like receptors (André et al., 2000), 
whereas the majority, accounting for above 85% resting CD56dim NK cells are KIR1 
and express low CD94/NKG2. CD56bright NK cells as well express CD62L, an 
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adhesion molecule L-selectin that mediates first interplays with vascular endothelium 
(Frey et al., 1998). CD56dim NK cells do not have this receptor but lately have been 
found to express an NK cell-restricted sulphated lactosamine epitope (PEN5,) that 
partly mediates the binding of L-selectin (André et al., 2000), therefore signifying the 
potential for differential transportation of human NK cell subtypes in vivo. 
Accordingly, CD56bright and CD56dim NK cells vary in their proliferative response 
to IL-2, adhesion molecule expression, inherent cytotoxic potential, and NKR 
repertoire (Cooper et al., 2001b). 
1.5.2 Macrophages  
Macrophages originate from circulating monocytes that migrate the entire organs and 
tissues of the body bearing organ-specific names, for example, Kupffer cells resident 
in the liver and tumour associated macrophages (TAMS) in the tumour 
microenvironment. Other than immunological roles, macrophages play a significant 
role in the turnover of ageing cell constituents such as erythrocytes that are constantly 
phagocytosed by splenic macrophages. Identification in natural immunity is expressed 
by interactions with pathogen-associated molecular pattern expressed by microbes 
(Gordon, 2002, Takeuchi and Akira, 2010). Pattern recognition receptors refer to the 
cellular receptors and comprise of mannose receptors (MRs), toll-like receptors 
(TLRs), and seven-transmembrane spanning receptors (TM7s)  (Kokate, 2011, Kawai 
and Akira, 2010, Akira et al., 2001).  TLR recognise bacterial and viral nucleic acids, 
bacterial peptides, flagellin, lipopolysaccharide (LPS) and other bacterial elements 
(Akira et al., 2006, Takeda et al., 2003). MRs have the ability to bind carbohydrate 
moieties on various pathogens including fungi, bacteria, viruses and parasites (Kawai 
and Akira, 2009, Delves et al., 2011), while TM7 receptors are typically stimulated by 
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endogenous chemokines or by bacterial peptides (Suresh and Mosser, 2013, Taylor et 
al., 2005). 
1.6 Cytokines 
Cytokines are small soluble cell-signalling protein molecules that are produced by 
cells, particularly the cells of the immune system and are used in the process of cell-
to-cell communication (O'Garra and Murphy, 1994, Weaver et al., 2007). These kinds 
of proteins are capable of changing and modifying the behaviour and features of 
diverse categories of cells. Even though functions are multifaceted, cytokine 
expression profiles are extremely applicable parameters of an immune reaction. 
Diverse cytokines have biological overlapping roles, and they have the capability of 
regulating the secretion of further cytokines (O'Garra and Murphy, 1994, De Jager et 
al., 2003). Cytokines encompass lymphokines, chemokines, interleukins (IL), 
interferons (IFNs), tumour necrosis factor (TNF) but commonly may not comprise the 
growth factors or hormones (Watford et al., 2003). These cell-signalling molecules 
are secreted by various types of cells and contribute significantly to several 
physiological reactions, including immune reactions, inflammatory responses, 
angiogenesis, apoptosis and cell production (Singh et al., 2014, Kantola et al., 2012, 
Balkwill and Burke, 1989, Watford et al., 2003). Cytokines perform their roles 
through receptors, and are particularly critical in the general immune system as they 
control a state of synergy between humoral as well as cell-based immune responses. 
They are also responsible for regulating the growth, maturation and receptiveness of 
specific cell types. Activities of some cytokines can enhance or inhibit the action of 
other cytokines in complex ways (Zhang et al., 2013). Certain cytokines are 
biochemical regulators that turn some immune cell categories on and off. They are 
significant in disease and health, particularly in responding to infectious agents, 
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immune reactions, inflammation, , sepsis, tumour and in reproduction (Schulte et al., 
2013). An example is, Interleukin 2 (IL-2) activates the immune system of the body to 
produce T cells. This immunity-boosting feature of IL-2 has conventionally made it a 
potential treatment for numerous types of illnesses (Kierszenbaum and Sztein, 1994). 
Recently, cytokine receptors have taken centre stage of more researcher than the 
cytokines themselves, partially due to their attributes, and because a deficiency of 
cytokine receptors has been reliably associated with some incapacitating 
immunodeficiency conditions (Spangler et al., 2015). Since the redundancy, as well as 
pleiomorphism of cytokines, are, a result of their homologous receptors, it is 
contemplated that categorising cytokine receptors is likely more clinically valuable. 
Research indicates that antagonising effects of cytokines are associated with several 
disease conditions from depression and Alzheimer’s disease to cancer with either 
raised or altered expressions (Herbert and Lucassen, 2015, Fillman et al., 2015). 
Serum levels of various cytokines may give information on the presence, or even 
predictive value of inflammatory processes involved in autoimmune diseases (Miller 
et al., 2009). The expression levels of serum cytokines are progressively being applied 
in population studies, however, there are insufficient studies that describe the 
epidemiology of cytokine levels in healthy cohorts (Tsunoda et al., 2003). Cytokines 
are hormonal passengers responsible for most of the biological effects in the immune 
system, such as in regulation of cell function in the innate and adaptive immune 
responses. Measurement of these immune mediators has become increasingly 
important as a means of understanding immune responses during disease or 
infections, or in response to therapy and interventions (Biancotto et al., 2013). In a 
nutshell, cytokines play a prominent part in intercellular communications in 
inflammatory responses as well as haematopoiesis (Gu et al., 2009b, Biancotto et al., 
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2015) while chemokines play a significant part in chemotaxis in conditions such as  
angiogenesis. 
1.6.1 Sources of cytokines 
Cytokines are produced by an extensive variety of cells, comprising mainly of 
immune cells such as macrophages, T lymphocytes, B lymphocytes, as well as mast 
cells, and not forgetting endothelial cells, fibroblasts, also numerous stromal cells.  
Individual cells can produce more than one kind of cytokine (Lackie, 2010, Zhang et 
al., 2013). Nevertheless, T lymphocytes have been recognised as principal producers 
of cytokines. These cells carry certain antigen receptors on their cell surface to permit 
identification of external pathogens. Similarly, these can identify normal tissues in 
episodes of autoimmune diseases. There exist two primary subsets of T lymphocytes, 
characterised by the appearance of cell surface molecules recognised by CD4 and 
CD8.  Also, T lymphocytes expressing CD4 are identified as helper T (TH) cells and 
are considered with the potential of being the most prolific cytokine producers. 
Furthermore, the TH cells can be classified into TH1 and TH2, and the cytokines that 
they produce are recognised as TH1-type cytokines as well as TH2-type cytokines 
(Dumortier et al., 2013). 
1.6.2 Classifications of cytokines  
Cytokines are categorised based on their source or according to their function, their 
range of actions, the group of actions they influence, the cell types they target, or on 
particular characteristics of their ligand-receptor synergy (Cohen and Cohen, 1996). 
By cell type as well as a more valuable utility in clinical and experimental practice, 
immunological cytokines are categorised into those that heighten cellular immune 
responses, as type 1 as well as ones that support antibody reactions as type 2 
cytokines (Ellyard et al., 2007). The TH1-type cytokines (for example, interleukin 
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(IL)-12, IL-15, interferon γ (IFN-γ) plus transforming or tumour growth factor-β 
(TGF-β)) support cellular immune responses and deemed crucial for an efficient 
response against tumour cells. On the other hand, TH2-type cytokines (comprising IL-
4, IL-5, IL-10, and IL-13) may contain the tumour-specific immune response (Ellyard 
et al., 2007, Cui and Florholmen, 2008, Kantola et al., 2012). Besides, the TH1-type 
cytokines incline to secrete the proinflammatory responses accountable for killing 
intracellular organisms and for the role of perpetuating autoimmune reactions. The 
principal TH1 cytokine is interferon γ (IFNγ). Excessive pro-inflammatory reactions 
can cause unrestrained tissue harm. Therefore, there is the need to have a 
counterbalancing mechanism. On the other hand, the TH2-type cytokines are linked to 
the elevation of immunoglobulin-E (IgE) and eosinophilic reactions in atopy, and 
besides IL-10 has more of an anti-inflammatory response. In surplus, TH2 responses 
will counter the TH1 arbitrated microbicidal action. The optimal situation would thus 
appear to be that persons ought to produce a well-balanced TH1 and TH2 response, 
suitable for the immunologic provocation. Upholding metabolic homoeostasis  
necessitates a balanced immune response, which is achievable by extracellular 
signals, as well as cytokines (Dumortier et al., 2013)  
By chemical compositions, cytokines can be categorised as peptides, proteins, or 
glycoproteins. Despite they are plentiful; cytokines can be broadly grouped into 
proinflammatory and anti-inflammatory cytokines. The proinflammatory cytokines 
may comprise, for instance, IL-1α, IL-6, IL-8, GM-CSF, GRO-α, MCP-1, TNF-α; and 
mediators that include IL-1β, IL-33, IFNγ, TGFβ, IL-11, IL-12 and IL-17 as well as 
IL-20 family. On the other hand, the anti-inflammatory group, for example, IL-4, IL-
10, IL-13, IL-35 and other mediators including IL-16, IL-1ra, G-CSF that encourage 
allergic responses (Li et al., 1998, Mamet et al., 2002). Furthermore, cytokines have 
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been categorised as lymphokines, interleukins, as well as chemokines, by their 
supposed role, the cell of secretion, or target of their action. The word interleukin was 
applied initially by scholars for those cytokines whose alleged targets are mainly 
leukocytes (Hegazi and Abdel-Rahman).  
1.6.3 Expression levels and profiles of cytokine in a variety of human diseases 
Measuring cytokine types and levels in a range of human illnesses has been useful in 
providing understanding of the pathogenesis of infections and disorders, immune 
responses in the course of disease or response to treatment and interventions 
(Whiteside, 1994). The elevation and decrease levels of a cytokines can be used as 
valuable biomarkers to evaluate disease condition, particularly to compare variations 
in the biomarker to disease situation or treatment (Gu et al., 2009a, Bastarache et al., 
2011). For instance, the elevated levels of TNF and IL-6 in serum have been reported 
in septic compared to nonseptic shock (Pinsky et al., 1993). Besides, the level of IL-6 
in serum was observed to correspond to the severity of the disease in septic shock 
(Damas et al., 1992). Also, raised levels of serum TNF-α and IL-6 have been 
associated with severe dysfunctions of body organ in human Plasmodium falciparum 
(P. falciparum) malaria. Therefore, disparities in the cytokine system in untreated P. 
falciparum infection serve as markers of the severity of disease (Kern et al., 1989).  
In colorectal cancer, higher levels of serum IL-6 have been reported in patients whose 
tumours were more than 5.0 cm in width or that had metastasized in a circumferential 
manner. Higher levels of Serum IL-6 and IL-8 were described in patients who had 
liver metastasis as compared to ones with no liver metastasis. Similarly, higher serum 
levels of both cytokines were seen in patients with lung metastasis than in patients 
with no lung metastasis. These findings suggest that IL-6 and IL-8 might have a 
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significant role in the haematogenous metastasis of colorectal cancer (Ueda et al., 
1994). 
A comprehensive analysis of serum cytokine expression to help in the development of 
predictive panels for diagnosis, staging and the process of observing cancer vaccine 
trials has associated serum IL -6 with poor survival rate in patients that have 
hormone-refractory metastatic breast cancer (Bachelot et al., 2003).  
Colorectal cancer (CRC) has been linked to extensive modifications in serum 
cytokine expression, stressing the significance of studying comparative cytokine level 
alterations (Kantola et al., 2012). The expression of serum cytokine levels provides a 
promise in splitting CRC patients from healthy controls but then again its clinical 
importance is yet to be established. Likewise, a study proposes that high serum 
concentrations of IL-6, IL-10, and IL-12 in people who are of African Americans 
origin and IL-6 and TNF-α in Caucasians are linked with a prognosis of lung cancer. 
It established that IL-6 associated with good life in both populations that reinforces 
the indication for the role of IL-6 in the prognosis of lung cancer (Enewold et al., 
2009). Certainly, the profile of serum cytokine has been valuable as an analytical and 
predictive tool in ovarian cancer. This research group established that a mixture of IL-
7 and CA-125 serum levels was likely to predict 69% of the ovarian cancer patients in 
an accurate manner, with no false classification of patients with the help of benign 
pelvic mass. Besides, IL-6, IL-7, IL-8, IL-10, monocyte chemotactic protein-1 (MCP-
1), and IP-10 and CA-125 were related with disease-free as well as overall survival in 
univariate analysis. On the other hand, in multivariate analysis, IL-7 and IP-10 were 
autonomous predictors of overall survival, even though after including the 
clinicopathological features, merely stage as well as the residual disease continued to 
be the independent forecasters of the rates of survival. This study demonstrated that 
37 
 
IL-7 levels were established to be intensely connected with ovarian cancer and might 
be applied in combination with CA-125 to differentiate amid malignant and benign 
ovarian tumours (Lambeck et al., 2007).  
In a research study via the use of human pancreatic cancer cell lines, pro-
inflammatory cytokines, IL-6 and IL-8 concentrations in serum were raised in 
comparison with negative controls that could hypothetically facilitate systemic 
inflammatory response (Wigmore et al., 2002). Unfortunately, the overall survival of 
patients with pancreatic ductal adenocarcinoma remains remarkably inferior. 
Therefore, the need to identify prognostic markers is urgent. To this effect, Torres, 
Carolina; at al undertook an extensive analysis of serum prognosis biomarkers using 
an antibody array comprising 507 human cytokines, and a panel of serum cytokines 
including B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-β1/HRG1-β1, and PD-ECGF 
showed correlation to poor prognosis for patients with pancreatic cancer (Torres et al., 
2015).  Moreover, it has been shown that serum cytokine profiles were potentially 
valuable biomarkers in the differentiation of pancreatic ductal adenocarcinoma 
(PDAC) from patients suffering from a benign pancreatic disease (Shaw et al., 2014).  
The majority of the cytokines long-established to date are to some extent thought to 
relate to cancer biology including cancer immunity and cancer progression (Tazaki et 
al., 2011). It has been reported that abnormally unbalanced production of cytokines 
was related to the pathophysiology of prostate cancer (Pca), and cytokine profiles in 
Pca patients were distinct according to the stage of the disease. IL-1β and IL-12 have 
indicated a promise as early diagnostic pointers of Pca  (Tazaki et al., 2011). 
Increased levels of serum IL-4, IL-10 and high-sensitivity C-reactive protein (hs-
CRP) have been found to associate with persistent or recurrent disease in papillary 
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thyroid carcinoma (PTC) and PTC with Hashimoto's thyroiditis (HT) patients. This 
information can be helpful in improving patient stratification according to the risk of 
recurrence, especially in patients with PTC plus HT, where thyroglobulin (Tg) levels 
are not reliable due to the presence of antithyroglobulin antibodies (TgAb) (Stanciu et 
al., 2015). Cytokine expression levels have also been studied in head and neck cancer 
to help understand the pathogenicity and prove useful as biomarkers or targets for 
therapy for head and neck squamous cell carcinoma (HNSCC). The serum 
concentrations of IL-8 and vascular endothelial growth factor (VEGF) were found to 
correlate weakly with large primary tumour volume in HNSCC. Raised IL-1- and IL-
6-inducible acute-phase reactions were also noticed in cancer patients but this was not 
the case in patients that were suffering from papilloma or control individuals (at P < 
0.05). This research demonstrated that cytokines that are significant in 
proinflammatory, as well as proangiogenic reactions, are noticeable in cell lines, 
tissue specimens, as well as serum from  HNSCC patients (Chen et al., 1999). 
Gupta et al. undertook a case-control study using pretreatment serum samples from 68 
newly diagnosed T-cell neoplasms patients and 14 healthy controls. He analysed the 
expression pattern of thirty cytokines and compared findings with clinical end points 
(Gupta et al., 2015). Epidermal growth factor (EGF), IL-6, IL-12, interferon γ-
induced protein (IP)-10, soluble interleukin (sIL)-2Rα, monokine induced by γ 
interferon (MIG), and IL-1RA were significantly elevated in all T-cell neoplasms 
compared to the controls (Gupta et al., 2015). Raised levels of epidermal growth 
factor were predictive of a poor event-free survival; IL-1RA, sIL-2Rα, and monokine 
induced by γ interferon (MIG predicted a poor overall survival (Gupta et al., 2015). 
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1.6.4 Serum Cytokines in Follicular lymphoma 
The impact of cytokines in lymphoma biology appears to be complex (Kimby, 2015).  
A subtype of B lymphoma cells express the IL-2R, and IL-2 is a precocious 
homeostatic cytokine necessary for growth, development, as well as the activity of 
regulatory T cells (Kimby, 2015). IL-2 is likewise essential for the growth of 
cytotoxic T-cell function and has been applied for the systemic immune treatment to 
increase immunity against tumour  (Kimby, 2015). However, a variety of cytokines 
and growth factors, such as TNF-α, transforming growth factor-β (TGF-β), hepatocyte 
growth factor (HGF), epidermal growth factor (EGF), etc., have been implicated in 
tumour–stroma cross-talk (Singh et al., 2014). 
Due to high variability in the progression of follicular lymphoma (FL) that resulted in 
several treatment options, identifying reliable markers that can help streamline cancer 
type and for predicting outcome are undoubtedly demanding. Happily, serum 
cytokines and chemokines have been shown to reflect tumour biology and host 
response in FL, demonstrating the prognostic value of cytokines (Mir et al., 2015, 
Kimby, 2015). The action of the primary cells in the tumour microenvironment, as 
well as tumour-reactive T cells, follicular dendritic cells (FDCs), also macrophages, 
are likely to be reflected by the state of serum cytokines (Mir et al., 2015, Labidi et 
al., 2010). The overall “cytokine milieu” can be of significance for T cell–mediated 
antitumour protection. 
Recently, an enzyme-linked immunosorbent evaluation (Multiplex) was used by the 
group of Mir et al., and they established that raised levels of IL-2R, IL-1R1, and 
CXCL9 are related with shorter event-free survival (EFS) in FL patients on 
chemotherapy or chemoimmunotherapy. Meanwhile, IL-1R1 and IL-12 were linked 
40 
 
with a shorter EFS in patients in a wait-and-watch cohort, and a similar outcome in 
patients who were treated with rituximab single-therapy (Mir et al., 2015).  In this 
research, serum levels of IL-1R1, IL-6, IL-7, IL-10, IL-13, TNF-α, vascular 
endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) were 
raised in 60 FL patients in comparison with controls (Mir et al., 2015). Early stage 
and high TGF-β levels have been identified as independent predictors of improved 
overall survival in FL, while high lactate dehydrogenase (LDH) and VEGF levels 
were independently associated with poorer progression-free survival (Labidi et al., 
2010). These serum factors seem independent of the FL international prognostic index 
(FLIPI), a validated prognosticator, and might be of great clinical impact, especially 
as they are readily available in the blood (Kimby, 2015). Furthermore, it has been 
shown that elevated soluble IL-2R levels before treatment were associated with 
reduced survival in FL patients (Yang et al., 2011). It has also been reported that IL-
12 and IL-1R1 are predictive for poor outcome in FL patients who are initially 
observed (or getting rituximab monotherapy) (Yang et al., 2011). 
Herewith, evaluating cytokine expression levels and profiles in FL, and understanding 
how they relate to disease biology and other clinicopathological features of patients 
will undoubtedly impact positively on the treatment and management of FL.  
1.7 Cytomegalovirus (CMV) 
Herpes viruses are big, sophisticated viruses that comprise of double-stranded 
deoxyribonucleic acid (DNA). More than 100 herpesviruses are identified, but then 
again only eight passes on a disease to humans (Berman, 2011). The human 
herpesvirus (HHV) family is classified into three subfamilies grounded in the period 
of viral reproduction cycle, capacity for cell culture growth, as well as the site of viral 
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dormancy in the human body. The subfamilies are α-herpes virinae encompasses the 
simplex viruses (HSV-1 and HSV-2) as well as varicella virus (VZV), whereas β-
herpesvirinae comprises of cytomegalovirus (CMV) in and Roseolovirus (HHV-6 and 
HHV-7). The γ-herpesvirinae comprises of lymphocryptovirus(Epstein-Barr virus, or 
EBV) plus Kaposi’s sarcoma-associated herpesvirus (HHV-8) (Berman, 2011).  
CMV is a species of β-herpesvirus (Harari et al., 2004, Emery, 2001, Chiche et al., 
2012). It infects nearly all human beings and typically leads an asymptomatic chronic 
course in a large set of an estimated 40 -100% of the global human population 
(Papadakis et al., 2001, Khan et al., 2002, Gandhi and Khanna, 2004, Ludwig and 
Hengel, 2009, Mustakangas et al., 2000). In immunocompetent persons, CMV 
infection is frequently chronically asymptomatic and infrequently leads to a light 
mononucleosis-like set of symptoms, it continues to be an essential source of deadly 
diseases of different organs like the liver, the lung, the retina, and the CNS (central 
nervous system) among immune-deficient hosts(Almanzar et al., 2005). Beneficiaries 
of allogeneic stem cell and bone marrow transplantation (Mori et al., 2004, Kotton, 
2010), HIV positive individuals, new-borns that are infected by birth (Khan et al., 
2002); cancer patients,  and patients on the course of chemotherapy and 
corticosteroids (Vega et al., 1999) are listed in the high risk group.  
A wide-ranging meta-analytical assessment of severe CMV infection in 
immunocompetent grown-ups established that CMV infection usually involves 
gastrointestinal tract (mainly colitis), then the CNS (as well as meningitis, 
encephalitis plus myelitis) and at that point haematological abnormalities (Lancini et 
al., 2014). CMV illness of the eye, liver, lung and vasculature were also recognised, in 
the middle of other diseases.  Research Studies have discovered that the occurrence of 
severe exhibitions of CMV infection in immunocompetent persons seemed to be 
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meaningfully more prevalent than previously understood (Lancini et al., 2014). 
Besides, a higher risk of CMV-related disease and death rates in “immunocompetent” 
patients that are critically ill has been documented (Lancini et al., 2014).  It is 
consequently highly possible that incomplete immune dysfunction might signify a 
presently ignored risk factor for severe CMV disease.   
While clinical indicators of CMV infection  in immunosuppressed patients might 
include asymptomatic viraemia, CMV syndrome (viraemia with symptoms that 
comprise of  fever and malaise) as well as tissue-invasive sickness like, colitis, 
retinitis, pneumonitis, hepatitis, and disease in other locations (Kotton, 2010); the 
nonexistence of clinical manifestation, mainly among immunocompetent persons 
credited to the fact that CMV-specific CD8+ T cells, most of which possess 
specificity for the immediate-early protein 1 (IE-1) and the structural Tegument 
Protein pp65 (ppUL83), can regulate the virus by stopping its replication as well as  
eliminating cells that harbour the virus (Almanzar et al., 2005).  
After the first infection, this βherpesvirus is not eliminated but starts a life-long viral 
perseverance in its host (Chiche et al., 2012, Libard et al., 2014). CMV starts to 
spread and eventually grows dormant in manifold end organs; this situation is known 
as “latency",  nevertheless, endogenous resurgence can take place at in the course of 
time in circumstances that undermine immune function like in inflammation and 
immunosuppression (Cook, 2007, Goodman et al., 2015, Chiche et al., 2012).  For 
example, it has been established that during a severe illness, and precisely in sepsis, 
CMV is reenergized in approximately 30% of latently infected persons  (Cook, 2007). 
Information also proposes that immunocompromised in the type of NK cell 
dysfunction has the possibility of setting the platform for viral recurrence. NK cell 
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action is essential to viral restraint following acute infection and control for a 
resurgence (Amadei et al., 2010).  
1.7.1 Pathophysiology of CMV  
The pathological trademark of CMV infection in an individual is the presence of a 
giant cell full of viral bodies (Varani and Landini, 2011). Also, cytomegaly is 
observed in infections due to other β-herpesvirinae superfamily viruses. The 
microscopic characteristics of these enlarged cells are commonly described as the” 
owl eyes”. Though these may be regarded as diagnostic, such histologic findings may 
be insignificant or even nonexistent in infected organs. During CMV infection, the 
polymerase chain reaction (PCR) is employed to detect CMV DNA in various cells of 
the body organs (A Ross et al., 2011). At the first stage of infection, the epithelial 
cells of the salivary glands are infected leading to the viral persistence in the body and 
viral exuviating (Gerna et al., 2004). However, when the infection goes to the 
genitourinary system, it causes insignificant viruria. Nonetheless, the virus can resist 
treatment and still continue multiplying to various parts of the body of the host. 
Nevertheless, this can lead to other complications such as kidney failure and the renal 
dysfunction, though it is not common unless for the patients who have had a renal and 
kidney transplant. Such patients show few cases of glomerulopathy as well as chances 
of graft rejection (De Souza and Olsburgh, 2008). 
1.7.2 The immunology of CMV Infection  
The primary CMV infection is commonly referred to patients who before CMV 
infection had been CMV seronegative (Ljungman et al., 2002). Such patients express 
detectable CMV immunoglobulin M (IgM) antibodies as early as four to seven weeks 
following the first infection. The IgM viral antibodies produced can persist for some 
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time such as 16 to 20 weeks. The neutralising antibodies neutralise the enclosed 
glycoprotein B (gB). It has been reported that over 50% of this neutralising process in 
patient serum is directed towards the glycoprotein B (gB). The viral tegument proteins 
including pp150, pp28, as well as pp65 elicit powerful and long-lasting antibody 
responses.  CMV is a virus which weakens the immune system of individual 
exacerbating hidden immune diseases. The CMV-seropositive healthy people express 
CMV DNAenemia as well as viruria. During this point, the natural immunity is not 
able to stop reinfection (Walter et al., 1995). Cell-mediated immunity (CMI) is 
considered the most important factor in controlling CMV infection. Patients deficient 
in CMI are at greatest risk for CMV disease and reactivation (Kumar et al., 2009). 
Essentially, the immune protection can be handled by the help of CMV-specific 
CD4+ and CD8+ lymphocytes following primary infection. It has been documented in 
bone marrow transplantation experiments that individuals who did not develop CMV-
specific CD4+ or CD8+ cells following transplantation of bone marrow are at greater 
risk of contracting CMV pneumonitis. However, patients that received allogeneic 
marrow transplant with CMV-specific CD8+ cells infusion did not present with CMV 
pneumonia (Bonkowsky et al., 1975).  
1.7.3 The Influence of CMV infection on Normal Immunity 
Various chronic illnesses and impaired immune responses are linked to the CMV 
infection (Alonso Arias et al., 2013). The latent CMV infection expedites age-
associated alterations in the T cell repertory in the aged people, particularly those who 
are using drugs that suppress the immunity (Welzl et al., 2014). The CMV-infected 
HSCT patients have high chances of contracting bacterial and fungal infections due to 
the additional suppressive adverse effects of drug leading to tremendous immune 
impairment. Similarly, CMV infection continues to exert significant problem in 
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beneficiaries of haematopoietic stem cell transplantation (HSCT)  (Holtappels et al., 
2008). Also, CMV infection is implicated in the pathogenesis of the cardiovascular 
diseases, immunosenescence,  as well as cancer (Ohlin and Söderberg-Nauclér, 2015).  
Because CMV evokes a powerful antigenic response in immunologically unimpaired 
persons, which increases with increasing age (Freeman Jr, 2009), the virus has 
developed many ways to suppress as well as escape this response to remain latent. 
Various sources of evidence show that the mechanisms deployed by CMV to evade 
the host’s immune response are by downregulating the inherent and acquired parts of 
the immune system (Freeman Jr, 2009). For example, CMV reduces the expression of 
the HLA classes I and II antigens on the APCs (Söderberg‐Nauclér, 2006) and on T 
cells (Fletcher et al., 1998). It later yields an HLA class I homologue which impedes 
the process of antigen presentation by the infected cells to prevent it from being 
recognised by the NK as well as the T cells (Reyburn et al., 1997). Moreover, the 
virus also produces various proteins which particularly antagonise the delivery of 
peptides by APCs hence reducing the activation of the CMV-specific T-cell reactions 
(Ahn et al., 1996). Various studies have revealed that CMV may directly repress 
proliferation T-cells that are active (Schrier et al., 1986) that increases their 
presentation PD-1, which influences the apoptosis of the T-cells that are stimulated. 
Consequently, this minimises their capacity to produce the IL-2 as well as INF-c 
(Sester et al., 2008). Another growing body of evidence suggests that the CMV does 
the suppression of the immunity of the host through stimulation of the Fc receptors on 
infected cell surfaces through the production of their Fc receptor homolog (Rahman et 
al., 1976, Atalay et al., 2002). The receptors then attract the circulating 
immunoglobulin G (IgG) to attach to the infected cells, causing the virally infected 
cells to evade binding to the immunoglobulins directed against other viral proteins 
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carried on the infected cell surface. This can potentially decrease the binding process 
along with the CMV’s induction of the patient’s complement inhibitors (Spiller et al., 
1997). Also, CMV expresses various chemokine receptors homologues which bind 
the local MCP-1 as well as MIP-1α chemokines that reduce the concentration of the 
chemoattractant in the microenvironment. As a result, it affects the attraction of 
inflammatory cells to CMV vicinity (Neote et al., 1993). Moreover, CMV infection 
interrupts the macrophage cytoskeletal structures and increases the production of the 
macrophage migration inhibitory factor (MMIF) that consequently reduces the 
trafficking of the macrophages to blunt the natural immune reaction (Frascaroli et al., 
2009). 
The combination of all these CMV-arbitrated reactions will potentially lead to 
nonspecific inhibition of the cell-mediated and antibody-mediated immune responses. 
Data from in vitro studies indicate that CMV may engage some other mechanisms 
which make the host vulnerable to other diseases. The reduced expression of HLA 
impedes antigen presentation to decrease the host cellular response to pathogenic 
challenges. On the other hand, increased Fc receptors and homologues bind 
circulating immunoglobulin, which reduce the ability of the humoral immune systems 
to identify and attack other pathogenic antigens. The ability to repress complement as 
well as chemotaxis and macrophage migration implies that CMV is likely to intervene 
with far-broad aspects of the humoral immune system. Previous studies have provided 
possible reasons for increased chances of fungal and bacterial infection among 
patients with CMV viraemia and as well as in kidney and liver transplant patients.  
Another study indicates that the immunosuppressive feature of CMV occurs due to 
offensive episodes of HCV among HCV-infected liver transplant beneficiaries who 
had records of CMV infections (Falagas et al., 1996). By implication, patients with 
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CMV infections have had abnormal antiviral responses to other viruses different from 
the CMV. Also, the study states that the active CMV infection can exercise an 
immunosuppressive influence which makes the patients highly vulnerable to other 
infectious agents.  A meta-analysis shows that prophylaxis on the primary CMV 
infection leads to a lasting survival (Hodson et al., 2013) as well as reducing the 
incidence of secondary infections (Snydman, 2006). The is assumed to be achieved by 
limiting CMV primary infection and minimise the consequences of CMV on the 
immune system as well as reducing the expedition of inflammatory responses by 
dividing CMV (Freeman Jr, 2009). 
1.7.4 Human cytomegalovirus (HCMV) and tumours  
The pathophysiology of quite many tumours including colorectal cancer, primary 
intracerebral tumours, non-melanoma skin carcinomas,  intracerebral tumours, 
prostate cancer, and neuroblastoma have been linked to HCMV (Cobbs et al., 2002, 
Harkins et al., 2002, Samanta et al., 2003, Zafiropoulos et al., 2003, Sehic et al., 2013, 
Wolmer‐Solberg et al., 2013). The relationship between HCMV protein expression 
and primary non-curable brain tumours like glioblastoma (GBM) has been 
demonstrated (Baryawno et al., 2011, Scheurer et al., 2008, Cobbs et al., 2002). 
Despite this growing body of evidence, however, the effects of HCMV protein 
expression have been investigated only in a few tumour types such as glioblastoma 
(Scheurer et al., 2008, Cobbs et al., 2002, Lau et al., 2005, Sabatier et al., 2005). 
Recent studies have reported that by treating for HCMV infection results in reduced 
glioblastoma, although it is not statistically significant (Stragliotto et al., 2013). 
Consequent to the findings and the increased rate of the occurrence of the HCMV 
protein expression in glioblastoma, HCMV is considered a therapeutic target despite 
only a progress associated impact is accomplished. Therefore, the modern studies are 
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including the antiviral therapies as a paired treatment for glioblastoma (Stragliotto et 
al., 2013, Rahbar et al., 2013, Hadaczek et al., 2013). 
The HCMV virion consists of the three main structural units just like other herpes 
viruses. The three units include the envelope, capsid, and tegument. The tegument 
unit connects the envelope to capsid and contains regulatory proteins, pp65 and pp71 
that passed into the host cell in the course of infection by the virus (Libard et al., 
2014). It has been shown that pp65 is the most common virion protein and plays 
immunomodulatory functions (Libard et al., 2014). Also, it contains the dense bodies 
which are non-infectious viral particles which accumulate during the infection (Becke 
et al., 2010, Landolfo et al., 2003). However, pp71 is known as a transcriptional 
transactivator. HCMV resides in the monocytes during the latent stage of an infection, 
and the virions are not yet produced.  At this point, the viral DNA divides in 
proximity to the host DNA through host-to-cell replication machinery. Sensitive 
techniques like polymerase chain reaction (PCR) can be applied to detect the HCMV 
DNA at this stage. However, during the active stage of infection, the virions are 
released leading to the presence of viral elements as intranuclear inclusions in the 
infected cells, known as the owl eyes (Trgovcich et al., 2006).  
Immunohistochemical techniques (IHC) are efficient for detecting the HCMV 
proteins in the various human cellular compartments (Landolfo et al., 2003). The 
components of tegument and envelope of the virion are some of the HCMV viral 
proteins that have been studied. These proteins are exhibited at various stages of the 
HCMV cycle. The cycle and proteins expressed may include the immediate-early 1 
(IE1), immediate-early (IE), early - envelope glycoprotein GP48, early/late-protein 
polymerase processivity factor (p52) and finally the late - tegument protein (pp65) 
(Cobbs et al., 2002, Scheurer et al., 2008, Mitchell et al., 2008, Slinger et al., 2010).  
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The HCMV proteins are reported to be connected to many activities which are 
essential for tumour advancement (Libard et al., 2014). They are said to regulate 
immunosuppression, the telomerase activation, chronic inflammatory environment, 
angiogenesis, cellular motility and invasion, anti-apoptotic, as well as cell-cycle 
modulation (Dziurzynski et al., 2012, Soroceanu et al., 2011, Michelson, 1999, 
Michaelis et al., 2004, Michaelis et al., 2009). Evidently, there have been no cases of 
the low levels of HCMV proteins in regions of necrosis in tumours, healthy brain 
tissues next to tumour; brain tissues collected from controls or people suffering from 
several neurodegenerative diseases (Landolfo et al., 2003, Soroceanu et al., 2011). By 
implication, the HMVC proteins may be essential to the tumour induction or growth. 
1.7.5 Diagnosis of CMV  
Based on the pathogenesis of CMV and the need for effective control of the patients, 
it is important to implement a diagnosis protocol which can differentiate between the 
CMV invasive disease as well as latent CMV infection. There are various methods of 
diagnostic tests for CMV. However, there have been various limitations regarding 
these tests. The serological method gives the impression of the pre-exposure to the 
CMV, and testing for the active disease may require the quantitative nucleic acid 
testing (QNAT), antigenaemia, histopathological examinations, as well as culture. 
The immunological analysis they are meant to reveal the cellular immune response to 
the CMV (Lancini et al., 2014). 
CMV IgG status and IgG avidity can be determined serologically to assist in 
differentiating between the primary and secondary CMV infections. The IgM 
antibody will only be positive for approximately 12 months following the initial 
infection (Goodman et al., 2015, Ross et al., 2011). hence the suggested use of the 
anti-CMV IgG as well as improved specificity . Appraised immunological methods 
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that can be employed to diagnose CMV IgG antibodies may include 
radioimmunoassay (RIA), indirect haemagglutination (IHA), complement fixation 
(CF), enzyme-linked immunosorbent evaluation (ELISA), and immunofluorescence 
(IF) (Ross et al., 2011). False negative results of CMV serological assay such as low 
immunoglobulin status and plasmapheresis, and transfusion of blood products can 
lead to the false positive. Therefore prior transfusion samples can be more reliable. 
Nevertheless, active HCMV disease tends to elude both IgG and IgM serology and are 
not as such effective in the detecting the active CMV disease (Lancini et al., 2014). 
The antigenaemia test or the QNAT have been employed to determine CMV 
viraemia. By principle, this test is based on the use of monoclonal antibodies which 
detect for the viral pp65 antigen which is structurally late protein that is expressed in 
the leukocytes in the first phase of the CMV replication cycle (Ross et al., 2011). 
Testing for CMV pp65 antigen gives a semiquantitative assessment which has been 
instrumental in the commencement of preventive treatment, disease diagnosis and 
monitoring of the patient's response to treatment (Lancini et al., 2014). This method is 
relatively easier to perform as it does not need expensive tools though it lacks test 
standardisation. 
Therefore, the CMV QNAT or CMV viral load testing can be an option for testing the 
antigenaemia. This type of test needs expensive tools as well as skilled professionals. 
The viral load changes profusely between plasma and the whole blood samples and 
CMV DNA is detectable earlier and ordinarily higher quantities in the blood. It is, 
therefore, advisable that one type of specimen used when monitoring treatment 
progress in follow-up patients. The QNAT data can differ in various settings because 
of the variation in the methods of extracting nucleic acid and test designs. 
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The choice of assay category can be affected by the availability of resources, technical 
speciality, and the number of patients, turnabout time, and the number of samples as 
well as the expenses to be incurred. Antigenaemia and QNAT viral load tests have 
both given great results that are applicable in clinical practice. Nevertheless, the 
relationship between QNAT viral load and CMV antigenaemia levels has not been 
compatible. A study shows that even other tissues, as well as body fluids such as 
biopsies, bronchoalveolar lavage and CSF specimens, can be tested for CMV by the 
QNAT since it enhances the sensitivity and possibly with quicker results compared to 
the traditional culture method. 
The conventional technique for the detection of CMV infection is via conventional 
cell culture (Ross et al., 2011). The process requires clinical specimen inoculation 
onto human fibroblast, which is then incubated and observed for 2 to 21 days. This 
method may seem slow, costly and associated with low sensitivity. Also, seropositive 
individuals may pass CMV via their bodily secretions, particularly during periods of 
stress, thus yielding positive cultures, do not, in reality, translate to an active disease 
phase. Blood viral culture for CMV is known to have inferior sensitivity, whilst 
cultures of CMV sputum, urine and stool cultures are associated with reduced 
specificity. The culture of a specimen from tissues remains the appropriate options for 
the diagnosis of diseases that are tissue invasive, especially for samples from the 
gastrointestinal tract, where PCR or antigenaemia testing on blood may fail to be 
positive, even in the presence of invasive disease. To boost assay sensitivity, 
Immunohistochemistry should typically be conducted on every biopsy specimen 
during cases where CMV infection is suspected. Detection of viral antigens or 
inclusion bodies in bronchoalveolar lavage or biopsy tissues is highly specific for 
CMV infection, particularly with a positive culture. CMV infections that are tissue 
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invasive, for instance, hepatitis or colitis is supposed to be confirmed via 
immunohistochemistry or through in situ DNA hybridization. Immunologic 
techniques represent an emerging technology, which will potentially offer 
personalised prophylaxis and treatment of CMV. 
1.7.6 Treatment Options for CMV infection 
Therapy for CMV infection may involve antiviral treatment, which can be followed 
by prophylaxis or monitoring; occasional application of CMV immunoglobulin and 
reducing immunosuppression.   
1.7.6.1 Antiviral therapy  
Typically, ganciclovir forms the first-line anti-CMV therapy. Nonetheless, its 
associated low oral bioavailability restricts its application and thus intravenous 
treatment has been made compulsory. Valganciclovir represents a prodrug of 
ganciclovir with over 60% bioavailability and is now a substitute to intravenous 
ganciclovir. Valganciclovir has increasingly continued to be the drug of choice for 
treating recipients of solid organ transplant (SOT) having a mild-to-moderate CMV 
infection. Studies have shown that CMV oral valganciclovir is no inferior to 
intravenous ganciclovir for the therapy of CMV infection. Regarding patients 
suffering from severe CMV infections, intravenous ganciclovir remains the drug of 
choice since there is no documentation of oral treatment as an equivalent therapeutic 
intervention. It is supposed to be used in patients who fail to tolerate oral therapy or 
have demonstrated suboptimal valganciclovir absorption. Secondary prophylaxis 
using antivirals for one to three months following treatment differs significantly with 
respect to transplant centres. Nonetheless, it is often used particularly when there is a 
high relapse risk. Close clinical as well as microbiologic check-ups within the initial 
few months following therapy is still an intervention that is often adopted. 
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1.7.6.2 Reduction of the immunosuppression 
Immunosuppression reduction can be adopted in cases of severe CMV infections, 
with increased viral loads in diseases that are not responding to treatment and with 
leukopenia. It may also be appropriate in cases of CMV infections that are less severe. 
Data on the impact of the intensity of immunosuppressive therapy on the result of 
CMV infection treatment in recipients of organ transplant tends to show that better 
early elimination of viral load took place with dual versus triple immunosuppressive 
treatment, reduce levels of calcineurin inhibitors in blood, and a longer time after 
transplantation. 
 1.7.6.3 CMV immunoglobulin  
The activity of CMV immunoglobulin in the therapy of CMV infections has not yet 
fully elucidated. Rather, at times, it is applied as a concomitant therapy for serious 
CMV infections like pneumonitis and with a virus that is resistant. Adoptive infusions 
of T-cells that are specific for CMV, even though it is still being tested, may seem 
promising in some circumstances.  
The primary methods of preventing CMV infection, which involve preemptive 
therapy and universal prophylaxis, are known to lower the CMV infection risk, even 
though each method has its merits and demerits. Late CMV is mainly detected in 
individuals undertaking universal prophylaxis. This is suggestive of the notion that 
CMV may be delayed efficiently than prevented, particularly during cases of primary 
infection. Research findings reveal that NHL including FL patients under rituximab 
therapy within one year prior to autologous HSCT have an elevated risk of CMV 
infections following HSCT (Lee et al., 2008). Anti-CMV drugs like ganciclovir and 
immunoglobulins that are specific for CMV may serve as efficient therapy for CMV 
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infections in FL patients under rituximab therapy and autologous HSCT (Lee et al., 
2008).  
1.8 Study Aims and Objective 
The overall aim of this study is to appraise the impact of CMV infection on FL 
biology.  As a result, four primary objectives are set out to achieve the aim of the 
project: 1. Assess the impact of CMV infection on the quantities of lymphocyte and 
NK cell subsets in circulating blood of FL patients by flow cytometry. 
2. Evaluate the effect of chronic CMV infection on serum cytokine levels and profiles 
of the study cohort using Luminex assay 
3. Examine the intensities of accessory infiltrating cells in the FL microenvironment 
using dual IF staining of tissue sections from FFPE tissue biopsies. 
4. Undertake an explorative analysis relating lab data to clinical data and evaluating 
the impact of CMV infection on drug toxicity, response and infection status. 
1.9 Study Rationale 
CMV infection has been implicated in impairing the immune response, expedited 
immune senescence as well as in different chronic ailments (Almanzar et al., 2005, 
Alonso Arias et al., 2013). Nevertheless, latent infection with CMV leads to an 
accelerated age-associated variations in the repertoire of T-cells in immunosuppressed 
elderly individuals (Welzl et al., 2014). Additionally, it has also been demonstrated 
that some high grade chronic viral infections such as lymphatic choriomeningitis virus 
(LCMV), adenovirus, polyomavirus, HIV, HBV, HCV, Friend leukaemia virus as 
well as malignancies lead to exhaustion of T-cells. T cell exhaustion is characterised 
by T-cell dysfunction demonstrated by the inability of T cells to display the typical 
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array of effector functions (robust, protective) and memory T-cell populations 
(Wherry, 2011, Yi et al., 2010). As a cohort of FL patients will be CMV-positive 
elucidating the effect of CMV infection on T-cells and the subsequent effect on FL 
may offer insight into the disease, which will consequently lead to enhanced patient 
management. 
1.10 Study Hypothesis 
The hypothesis being tested is that CMV infection alters immune function in follicular 
lymphoma in two ways:  
1. CMV infection induces premature immune senescence, that would increase the risk 
of infection following immunosuppressive chemo-immunotherapy; and  
2. CMV infection alters the composition of the tumour microenvironment and would 
modulate the behaviour of the lymphoma and/or its response to therapy. 
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Chapter 2 : Research Design & Methodologies 
2.1 The Study Design  
This chapter provides a general overview of the study design, approach, materials and 
laboratory methodologies employed to test the study hypotheses as well as to answer 
the research questions. It also presents highlights on the patient recruitment and 
selections of the study cohort, sample types, research consent and ethical 
considerations. Furthermore, it includes the optimisation of protocols and statistical 
approaches. 
The study design as depicted in Figure 2-1 comprised of five complementary research 
strands. Chapter 3 of the thesis, which is the first result chapter, explored the 
quantities of T- and NK- cell populations and subpopulations using stored peripheral 
blood mononuclear cells (PBMCs) from a small cohort of PACIFICO trial patients. A 
multicolour flow cytometric analysis was employed to undertake immunophenotyping 
of circulating peripheral T and NK cells. The second result chapter presented in 
Chapter 4 looked at the levels and patterns of serum cytokines using pre-treatment 
stored serum samples. 
The third result chapter (Chapter 5) used immunofluorescence (IF) to analyse cells 
within the tissue microenvironment of FL. Immunohistochemistry (IHC) was used to 
optimise for the working dilutions of the primary antibodies. The fourth result chapter 
(Chapter 6) presents an explorative statistical analysis of the effect of CMV infection 
on treatment efficacy and toxicity in patients. The last result chapter (Chapter 7) 
explores the relationship between laboratory variables and the treatment response 
data.     
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Figure 2-1: Study design.  
The design was set to evaluate the impact of CMV infection on the biology of FL. 
The cohort of patients, source of samples and clinical data used in this study is 
represented on the upper bar. The study evaluated CMV-positive and CMV-negative 
FL patients illustrated by the two arrows pointing to the separate two blocks below the 
study patients. The bottom box shows the laboratory methods and clinical analysis 
employed to test the hypothesis. These include flow cytometric analysis (FACS), 
Luminex assay (correlated with sandwich ELISA (sELISA) and immunofluorescence 
(IF) using immunohistochemistry (IHC) to determine working volumes of 
monoclonal antibodies (mAbs). Furthermore, the relationships between clinical data 
and CMV infection status or laboratory data were explored. 
2.2 The study Cohorts and patient samples 
The project benefited from stored pre-treatment samples from patients recruited into 
the National Cancer Research Institute (NCRI) PACIFICO trial (Purine-Alkylator 
Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients). 
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This is a two-arm, open label, multi-centre, parallel group phase 3 randomised clinical 
trial. The trial targeted patients with previously untreated follicular lymphoma aged 
60 years or more and compared two alternative chemo-immunotherapy induction 
regimens: R-CVP (rituximab, cyclophosphamide, vincristine and prednisolone) versus 
R-FC (rituximab, fludarabine and cyclophosphamide). Patients who achieved a 
complete or partial remission then received 2 years of maintenance treatment with 
rituximab. The co-primary endpoints were progression-free survival (PFS) and 
infection ≥grade3. Secondary endpoints included response, survival and toxicity 
which was defined and quantified in accordance with the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0. The study was approved by the 
National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group 
(CSG), Cancer Research UK, the Medicines and Healthcare Regulatory Agency 
(MHRA), Liverpool Adult Research Ethics Committee (LREC), and local NHS 
Research and Development departments. Central running costs were covered by 
Cancer Research UK with contributions from Roche and Chugai, while local research 
costs were covered by the National Institute for Health Research (NIHR). The trial 
was jointly sponsored by the University of Liverpool and Royal Liverpool and 
Broadgreen University Hospitals NHS Trust and centrally co-ordinated by the Cancer 
Research UK Liverpool Cancer Trials Unit (LCTU). The trial opened on 9
th
 
September, 2009 and closed on 30
th
 April, 2016 after recruiting 360 patients. It is 
anticipated that analysis of the primary endpoint will take place in 2018 once a 
sufficient number of events have accumulated. Until then, only limited data is 
available for correlative translational studies, and it is not possible to compare data 
across the two treatment arms. Toxicity and efficacy data from individual patients 
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were obtained from local sites via Case Report Forms (CRFs), collated by the Cancer 
Research UK Liverpool Cancer Trials Unit and made available by the trial statistician. 
The trial protocol included the collection of baseline samples from all patients. The 
PACIFICO Clinical Trial Sample Collection Kits (each with their own unique kit 
identification code) are prepared to contain all components to collect samples from 
patients, with documentation. All kits sent out to the sites to obtain patients samples 
for the PACIFICO clinical trial were prepared according to the GCP Lab Facility 
Protocols. Deviations from the protocols were logged as quality incidents. Blood and 
formalin-fixed paraffin-embedded (FFPE) lymph node biopsies were taken at baseline 
for all consenting patients. It is expected that the blood samples arrive within 24 hours 
of being taken from the patient. Whilst being transported a data logger within the 
package records the temperature the samples are exposed to. Upper and lower limits 
are set to alert if the sample has been outside of the range defined e.g. a lower limit of 
2°C would alert that blood maybe compromised. The data from the loggers is then 
down loaded once the sample is received in the lab. As part of the Quality Assurance 
for the lab any deviations from protocols are recorded as quality incidents against the 
sample, eg if the sample is delayed in the post, or if another tube was used to that 
supplied.  The samples stored for the trial are tissue blocks (to be returned), germline 
DNA, plasma and peripheral blood mononuclear cells (PBMCs, from anti-coagulated 
blood) and serum from coagulated blood. On arrival after logging receipt and coding 
of the samples the anti-coagulated blood samples had an aliquot removed and stored 
in the -80
o
C freezers before processing into DNA. The remaining anti-coagulated 
blood was processed using density centrifugation (see Section 2.6.3 for PBMC 
Isolation) to plasma and PBMCs, which were stored in the -80
o
C and -150
 o
C freezers, 
respectively, in the GCP Lab Facility freezer room. The clotted blood samples were 
60 
 
centrifuged at 2500g for 10 minutes before preparing 1ml aliquots of serum and 
stored in the -80
o
C freezers in the GCP Lab Facility freezer room. The Formalin-
fixed, paraffin-embedded (FFPE) tissue blocks were stored in tissue cabinet at room 
temperature (RT). 
As a nested case-control study, sample types were selected from patients that tested 
positive for CMV-IgG antibodies and those that were negative for the CMV-IgG 
antibodies.  The CMV -IgG antibodies statuses were determined by the local (trial) 
participating recruiting sites. For FACS and Luminex analysis, 42 sample types were 
selected from patients within relatively similar clinicopathological characteristics as 
in Table 3-1 (Chapter 3). The clinical features of patients included Follicular 
lymphoma prognostic index (FLIPI), Ann Arbor stage, haemoglobin value, Lactate 
dehydrogenase (LDH), cumulative illness rating scale (CIRS), Gender, Age and 
number of lymph nodes involved. Patient samples were carefully chosen to reduce the 
impact of confounders in the analysis and to enhance the chances of accurate 
evaluation of the biological effect of CMV infection status on FL.  
The data generated from this design will offer an opportunity for a comparative 
analysis of the relationship between circulating peripheral lymphocytes and levels of 
serum cytokine in follicular lymphoma. 
For the FACS and cytokine analyses in Chapters 3 & 4, PBMC and corresponding 
serum samples from 42 patients with  21 being CMV positive & 21 CMV negative 
were used. The study on cellular infiltrates in the FL microenvironment used FFPE 
tissue blocks from 42 patients (including 20 CMV positive & 22 CMV negative) with 
only 6 patients included in the FACS/cytokine cohort. The explorative analysis of 
clinical data in Chapters 6 and 7 included patients from the entire trial cohort whose 
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clinical data had been verified and available. A summary of study cohorts regarding 
sample size and overlap is displayed in Figure 6-1. The cohort of patients used for the 
study of cellular infiltrates in the FL microenvironment was selected based on the 
availability of FFPE tissue material for the immunofluorescence. Only a small 
proportion of the cases were available for use. Therefore no particular consideration 
was made regarding the demographic features of patients on both arms of the CMV 
status (Table 5-1; Chapter 5). The cohort used for the explorative analysis of the 
overall trial according to CMV infection status, were 360 patients.  Of these, 269 
(75%) had information on CMV status,   of which, 59% were CMV negative, and 
41% were CMV positive.  Table 6-1 in Chapter 6 gives patient demographics broken 
down by CMV status as well as some initial investigation of response rate and 
toxicities. 
2.3 Inclusion and Exclusion Criteria 
The summary of the inclusion criteria for recruiting patients into the NCRI 
PACIFICO phase III clinical trial includes established grades 1, 2 and 3a patients of 
mainly 60 years or above, at Ann Arbor stages II to IV without prior treatment, as 
well as minimal haematological and other health complications. The exclusion criteria 
can be summarised to include Grade 3b FL and over, cases of transformed FL to 
DLBCL and other health complications that may not withstand the adverse effects of 
chemotherapy.      
2.4 Ethical Approval & Informed Consent  
As part of the PACIFICO trial ethics application, this project was included in the 
context of the translational work. This trial has approvals of the European Union Drug 
Regulating Authorities Clinical Trials (EudraCT) on a unique number 2008-004759-
31 and the International Standard Randomised Controlled Trial (ISRCTN) number 
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ISRCTN99217456. Written informed consent to participate in the NCRI PACIFICO 
trial was obtained before recruitment to the study as per the International Council for 
Harmonisation (ICH)-Good Clinical Practice (GCP) regulations  
2.5 Study Sample Size Estimation 
The aim of the project is to compare CMV status from patients taking part in the 
PACIFICO trial.  The interest lies in correlating CMV status to biological samples of 
interest.  Sample size calculations are carried out based on pilot data collected prior to 
the start of the project.  
The previous investigation found that 8 out of the 27 cytokines to be studied were 
shown to be significantly different between CMV-positive and CMV–negative 
patients with FL. 
Based on replicating these results, sample size calculations are based on a Bonferroni 
adjusted α level of 0.00625 to control the overall type I error rate at 0.05.  As 
cytokines are measured on different levels, sample size calculations assume the data 
are measured on the standardised normal distribution. From this, it was determined 
that difference would be interesting if the difference between CMV-positive and 
negative cytokines were at least 1 standard deviation. Given each cytokine is 
measured on a different scale; each cytokine will have its standard deviation. 
Therefore, the parameters used for the sample size calculation for comparison 
between two groups with equal number of patients include the statistical power at 
80%, α level at 0.00625, standard deviation of 1 and clinically relevant difference of 
1. This gives an overall sample size of 42 patients. 
Further to this, patients for FACS and cytokine analyses were selected from the 
PACIFICO trial by the trial statistician who also ensured that 21 CMV-positive and 
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21 CMV-negative patients were selected and that these groups were balanced in terms 
of the CIR score, FLIPI score and treatment allocation to help account for any 
confounding that may occur due to these covariates. 
2.6 Laboratory and experimental methodologies  
2.6.1 Instrument used flow cytometric analysis - BD LSRFortessa™ 
The flow cytometer used for data acquisition is the BD LSRFortessa™ Special Order 
Research Product (BD Biosciences, Oxford, UK), an air-cooled multi-laser benchtop 
flow cytometer, equipped with Red, Yellow/Green, Blue, Violet and UV lasers and 
capable of supporting the analysis of up to 18 parameters 
2.6.2 Cytometer Setup and Tracking (CS&T) 
The CS&T is a fully automated BD FACSDiva software and reagent research system, 
unique to BD digital cytometers, designed to provide Characterization, Setup and 
Tracking for baseline settings. This system optimises and standardises cytometer 
setup and tracks cytometer performance ensuring consistency and reproducibility of 
FACS data by offsetting the routine instrument variability. The BD FACSDiva CS&T 
Research Bead set (Cat #: 655051, BD Biosciences, Oxford UK) consists of uniform 
beads of different intensities (bright, mid and dim beads) designed to fully 
characterise the flow cytometer. 
For daily performance checks, a CS&T passed result was considered essential for 
running FACS samples for the day.  
2.6.3 PBMC isolation 
In a biological class II safety Saftey Cabinet, Lymphoprep (Product #: 1114740, Axis-
Shield, Alere Ltd., Stockport-UK) was pipetted into prelabeled tubes in a 2:1 ratio of 
blood to Lymphoprep.  Blood was gently layered on top of the Lymphoprep using a 
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serological pipette or sterile pastette. The tubes were centrifuged at 800 g for 30 
minutes at RT with the brake setting at low. Following centrifugation, mononuclear 
cells in the buffy coat layer were carefully removed into a tube, which was filled up 
with Roswell Park Memorial Institute (RPMI)-1640 medium (LM-R1641/500, 
Labtech International Ltd, East Sussex, UK) and centrifuged at 550 × g for 10 
minutes to wash and pellet the cells with the brake on. The supernatant was discarded, 
and cells were resuspended in appropriate volume of freezing solution A (10% foetal 
calf serum (FCS) in RPMI 1640 media). Cells were counted to determine live and 
dead cells using ChemoMetec Nuclear Counter in the GCP Lab facility and an equal 
volume of medium B (10% FCS, 20% Dimethyl sulfoxide (DMSO in RPMI) was 
added slowly. Cells were aliquoted in vials and placed in Nalgene cryofreezing 
containers to -80 oC freezer for a minimum of 12 hours before moving to -150
o
C 
freezer in the GCP Lab Facility freezer room. 
2.6.4 The PBMC Samples: Thawing and recovery of cells  
Frozen specimens were thawed by being held in a closed fist before transferring the 
cells to pre-label Universals on ice.  Each 1mL of thawed cell suspension was slowly 
diluted with 10mL of RPMI- 1640 medium supplemented with 10% foetal calf serum 
(FCS). The RPMI 1640 solution was added to cells gradually in a drop-wise manner 
with constant and careful agitation throughout the process. The Universals were 
centrifuged at 500 × g for 5 minutes, and the supernatants were discarded.  Then the 
cell pellets were resuspended, counted and assessed for viability using ChemoMetec 
NucleoCounter (ChemoMetec A/S, Denmark), by detecting total and dead cell counts. 
Cells were resuspended in BD FACSFlow Sheath Fluid (Cat #: 342003, BD 
Biosciences, Oxford UK) for lymphocyte immunophenotyping. 
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2.6.5 The Compensation Set up 
After vortexing the BD™ CompBeads(Cat #: 552843, BD Biosciences, Oxford UK) 
had one drop each of the negative control and anti-Mouse Ig, κ was added to each of 
12 prelabelled compensation tubes representing each fluorochrome. The optimal 
working volume of each conjugated primary antibody was added to the respective 
tube. The tubes were mixed gently and incubated for 30 minutes in the dark at RT. 
Subsequently, 2ml of CellWash (Cat# 349524; BD Biosciences, Oxford UK) was 
added to each tube and centrifuged for 5 minutes at 300 × g with a low brake setting 
to wash beads. Supernatants were discarded, and the bead pellets were resuspended in 
500µL BD FACSFlowTM Sheath Fluid and vortexed thoroughly before analysis. Five 
thousand events were acquired from each of the 12 compensation tubes. Using BD 
FACSDiva software version 7, the bead population is carefully gated, and the positive 
and negative populations were identified before the compensation values were 
calculated.   
2.6.6 Determination of working volumes of conjugated mAbs  
As part of the optimisation protocol, optimal working volumes of all the 26 
fluorochrome-conjugated monoclonal antibodies in the panel were determined by 
single fluorescent staining of washed PBMCs from healthy volunteers (HV) using 
three different concentrations of the antibodies. The recommended volume by the 
manufacturers was used as the starting point for the working volumes, and a value 
above and one below for each was also used. Table 2-4 shows all the antibodies, and 
the dilutions tested. 
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Table 2-1: Protocol for determination of working volume experiments 
 
A total of between 10,000 and 50,000 events were acquired per FACS tube. A 
representative process used for the determination of working volumes of CD45-
BV510 with CD45-BV510-Isotype control is illustrated in Figure 2.2. The dot plots of 
events for the three different volumes of antibodies were created, and the lymphocytes 
population gated as P1 on the FSC/SSC plot. A histogram of the lymphocytes 
population (P1) was drawn, and the amount of the respective fluorescent cells in P1 
was determined on the AmCyan channel. An interval gate was drawn on the Isotype 
control for the lowest concentration so that approximately 0.5% of this population 
was included in P2. This interval (P2) was retained for all the antibody dilutions. 
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Figure 2-2: Determining the working volume of CD45-BV510.  
Panel A represents the Isotype control and anti-CD45-BV510 antibodies at 2.5μl; 
panel B represents 5μl of antibodies, and panel C represent 10μl of antibodies 
incubated with. PBMCs from a healthy volunteer (HV). The statistics displayed 
underneath the histograms represent the number of events and the mean fluorescent 
intensity (MFI).  
The criteria used for the choice of optimum working volumes of the fluorochrome-
conjugated antibodies was a combination of the values of the MFI for P2, the number 
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of events in P2 as well as the clearance of the Isotype control histogram peak from P2. 
In Fig 2.2, panel A CD45-BV510 Isotype control had the highest MFI of 16,053 (P2) 
and the lowest MFI for CD45-BV510 compared to the other two tubes. In panel B the 
CD45-BV510 Isotype control had the least MFI of 5,791 with an MFI of 43,227 for 
CD45-BV510. Although panel C (10µl) had a slightly higher MFI for CD45-BV510 
than the 5μl tube, the MFI for the Isotype control is higher. Therefore the 5μl volume 
of CD45-BV510 was used for all other staining work.  This process was carried out 
for all the 26 monoclonal antibodies (mAbs). 
2.6.7 The staining and acquisition of cells for FACS 
Since more than two mAbs are conjugated with BD Horizon Brilliant fluorescent 
polymer dyes in each FACS tube, 50µL of the BD Horizon™ Brilliant Stain Buffer 
was added to each tube to minimise spectral overlaps. As illustrated in Figure 2-3, 
respective quantities of the conjugated mAbs shown in brackets were added to the 
respective tubes. 
Following the addition of antibodies, 100µL of well-mixed washed PBMCs 
containing about 2 × 10
5
 to 1 × 10
6
 were placed in the prelabelled FACS tubes. Tubes 
were incubated for 30 minutes in the dark, at room temperature, after which 2ml of 
CellWASH (Cat #:349524, BD Bioscience Oxford, UK) was added and the tubes 
centrifuged at 300 × g for 5 minutes with low brake. The supernatants were discarded 
before repeating the washing process. Finally, the cells were resuspended in 500µL of 
BD FACSFlowTM Sheath Fluid before being gently vortexed.  The aim was to count 
a minimum of 500,000 events per patient sample, however, in some cases there were 
less than 500,000 cells per tube. In a minority of cases more than 500,000 cells were 
acquired due to the availability of material.    
69 
 
 
Figure 2-3: Illustrating the 3-tube design and the respective panels of mAbs.  
All mAbs were purchased from BD Bioscience, Oxford UK with exception of LAG-
3-FITC (Enzo Life Sciences, UK) and TIM-3-APC (R & D Systems, UK). The values 
in brackets represent the respective optimal working volumes of the mAbs in 
microlitres. 
2.6.8 Multiplex (Luminex) Assay for Serum cytokines 
The multiplex instrument, Bio-Rad Bio-Plex 200 system (Bio-Rad Laboratories, 
Hertfordshire, UK) powered by Luminex xMap Technology was used for the Bio-
Plex Pro™ Human Cytokine 27-plex assay. Consequently, all reagents comprising 
cytokine standards, coupled beads, 96-well plates, detection antibodies, streptavidin-
PE and diluents as well as the software used for the analysis of data were purchased 
from Bio-Rad Laboratories (Cat #: M500KCAF0Y: Bio-Rad Laboratories, 
Hertfordshire, UK).  
As part of the validation protocol for Luminex assay and before data acquisition, each 
bead region number of the cytokine was entered against each cytokine in the Bio-plex 
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manager software. The Human Cytokine Standard was reconstituted following the 
manufacturer’s instructions and incubated on ice for 30 minutes prior use.   
2.6.8.1 Preparation of the Standard Curve  
An 8-point standard curve design with a fourfold dilution between each point was 
used. The reconstituted standard was vortexed gently for 1-3 seconds before 
transferring the reconstituted standard to tube one (denoted as S1) containing standard 
diluent.Tube S1 content was thoroughly mixed, and 100µl of the standard diluent 
mixture in tube S1 was transferred to tube S2 containing 300µl of standard diluent. 
The dilution process was repeated through to the S8 tube. This preparation is for a 
standard triplicate run assay. 
2.6.8.2 Preparation of Coupled Beads for 96 wells 
A 1× working concentration of the 10 × Coupled Beads was prepared using Assay 
Buffer in a 15 ml tube. The diluted coupled beads were vortexed for 30 seconds at 
medium speed. A multichannel pipette and reagent reservoir were used to add 50µl of 
beads to each well of the 96-well microplate. The plate was sealed with a transparent 
sealant and wrapped in aluminium foil and allowed to equilibrate for 20 minutes at 
RT. The microplate was washed twice with Bio-Plex wash buffer (Catalogue #: 171-
304500) using Fisher Scientific™ Wellwash 4 Mk2 Microplate Washer.  Fifty 
microlitres (50µl) each of the diluted standards, internal controls, blank (diluent) and 
respective samples were added to the designated wells of the 96-well Bio-Plex Pro 
flat-bottom microplates (cat #: 171-025001) in triplicates as in the plate layout in 
Figure 2-4.  The preparation was incubated at RT for 30 minutes whilst gently shaken 
on a microplate shaker (Cat #: 444-7094, VWR England, UK). 
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Figure 2-4: Illustrating a 96-well plate layout for Cytokine Multiplex assay.  
S1 – S8 for standards S1 to S8, internal controls (IC) for interassay quality control, 
blank (B) for background noise. 
2.6.8.3 Addition of Detection Antibodies (DAs) 
The 10 × DAs supplied by the manufacturer was diluted with Detection Antibody 
Diluent to make a 1 × working solution. Following the incubation period; the sealing 
tape was removed gently and slowly. The plate was washed three times with Bio-Plex 
wash buffer using Fisher Scientific™ Wellwash 4 Mk2 Microplate Washer, before 
adding 25µl of 1 × DAs. The microplate was covered with a new sheet of sealing tape 
and incubated at RT for 30 minutes with a gentle shake on a microplate shaker.  
2.6.8.4 Addition of Streptavidin-PE 
A 1:100 dilution of the stock streptavidin-PE was made in Assay Buffer, vortexed at 
medium speed for 3 – 5 seconds and 50µl added to each assay well. Again, the 
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multiplex microplate was carefully covered with a new sheet of sealing tape and 
incubated at RT for 10 minutes with gentle shaking on a microplate shaker. Following 
the incubation; the microplate was washed 3 × with 300µl of Bio-Plex wash buffer 
using Fisher Scientific™ Wellwash 4 Mk2 Microplate Washer, and 125µl of Assay 
Buffer was added to each well. This was covered with a new sealing tape and 
incubated at RT on a shaker at 1,100 rpm for 30 seconds prior plate reading. The Bio-
Plex was calibrated with Bio-Plex Manager software before setting up the assay and 
following the start-up and calibration processes for CAL1 and CAL2 calibration. 
Before sample acquisition, the system must pass the calibration.  
2.6.8.5 Data acquisition and analysis 
The multiplex assay employs Luminex platform to detect targets using antibody-
coupled bead systems. The unique content of two addressing colours recognised each 
bead in the set and a third dye is used to censure the coupling of the target analyte 
through a biotin-coupled antibody plus streptavidin conjugated secondary step 
indicator. A dedicated flow cytometer of the Bio-Plex® 200 system platform 
(Luminex MAP Technology, Texas, USA) was used to acquire the data. 
Data was acquired in Bioplex reader after calibrating the Bioplex manager software.  
The values that fell way beyond the curves had an asterisk (*) and were removed 
before analysis. For the evaluation of assay reproducibility, the inter-assay % 
coefficient of variation of most of the cytokines appears within the acceptable limit of 
20% and below. However, cytokines with low levels of abundance that fall below the 
limit of detection of the assay expressed zero scores, for instance, IL-1β, IL-2, IL-5, 
IL-15 had unacceptably high %CV of above 100%.Also, cytokines with elevated 
levels of abundance for example RANTES, the %CV  appeared very high. This is 
because the %CV can usually be higher due to cytokine levels that were ‘out of range’ 
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(OOR).  The intra-assay precision of triplicate wells for the 27-plex assay was 
excellent, with %CV of ≤ 20% across most of the 27 analytes from the two Luminex 
plates, except IL-2, IL-15 and IL-17A that had %CV of 173.21% in plate-1, plate-2 
and plate-1 respectively. Assay precision data was obtained using healthy serum 
control and test samples. The standard curves for the two plate assays appear 
comparable, an indication that raw MFI values for each point in the standard curve are 
highly reproducible from run to run. 
2.6.9 Sandwich ELISA for Cytokines 
The ELISA Development Kits contains essential components for the quantitative 
measurement of human cytokines in a sandwich ELISA format including capture 
antibodies (CAs), detection antibodies (DAs) Wash Buffer, Block Buffer and Diluent 
were supplied by PeproTech EC Ltd, London, UK. Additional materials and reagents 
required and not provided in the kit are ELISA microplates, ABTS Liquid Substrates 
solution (Sigma Cat. #: A3219), Bovine serum albumin (BSA; Sigma Cat. #: A-
7030), Dulbecco’s Phosphate buffered saline (PBS; [10 ×]) (Gibco BRL. Cat #: 
14200-075), Wash Buffer, Block Buffer, Diluent and Tween-20 (Sigma Cat. #: P-
7949). The sELISA assay targets included the human IL-4 (Cat. #: 900-K14), IL- 6 
(Cat. #: 900-K16), IL-8 (Cat. #: 900-K18) and IL-9 (Cat. # 900-K20) (PeproTech EC 
Ltd, London, UK).  
2.6.9.1 Reconstitution of Standards and Antibodies 
Following manufacturer’s instructions (PeproTech, USA), CAs, DAs and standard 
cytokine reagents were reconstituted to stock concentrations by the addition of the 
respective amounts of sterile distilled water (dH2O). This forms the stock working 
reagents.  
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2.6.9.2 Plate Coating with Capture Antibodies 
Following manufacturer’s instructions (PeproTech, USA), respective cytokine 
working CA and DA reagents were prepared by diluting the stock reagents in 1 × PBS 
thereby producing the recommended working concentrations as contained in the Table 
2-2 for each cytokine. The working reagents were prepared for a single 96-well 
ELISA experiment and were not stored.   
Table 2-2: Preparation of working capture and detection antibodies 
 
Reagents are prepared by diluting the stocks in 1 × PBS sufficient for a 96-well 
ELISA plate.  
The vials of CAs were gently vortexed avoiding air bubbles and100 µL of the 
working CA solution was added to each well of the ELISA plate. The microplate was 
sealed firmly with sealing film and incubated overnight at RT. The following day, the 
plate was washed four times using 1× Wash Buffer and blotted on clean, dry paper 
towel. To block for non-specific binding, 300 µL of ready-to-use Blocking Buffer was 
added to each ELISA well and incubated for 1 hour at RT. 
2.6.9.3 Addition of Cytokine Standards & Samples – Specific Binding of Antigen 
The 8-point concentrations of standard cytokines were prepared by diluting each 
cytokine in 1× Diluent. Briefly, 400µL of Diluent was added to standard tubes except 
for the first tube. Then 800µL of the reconstituted cytokine standard solutions were 
added to the first (highest) standard tube (S1) and 400µL was transferred to the 
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second tube (S2). This was mixed carefully, making a 1:2 dilution of S1. The serial 
dilution process was repeated through to the 8th concentration (S8) where 400µL of 
the standard diluent solution was discarded. Each standard curve tube contains a final 
volume of 400 µL for a triplicate of each point of the standard curve. 
Table 2-3: 8-point Concentrations for the cytokine standards 
 
Samples were either assayed neat or diluted depending on the concentration of the 
analyte as determined by ELISA optimisation experiments for optimal results. Then 
100µl of each standard concentration, samples, internal control (IC) and blank (B) 
were added to assay wells in triplicates as shown on the plate layout on table 2-6. 
ELISA plates were sealed and incubated for 2 hours at RT.  This plate layout allows 
for the inclusion of 8-point standards S1-S8 with a 2-fold serial dilution between each 
point, twenty-one test samples, one internal control (IC) or human AB serum (hABs) 
and two blank (B) rows in triplicates.The blanks are essential in determining the 
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efficacy and validity of the measurements of the samples. After the 2 hours 
incubation, the plate was removed and washed four times in 1 × Wash Buffer ready 
for the addition of DA reagent.  
 
Figure 2-5: An illustration of a 96-well ELISA plate layout 
S1 – S8 for standard points 1 to 8, internal controls (IC) for interassay quality control, 
blank (B) for background noise. All standards, controls and patient samples were 
tested in triplicates indicated by numbers and colours). 
2.6.9.4 Detection 
DAs were prepared fresh and enough for a single experiment. Each assay well had 
100 µL added immediately before the plate was sealed and incubated for 2 hours at 
room temperature.  
After incubation, plate content was discarded and washed four times in 1 × Diluent 
and a 1:2000 dilution of Avidin conjugated with horseradish peroxidase (HRP) was 
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prepared in 1 × Diluent. The solution was mixed gently, and 100 µL was added to 
each ELISA well immediately. The ELISA plate was sealed and incubated for 30 
minutes at room temperature. 
ELISA plate was aspirated and washed four times in 1 × Diluent. A multichannel 
pipette was used to add 100ul of ready-to-use ABTS substrate to each ELISA well. A 
SPECTRAmax PLUS 384 ELISA Plate Reader (Molecular Devices, California, USA) 
set at 405nm with wavelength correction at 650nm was used to monitor colour 
development at 5 minutes intervals at RT for up to 50 minutes. Colour development 
was recorded by reading of optical density (OD) of the wells and SOFTmax Pro 
software (Molecular Devices, California, USA) was used for endpoint reading. When 
readings fall between zero and the highest standard values; reliable standard curves 
are said to be obtained.  
2.6.10 Immunofluorescence (IF) of FFPE tissue sections 
Immunohistochemistry (IHC) was used to determine the working dilutions of the 
primary antibodies used for the immunofluorescence staining of FFPE tissue sections. 
2.6.10.1 IHC protocol for working dilutions of primary antibodies  
IHC technique was employed for the determination of optimal working dilutions of 
the respective primary antibodies by staining three microns sections of recommended 
positive FFPE tissue using three dilutions of the primary antibodies and an Isotype 
control (used at the highest concentration). To dewax, rehydrate, and retrieve antigens 
the Dako PT-Link water bath with high PH buffer system was used as described 
elsewhere (Shi and Taylor, Pirog, 2015). Briefly: The PT-Link system was preheated 
at 65°C, and well-labelled tissues sections on slides in staining racks were placed in 
the PT-Link tank and heated to 96°C for 20 minutes. It was allowed to cool back to 
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65°C before removing the rack from PT-Link. The dewaxed slides were immediately 
dipped into the Envision Flex-Wash buffer for 5-15 minutes. After circling tissue 
sections with PAP Pen (Cat # ab2601, Abcam, Cambridge, UK), Envision Flex-Wash 
buffer was used to wash sections on the staining tray. Then 100µl of Envision-Flex 
block was added to sections and incubated at RT for 5 minutes to block, and washed 
with Envision Flex-Wash buffer. The respective primary antibodies and Isotype 
controls were diluted in Envision-Flex antibody diluent accordingly, and 100µl of 
each dilution was added to sections, CD4 (Leica, Milton Keynes, UK), CD8 (Abcam, 
Cambridge, UK), CD16 (Abcam, Cambridge, UK),  CD21 (Abcam, Cambridge, UK), 
CD56 (Leica, Milton Keynes, UK), CD68 (Dako, Cambridgeshire, UK), CD163 
(Abcam, Cambridge, UK),  FOXP3 (Abcam, Cambridge, UK) and  PD1 (Abcam, 
Cambridge, UK). These were covered and incubated at RT for 30 minutes. 
FLEX buffer was used to wash sections 2 - 3 times before 100µl of HRP was added to 
section and incubated at RT for 20 minutes. Sections were washed with FLEX buffer 
briefly and 100µl fresh 3, 3’-diaminobenzidine (DAB) - substrate solution was added 
to the sections and incubated at RT for 20 minutes. Sections were washed with FLEX 
buffer again for 2 - 3 times before being dipped into distilled water. The sections were 
stained with haematoxylin for 30 seconds, dipped in acid alcohol briefly 
(immediately, and in ammonia water for 30 seconds while placing the rack into the 
bath of running tap water in between. Sections were dehydrated through the ethanol 
series of 3x IMS (Industrial Methylated Spirits) and 2x xylene in the fume hood and 
agitating vigorously for 10 seconds at each stage. Finally, a drop of DPX mounting 
medium was added to a coverslip and applied to slide removing all air bubbles. 
Positive control tissue was cut at 3 microns to give sections for optimising 
concentrations (dilutions) of antibodies, as shown in Table 2-4.  
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Table 2-4: Details of the primary antibodies and the positive control tissues used 
in determining the working dilutions 
 
2.6.10.2 IHC interpretation and working volumes of targets  
The images of stained IHC slides were digitalized using Aperio ScanScope. Digital 
images of sections stained with the three different dilutions of the primary antibodies 
and the corresponding Isotype controls were reviewed in ImageScope by a Consultant 
Pathologist for positivity, intensity and histological distribution. Taking the case in 
Figure 2-6, the positivity and distribution of FOXP3 on the tonsil sections at three 
concentrations were assessed for application in the immunofluorescence experiments. 
A1:100 dilution of anti-FOXP3 on a positive tonsil section was chosen as the optimal 
concentration as the cells are not overstained and the brown is just clearly visible. The 
working dilution of all the remaining 8 antibodies in Table 2-4 were determined using 
similar procedure, and the optimal working dilutions of the antibodies are presented in 
pairs in Figure 2-7 to Figure 2-10. 
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Figure 2-6: IHC staining of Rabbit anti- FOXP3  
IHC stained images from sections stained with Rabbit immunoglobulin-G (R-IgG) 
and the three dilutions of Rabbit anti-human FOXP3 showing dilutions in brackets. 
(All images were taken at × 40 magnification). 
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Figure 2-7: Working dilutions of Mouse anti human CD4 and Rabbit anti human 
CD8.   
Images A and C are of sections stained with CD4 and CD8 respectively, while the 
corresponding Isotype controls are shown in images B and D.  The dilutions of 
antibodies are shown in brackets.  (All images were taken at × 20 magnification). 
 
 
 
 
82 
 
 
Figure 2-8: Working dilutions of Rabbit human anti human CD16 and Mouse 
anti human CD56.  
Images A and C are of sections stained with CD16 and CD56 respectively, while the 
corresponding Isotype controls are shown in images B and D.  The dilutions of 
antibodies are shown in brackets.  (All images were taken at × 20 magnification). 
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Figure 2-9: Working dilutions of Rabbit anti human CD21 and Mouse anti 
human PD1.  
Images A and C are of sections stained with CD21 and PD1 respectively, while the 
corresponding Isotype controls are shown in images B and D.  The dilutions of 
antibodies are shown in brackets. (Images of CD21 and corresponding Isotype control 
were taken at ×40 while those of PD1 and Isotype at × 20 magnification). 
 
 
84 
 
 
Figure 2-10: Working dilutions of Mouse anti human CD68 and Rabbit anti 
human CD163. 
Images A and C are of sections stained with CD68 and CD163 respectively, while the 
corresponding Isotype controls are shown in images B and D.  The dilutions of 
antibodies are shown in brackets.  (All images were taken at × 20 magnification). 
 
After determining the optimal working dilutions for the primary antibodies, the 
working dilutions of the fluorochrome-conjugated secondary antibodies were 
determined. Three different dilutions around the manufacturers' recommended 
working dilutions for AF488-Donkey anti-Mouse, and AF647-Donkey anti-Rabbit 
antibodies were used to stain for sections of defined dilutions of Mouse anti-human 
CD56 (1:100) and Rabbit anti-human CD8 (1:500). Following a thorough assessment 
of the staining characteristics, optimal working dilutions of 1:2000 for AF488-
Donkey anti-Mouse antibody and 1:100 for AF647-Donkey anti-Rabbit antibody were 
determined for the immunofluorescence staining of the PACIFICO FFPE tissue 
sections. 
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2.6.10.3 The optimisation protocols for immunofluorescence (IF) Staining  
After determining the working dilutions of all the antibodies and adoption of the 
simultaneous double staining technique, a trial autostaining experiment was 
performed to test the suitability of the Autostainer for IF. Following the satisfactory 
images and minimal cross-reactivity observed, autostaining was adopted for double 
staining of the test FFPE tissue sections. 
2.6.10.4 Immunofluorescence staining of trial sections using Autostainer  
In all, five tissue sections from a total of forty-two PACIFICO trial tissue blocks 
(patients) were processed and stained. Four of these were double-labelled: CD4/CD8, 
CD16/CD56, PD1/FOXP3 and CD68/CD163, then one section were stained for a 
single target, CD21. 
The test sections were loaded onto the DAKO PT Link system for antigen retrieval. 
The Autostainer was programmed to stain for 42 test sections with a mix of diluted 
primary antibodies as in Table 2-4 and an isotope control section for 60 minutes. This 
was followed by blocking for non-specific binding with 10% normal donkey serum in 
PBS/1% bovine serum albumin for another 60 minutes, and finally, the addition of a 
mix of secondary antibodies for 30 minutes at room temperature. The required 
amounts of secondary antibody mix were prepared for each cycle of staining. A 
1:2000 dilution of Alexa Fluor 488 conjugated to Donkey Anti-Mouse IgG (Cat #: A-
21202, Life Technologies Ltd, Paisley, UK) and 1:800 dilution of Alexa Fluor 647 
conjugated to AffiniPure Donkey Anti-Rabbit IgG (Cat#711-605-152, Stratech 
Scientific Ltd, Suffolk, UK) was prepared. 
Envision FLEX wash buffer was used to rinse slides at each step of the process. 
During the staining, the Autostainer was covered with a piece of blackout material to 
protect the fluorochrome against the effect of light. At the end of staining, slides were 
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placed in Envision FLEX wash buffer for 10 minutes, and coverslips were 
immediately mounted using Vectashield Antifade Mounting Medium containing 
DAPI (Cat#: H-1200; Vector Laboratories Ltd, Peterborough, UK). The slides were 
stored in a dark cardboard overnight, and edges were sealed with nail varnish to 
protect from drying. Eight images were taken per section for analysis using an 
Olympus BX63 motorised upright microscope with a 40× objective, equipped with a 
Photometrics CoolSnap camera and MicroManager acquisition software (Edelstein et 
al., 2014). The filter sets used (Chroma Technology Corp) were as follows: DAPI: set 
49000 ET DAPI; AF488: set 49002 - ET - EGFP (FITC/Cy2); AF647: set 49006 - ET 
- Cy5.  
2.7 Statistical considerations and Data Analysis  
Descriptive statistics were performed for baseline characteristics, both overall and by 
CMV Status. Categorical variables are described as frequencies and proportion 
percentages. Continuous variables normally distributed are summarised with their 
mean and 95% confidence interval, while continuous variables that did not reach 
normality are presented with their median and IQ range. P-values, obtained after 
performing the Chi-squared test (or Fisher’s exact test, if any expected value was 
smaller than 5), t-test (or Mann-Whitney U test, if data was not normally distributed) 
using IBM SPSS Statistical software version 22.0 (SPSS, Inc., Chicago, IL, USA) are 
used to examine for any statistically significant differences in the outcomes between 
the groups.  
All correlation assessments were determined using the Pearson correlation coefficient. 
A statistically significant difference was considered if the test P value was <0.05. The 
hierarchical clustering and heat maps were generated using Partek Genomic Suite 
Version 6.6 (Partek Inc., St. Louis, MO, USA) and all data were floored (i.e. 0 
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transformed to 0.01) and logged. ImageJ (Schneider et al., 2012) macros and Java 
plugins were written in-house and used to analyse image intensities and 
colocalisation. Output data from image analysis was further analysed using Microsoft 
Excel as required.  
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Chapter 3 : Effect of CMV on the circulating lymphocytes 
3.1 Introduction  
A variety of cell types and subtypes such as granulocytes, macrophages, dendritic 
cells, T cells, and B cells at different populations constitute an essential part of the 
immune system (Lu et al., 2015). In CMV infection, a large fraction of T cell 
subtypes has been reported to be committed to keeping the virus under checks thereby 
causing alterations in the dynamics of T-cell populations, which strongly influence T 
cell immunity (Gamadia et al., 2001). Although not much is known about the role of 
circulating T and NK cells in FL, but depending on the frequencies and location of the 
different intratumoral T cell populations in the GCs, the tumour immunity and patient 
outcome in FL is influenced both negatively and positively (Yang et al., 2015). 
Therefore, quantitation, defining and ascribing specific roles played by the diverse T 
cell populations, for instance in the immunity of different pathological conditions, 
will help in providing diagnostic and prognostic evidence for patient management in 
FL. Multicolour flow cytometry can be used to quantify different subtypes of T cells 
and other cell types. Different research evidence has explained the events leading to 
cellular differentiation, acquisition of effector potential and eventual death of T cells. 
Activation of immature CD4+ T cells has been reported to present a linear 
differentiation model, in which cells continuously acquire functional abilities by every 
additional differentiation step (Lanzavecchia and Sallusto, 2002). However, persistent 
antigenic provocation over time can result in a gradual decline of memory and 
cytokine secretion capacities, and consequently, accumulation of short-lived CD4+ T 
cells (TEMRA cells) with poor cytokine production ability. At this stage of 
differentiation, further antigenic assault on the CD4+ TEMRA cells can activate the 
CD4+ T cell causing apoptosis. On the other hand, two alternative patterns of 
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differentiation have been reported for the production of CD8+ TCM cells and CD8+ 
TEM cells: linear differentiation and fixed lineage (Seder et al., 2008, Kaech and 
Wherry, 2007). A continued antigenic challenge will lead to accumulation of CD8+ 
TEMRA cells and death similar to the CD4+ T cells pattern; however, CD8+ TEM 
cells have the ability to regain IL-2 expression and become CD8+ TCM cells unlike 
CD4+ TEM cells (Seder et al., 2008). NK cells are a subcategory of lymphocytes of the 
innate immune system that form about 10% of the circulating blood mononuclear 
cells in humans (Milush et al., 2009), they are usually described as CD3−CD56+ cells 
(Lanier et al., 1986a), and can be subgrouped by the intensity of CD56 on the cell 
surface. The distinct subtypes of  NK cells can be classified based on relative 
expression of CD56 and CD16 surface markers (Yang and Ansell, 2012a). The 
majority of circulating NK cells (about 90%) exhibit low expression for CD56 
(CD56dim) with high levels of CD16 and perforin and are described as terminally 
differentiated NK cells (Cooper et al., 2001a). NK cell development is characterised 
by the reduction in the expression of CD56 and the addition of CD16 expression. 
However, the presence of activated CD56dimCD16+ has been shown to represent the 
highest level of NK cell activation, which implies that CD56dimCD16+ cells 
represent the most mature NK cells subtype (Senpuku et al., 2016, Dulphy et al., 
2008, André et al., 2000).  
In this Chapter I therefore set out to evaluate the impact of CMV infection on 
circulating peripheral T and NK cell populations in FL patients.  
3.2 Patients and materials 
As described in section 2.6.6, the optimal working volumes of the 26 conjugated 
monoclonal antibodies were determined by staining cryopreserved PBMC samples 
from healthy volunteers (HV) using three different experimental volumes.  For the 
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FACS analysis, 42 stored pre-treatment PBMC samples from PACIFICO trial 
patients, comprising 21-CMV- positive and 21-CMV- negative were used. Aside the 
strict inclusion and exclusion criteria that applied in the recruitment of FL trial 
participants as stated in section 2.3, a careful selection of study patients based on 
balanced clinical and pathological baseline characteristics as in Table 3-1 between the 
CMV groups was adopted. This approach is aimed to minimise possible influence of 
confounders in the analysis and to enhance the chances of accurate evaluation of the 
biological effect of CMV infection status on FL.  
A summary of demographic and baseline characteristics of this study cohort are 
described in Table 3-1. CMV- positive patients are marginally older compared to 
CMV- negative with median age of 73 years versus 69 years (p=0.055). Patients' risk 
factors and the prognosis are stratified according to the Follicular Lymphoma 
International Prognostic Index (FLIPI) score into three risk categories: good (0 or 1), 
Intermediate (2) and poor (3-4). The FLIPI score is determined using five adverse 
prognostic factors including Ann Arbor stage (III-IV vs. I-II), age (> 60 years vs. ≤ 60 
years),  haemoglobin level (< 120 g/L vs. ≥ 120 g/L), number of nodal areas (> 4 vs. ≤ 
4), and serum LDH level (above normal vs normal or below) (Solal-Céligny et al., 
2004). A slightly higher proportion of CMV- positive patients are on the high risk 
grade compared to the CMV- negative (71% vs.67%). The Cumulative Illness Rating 
Scale (CIRS) is used for the physical assessment of impairment of patients under 13 
near independent areas.  It is a 5-point rating of the degree of severity scale that 
ranges from none (1) to extremely severe (5) (Linn et al., 1968). There is no 
significant difference in the proportion of patients in Table 3-1 due to CIRS. Also, as 
can be seen in Table 3-1, there is no significant difference in the clinicopathological 
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variables of patients included in the two arms of study cohorts, the CMV- positive and 
CMV- negative.  
Table 3-1: The comparison of baseline characteristics with CMV infection status 
of patients studied in this chapter and Chapter 4 
 
*For continuous variables this refers to the Mean (SD), or Median (IQR) if indicated 
**P value by x
2 test or Fisher’s exact test for the difference between categorical 
variables or t test for the difference between two means. 
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3.3 The conjugated monoclonal antibodies  
The list and description of the conjugated monoclonal antibodies (mAbs) used for the 
FACS analysis are found in Table 3-2. 
Table 3-2: The description and sources of the mAbs used for the FACS  
 
All mAbs were purchased from BD Bioscience, Oxford UK with exception of LAG-
3-FITC (Enzo Life Sciences, UK) and TIM-3-APC (R & D Systems, UK). On arrival, 
all mAbs were kept in the fridge and any reagent that expired in the course of time 
were removed and replaced with new vials of preferably similar batches and working 
volumes determined. 
3.4 Establishment of FACS method for the study  
The 3-tube multicolour FACS design illustrated in Figure 3-1 is aimed at defining the 
several T and NK cell subpopulations in the peripheral blood. Tube 1 contains 10 
conjugated mAbs listed in Figure 3-1 designed to analyse for senescent T cells 
(CD57+CD28-), NKT and NK  cells (CD56 & CD16) of the study cohort, as well as 
B cells (CD19+) and monocytes (CD14+) gated as controls. 
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Figure 3-1: Illustrating the 3-tube design and the respective panels of conjugated 
mAbs.  
The values in brackets represent the respective working volumes of the mAbs in 
microlitres. 
Tube 2 contains 12 mAbs and is dedicated to examining the frequencies of the 
different differentiation stages to T cells including the naïve (CD45RA+CD45RO-
CCR7+CD62L+), central memory (CD45RA-CD45RO+CCR7+CD62L+), effector 
memory (CD45RA-CD45RO+CCR7-CD62L-) and effector (CD45RA+CD45RO-
CCR7-CD62L-) T cells.  Terminally differentiated T cells (TEMRA) subtypes are 
also defined using CD27 and CD28 as well as those of regulatory T cells (Tregs) 
(CD4+CD25+). The tube 3, an 11 mAbs panel is committed to the analysis of T cell 
exhaustion markers including PD-1, LAG-3, and TIM-3.  
TUBE #1 TUBE #2 TUBE #3 
CD3-FITC (20) CD3-FITC (20) LAG-3-FITC (10) 
CD56-PERCP-CY5.5 (5) CD27-PERCP-CY5.5 (5) CD3-PERCP-CY5.5 (2.5) 
CD57-APC (10) CD62L-APC (20) TIM-3-APC (5) 
CD8-AF700 (2.5) CD8-AF700 (2.5) CD8-AF700 (2.5) 
CD4-APC-H7 (10) CD4-APC-H7 (10) CD4-APC-H7 (10) 
- CD197 (CCR7)-BV421 (10) CD43-BV421 (10) 
CD45-BV510 (5) CD45RA-BV510 (10) CD127-BV510 (5) 
- CD45RO-BV605 (2.5) CD62L-BV605 (10) 
CD19-BV650 (5) CD45-BV650 (10) CD45-BV650 (10) 
CD28-PE (20) CD28-PE (20) CD279 (PD-1)-PE (10) 
CD16-PE-CF594 (5) CD25-PE-CF594 (10) - 
CD14-PE-CY7 (5) CD11a-PE-CY7 (2.5) CD69-PE-CY7 (5) 
 
   
 
Senescent T cells              Naïve T cells Exhausted T Cells 
NKT cells Central Memory T (TCM) cells  
NK cells Effector Memory T TEM)  cells  
Monocytes Effector T cells       
B cells Regulatory T Cells (Tregs)  
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Due to variations in the availability of material and the number of gated T cells 
(CD3+), the number of events acquired per tube was between 100,000 and 2,000,000, 
with majority of samples yielding 500,000 events and above. Isotype controls and 
single stained fluorescence histograms were used to gate for cut-offs for distinct 
lymphocyte populations on Diva software platform using respective surface markers.  
The number of events, percent parent and percent total events of the various cell types 
and subtypes are automatically defined and displayed using FACSDiva software. 
Conventionally, this provides the needed values for measuring the percent of 
lymphocyte subpopulations within the lymphocyte gate. A comparative analysis of 
the median values of percent parent (relative) frequencies of the different lymphocyte 
subtypes according to the CMV status was carried out using a nonparametric Mann-
Whitney U-test analysis to determine the significant difference. A p-value of < 0.05 is 
considered significant. 
3.5 Results of T & NK cell subtypes  
The analysis of cell surface markers has been used to define the various lymphocyte 
populations in stored PBMC samples using multiparametric flow cytometry. Essential 
FACS optimisation steps aimed at minimising errors and generating reliable results 
and subsequent interpretations were strictly adopted. Of note, the right approach to 
FACS data analyses and presentation of the cell population of interest are as 
important as cells acquisition design. Before commencement of the FACS 
experiments, optimal working volumes of fluorochrome-conjugated antibodies were 
determined, contour and dot plots were evaluated against polygon and rectangle 
gating strategies respectively, gating strategies for the three FACS tubes were 
evaluated, and fresh versus frozen FACS assessed.  
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3.5.1 An assessment of gating Strategies  
Routinely, the dot or quantile contour plots are applied to display FACS data for 
gating and analysis. The contour plots have been shown to produce a more reliable 
data representation than dot plots by maintaining the contours in the quantile contour 
plots despite the number of observations displayed (Herzenberg et al., 2006, Tung et 
al., 2004). In dot plots, higher numbers of events tend to get the dot plots saturated 
resulting in difficulties in gating for the populations of interest for analysis (Tung et 
al., 2004). 
The assessment of gating Strategies is set to evaluate the possible impact of using 
different gating strategies and plots on FACSDiva Software (BD Biosciences, Oxford, 
UK) in the analysis of the various cell populations and the overall analysis of data. 
Common antibody markers included in the three FACS tubes including anti-CD45, -
CD3, -CD4 and -CD8 were considered for the assessment. A fresh PBMC from 
healthy volunteer sample coded 3457 was stained with the different monoclonal 
antibodies, and cells acquired using FACSDiva Software.  
The first two upper rows (A & B panels) in Figure 3-2 depicts rectangle and polygon 
gating strategies for CD45-BV510 (Amcyan channel on Fortessa), CD3-Alexa Fluor 
488, CD8-Alexa Fluor 700 and CD4-APC-Cy7 populations displayed on Contour 
plots. Interestingly, no pronounced difference in the percent population of the cells 
due to gating method observed. Similarly, the two lower rows (C & D panels) in 
Figure 3-2 illustrates rectangle and polygon gating strategies for CD45-BV510 
(Amcyan channel on Fotessa), CD3-Alexa Fluor 488, CD8-Alexa Fluor 700 and 
CD4-APC-Cy7 populations displayed on dot plots. Again, no noticeable difference in 
the percentage cell populations was observed between the two gating techniques. 
Also, no huge difference in the percentage expression of gated cell types across the 
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two categories of plots is observed. Consequently, this study has adopted the use of 
both contour and dot plots and has applied both rectangular and polygon gating 
strategies individually or in combination depending on the evaluation type and the 
nature of discreteness of the cell populations of interest. 
 
Figure 3-2:  Evaluating gating Strategies.  
Contour plots (A and B panels) and dot plots (C and D panels) against polygon gating 
and rectangle gating strategies for adoption in the analysis of data on Diva Software 
(BD Biosciences, Oxford, UK).  
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3.5.2 Illustrations of gating strategies for the FACS tubes  
In the FACS design, consideration was made for the analysis of the various T cell 
populations by purposefully incorporating CD45, CD3, CD4 and CD8 markers in all 
the three FACS tubes to define hierarchy and facilitate data analysis. In the gating 
strategy for T-cell subpopulations and subpopulations, the first thing was to display 
cells based on the forward scatter (FSC) for size and side scatter (SSC) for cell 
characteristics to identify the various cell populations present in the suspension.  In all 
the tubes, analysis commenced with the gating of CD45, being the leukocyte-common 
antigen (L-CA) and all the cells of interest possess CD45 surface marker. 
The percentage circulating T cells was determined using the membrane determinant 
CD3. Due to high chance of dual positivity for CD4 and CD8 subtypes of CD3 
surface markers, CD4-APC-Cy7 and CD8-Alexa Fluor 700 were identified and gated 
from the CD3 population independently on the FSC axis. Figure 3-3 demonstrates the 
gating strategy adopted for tube one, which is a 9-parameter, 10-colour FACS designs 
as defined by the hierarchical tree in Figure 3-4. Senescent CD4 and CD8 populations 
were defined by plotting CD57-APC versus CD28- PE and gating for CD57+CD28-. 
For NKT cells, CD56-PerCp-Cy5.5 versus CD16-PE-CF594 were gated from CD3-
FITC and NKT cells population (CD3+CD56+CD16+) was defined. NK cell 
subcategories were determined from the CD45-BV510 population by gating CD56-
PerCp-cY5.5 versus CD16-PE-CF594. This population is CD3-. Also, monocytes and 
B cells were also identified by gating for CD14-PE-Cy7 and CD19-BV650 from the 
CD45-BV510 respectively. 
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Figure 3-3: Gating Strategy adopted for tube 1 of FACS design.  
Contour plots and rectangular gates identify populations of interest. All cell markers 
were gated from CD45 AmCyan-A (highlighted blue) and the arrows indicate the 
origin of parent cells while the markers on the top of each plot represent the parent 
name. The markers of interest for each plot are labelled on the x-and y-axis.  
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The arrows show the direction of the gating. From the gating strategy in Figure 3-3 
and the hierarchy used in differentiating the various cells types as display in Figure 3-
4, gating began with the identification of CD45+ population in all the three tubes on 
the FACS design. In tube 1, four main populations were gated from the leukocyte 
common antigen (CD45) including CD3-Alexa Fluor-488 (T cells), CD14-PE-Cy7 
(Monocytes), CD19-Qdot-655 (B cells) and CD56-PerCP (NK cells). Other 
downstream cell populations that were subsequently gated from CD3+ populations 
include senescent T cells and NKT cell populations. Figure 3-4 illustrated the 
hierarchy through which different cell markers were used to identify the various cell 
types in the tube 1 of the FACS design. 
 
Figure 3-4:  A hierarchical procedure used for analysis of cell types tested in tube 
1.  
A PACIFICO trial stored PBMC sample (pac0108) was used for this illustration 
showing number of events (#Events), percent parent cell (%Parent) and percent total 
(%Total) as displayed on FACSDiva software.  
The contour plot gating approach adopted for tube 2 is shown in Figure 3-5, a 14-
parameter, 12-colour FACS design. It is planned to define Naïve (N), central memory 
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(CM), effector memory (EM), Effector (E) T cells and terminally differentiated 
(TEMRA) T cells plus regulatory T cells (Tregs) as can be seen in the cells hierarchal 
distinctions in Figure 3-6. In this design, CD45RA-BV510 and CD45RO-BV605 
were gated separately from CD4 and CD8 populations respectively due to the likely 
existence of double-positive CD45RA+CD45RO+ T cells (Sandberg et al., 2001). 
Broadly, this categorises CD4 and CD8 populations into Naïve and memory T cells, 
an important platform for further definitions of the subsets of T cells using 
appropriate markers. To further discriminate between CM and EM populations and 
between naïve and effector populations, CD197 (CCR7)-BV421, a chemokine 
receptor was gated from both CD45RA (naïve) and CD45RO (memory) of the CD4 
and CD8 arms respectively. At this point, naïve (CD45RA+CCR7+), effector 
(CD45RO+CCR7-), CM (CD45RO+CCR7+) and EM (CD45RO+CCR7-) 
populations for CD4 and CD8 are defined. To increase the specificity of naïve and 
CM cells and characterization of the subtypes of effector and EM T cells, CD11a a 
mediator of leukocyte adhesion, and the cell surface expression of CD27 and CD28, 
costimulatory molecules were used. Therefore, CD11a-PE-Cy7 was gated from the 
FSC axis of the CD45RA+CCR7+ plots for both CD4 and CD8 arms. To define and 
quantify naïve T cells, CD27-PerCp-Cy5.5 versus CD28-PE was gated from the 
CD11a population, and CD27+CD28+ events on the top right quadrants were used to 
define the N-CD4 and CD8 T cell populations respectively. The CM T cells 
(CD27+CD28+) were gated from the CD45RO+CCR7+ plots. Also, to identify and 
quantify the subtypes of effector and EM populations, CD27-PerCp-Cy5.5 versus 
CD28-PE was gated from both CD45RA+ and CD45RO+ plots. The quadrants of the 
contour plots defined the T cell subtypes as pE1 (CD27+CD28+), pE2 (CD27+CD28-
) and effector (CD27-CD28-) populations from the CD45RA+CCR7- of the CD4 and 
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CD8. In a similar approach, the subtypes of EM were defined by the number of events 
in the quadrants of the contour plots as EM1 (CD27+CD28+), EM2 (CD27+CD28-), 
EM3 (CD27-CD28-) and EM4 (CD27-CD28+). 
 
Figure 3-5:  Gating Strategies adopted for tube 2 of FACS design.  
Contour plots and rectangular gates identify populations of interest. All cell markers 
were gated from CD45 AmCyan-A (highlighted blue) and the arrows indicate the 
origin of parent cells while the markers on the top of each plot represent the parent 
name. The markers of interest for each plot are labelled on the x-and y-axis. 
 
As a multicolour design comprising of cell surface markers, we could not include 
FOXP3, a specific marker for regulatory T (Treg) cells (Roncarolo and Gregori, 2008) 
to avoid subjecting the majority of the markers to the additional fixing and 
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permeabilizing requirements for the intracellular markers. Therefore, CD25-PE-
CF594 was used to define the population of regulatory T cells (Tregs) gating from the 
FSC axis of the CD4+ plot as CD4+CD25+. 
 
 
Figure 3-6: An example of hierarchical analysis of different cell types in tube 2. 
A PACIFICO trial stored PBMC sample (pac0108) was used for this illustration 
showing number of events (#Events), percent parent cell (%Parent) and percent total 
(%Total) as displayed on FACSDiva software.  
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The tube 3 of the FACS design is a 6-parameter, 11– colour analysis of T cell markers 
of exhaustion and gating strategy is as outlined in Figure 3-7, while Figure 3-8 shows 
the main exhaustion markers analysed to include PD-1, LAG-3 and TIM-3 for both 
CD4+ and CD8+ arms. 
As part of T-cell subpopulations, gating for exhausted T cells commenced with the 
CD45+ populations through to CD4+ and CD8+ T cells as in Figure 3-7. CD43-
BV421 versus CD62L-BV605 was gated from the CD4+ and CD8+ contour plots; 
CD127-BV510 versus CD69-PE-Cy7 was gated from the CD43+CD62L+ population. 
Exhaustion markers CD279 (PD-1)-PE, LAG-3-FITC and TIM-3-APC were gated 
individually from the CD127+CD69+ plot for CD4 and CD8 arms. 
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Figure 3-7:  Gating Strategies for tube 3 of FACS design.  
Contour plots and rectangular gates identify populations of interest. All cell markers 
were gated from CD45 AmCyan-A (highlighted blue) and the arrows indicate the 
origin of parent cells while the markers on the top of each plot represent the parent 
name. The markers of interest for each plot are labelled on the x-and y-axis. 
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Figure 3-8: An example of hierarchical analysis of different cell types in tube 3. 
A PACIFICO trial stored PBMC sample (pac0108) was used for this illustration 
showing number of events (#Events), percent parent cell (%Parent) and percent total 
(%Total) as displayed on FACSDiva software 
3.5.3 Fresh versus frozen FACS analysis 
Because the PBMC samples used for this study were stored frozen at -80°C and for 
the purpose of possible clinical translational and interpretational relevance of the 
FACS data, it is crucial to evaluate the impact of freezing on PBMCs FACS analysis. 
Consequently, before the commencement of FACS analysis of the stored trial PBMC 
samples, a fresh sample was treated to mimic freeze-thaw experience and FACS 
analysis of the fresh, frozen and purified PBMCs were carried out to evaluate the 
effect of freeze-thaw on for the major subtypes of cells. 
As demonstrated in Figure 3-9, panel A represents tube 1 of the FACS design. There 
was no significant variation in the percent parent cells of the various cell 
subpopulations except NK cells that have shown a clear reduction in the frozen and 
purified cells as compared to the fresh cells. By implication, FACS analysis of NK 
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cells may yield a more representative data by using fresh PBMC samples compared to 
stored PBMC samples. However, in this study, analysis of NK cell subtypes was 
carried out using the recoverable amount of NK cells in the thawed stored trial PBMC 
samples. For the FACS data from panel B (Figure 3-9; tube 2) and panel C in Figure 
3-9 (Tube 3), minimal variations in the quantities of the cell types in the three phases 
of treated cell categories observed and importantly, all parameters are detectable in 
the frozen PBMCs as well as in the fresh samples. Therefore, all other parameters 
within the study design have been determined with an acceptable degree of 
confidence.  
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Figure 3-9: FACS comparison of fresh, frozen and purified PBMCs.   
Local Biobank samples were used to compare the FACs staining and cell populations 
using fresh whole blood (blue bars), fresh PBMCs (green) and frozen PBMCs (red). 
Panels A, B and C have followed the hierarchy of cell types in Tubes 1, 2 and 3 of the 
FACS design. 
108 
 
3.5.4 The lymphocyte subtypes 
Using the established flow cytometry method and analysis strategies, I successfully 
quantified relative percentages of T and NK cell populations from parent cells (as in 
Figures 3-4, 3-6 and 3-8) in samples taken from a cohort of patients with FL (see 
Table 3-3).  Mann-Whitney U-test was used to compare the relative proportions 
(median percentage) of the various cell types between CMV-positive and CMV-
negative groups. Of interest, statistically significant elevation in the frequencies of 
pre-effector-2 CD4 (pE2-CD4; CD45RA+CD27+CCR7-CD28-), effector-CD4 (E-
CD4; CD45RA+CD27-CCR7-CD28-), effector memory-3 CD4 ( EM3-CD4; 
CD45RO+CD27-CCR7-CD28-), effector-CD8 (E-CD8; CD45RA+CD27-CCR7-
CD28-) and effector memory-3-CD8 (EM3-CD8; CD45RO+CD27-CCR7-CD28-) 
phenotypes were observed in CMV- positive compared to CMV-negative patients as 
shown in Table 3-3. The most striking common features of these T cell subcategories 
is the loss of CD28 and CCR7 (CD28-CCR7-) surface markers. The subtypes of 
effector cells express CD45RA+ isoform; those of the effector memory cells express 
CD45RO+.  
Also, looking at the results in Table 3-3, a statistically significant increase in the 
frequency of NKT cells (p=0.031) was detected among CMV-positive patients 
compared to CMV- negative cohort.  However, NKT cells are known to perform both 
protective and destructive consequences due to their abilities to produce cytokines 
that support either inflammatory responses or immune tolerance. 
Marginal differences were observed in the percentages of CD4+ T cells and CD4-
LAG3 subpopulations (p=0.051 and p=0.074; Table 3-3) due to CMV status. Also, a 
marginal difference is observed in the ratio of CD4+ and CD8+ T cell populations 
between CMV- Positive and CMV- negative groups (1.2 vs. 1.5, p=0.054; Table 3-3).  
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Table 3-3: The comparison of cell subtypes between patients with and without 
CMV infection 
 
The table shows median relative percentages of cells types as determined from the 
parent populations in the hierarchical procedure in Figures 3-4, 3-6 and 3-8. The cell 
markers analysed include CD4, CD8, the ratio of CD4 to CD8 (CD4: CD8), senescent 
CD4 (Snt-CD4), CD8 (Snt-CD8), natural killer T cells (NKT cells), monocytes, B 
cells, Naïve CD4 (N-CD4), pre-effector - 1 CD4 (pE1-CD4), pre-effector - 2 CD4 
(pE2-CD4), effector CD4 (E-CD4), central memory CD4 (CM-CD4), effector 
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memory -1 - CD4 (EM1-CD4), effector memory -2 - CD4 (EM2-CD4), effector 
memory -3 - CD4 (EM3-CD4), effector memory -4 - CD4 (EM4-CD4), regulatory T 
cells (Tregs), naïve CD8 (N-CD8), pre-effector - 1 CD8 (pE1-CD8), pre-effector - 2 
CD8 (pE2-CD8), effector CD8 (E-CD8), central memory CD8 (CM-CD8), effector 
memory -1 - CD8 (EM1-CD8), effector memory -2 - CD8 (EM2-CD8), effector 
memory -3 - CD8 (EM3-CD8), effector memory -4 - CD8 (EM4-CD8), Programmed 
cell death protein- 1 CD4 (PD1-CD4), PD1-CD8, Lymphocyte-activation gene -3 
CD4 (LAG3-CD4), Lymphocyte-activation gene -3 CD8 (LAG3-CD8), T-cell 
immunoglobulin and mucin-domain containing-3 CD4 (TIM3-CD4), T-cell 
immunoglobulin and mucin-domain containing-3 CD8 (TIM3-CD8), natural killer 
cells (CD56+/CD16+ and CD56+/CD16-). 
The CD4+ T cells have shown a reduced frequency in the CMV- positive FL patients 
compared to CMV- negative group. Notably, CD4+ T cells alongside CD8+T cells 
forms the bulk of T-lymphocytes. The CD4⁺T cells are critical in attaining a 
coordinated, efficient immune response to pathogenic agents. Following activation, 
CD4+T cells differentiate into distinct effector subtypes that participate actively in 
mediating immune response by secreting distinct cytokines and partake in many 
functions.  The functional activities of CD4+ T cells cover from the activation of the 
cells of the natural immune system, B-lymphocytes, cytotoxic T cells, as well as 
nonimmune cells, and also play a crucial part in the elimination of immune response. 
Although no striking observation is made on the values of exhaustion surface markers 
analysed, higher expression values of CD4+ and CD8+ PD-1, LAG-3 and TIM-3 
(Table 3-3) phenotypes are seen among CMV- positive cohort compared to CMV- 
negative arm. The CMV-negative group presents a marginal increase in the median 
value of CD4: CD8 ratio of 1.5 against 1.1 of CMV- positive FL patients.  
Also, no significant difference in quantities is observed of senescent CD4+ and CD8+ 
T cells in the study population. However, the CMV-positive patients show an 
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increased expression trend for both senescent CD4+ and senescent CD8+ T cell 
populations compared to the negative FL patients.   
 
Figure 3-10:  Boxplots of end-stage T cell subtypes and NKT cells that show 
significant difference between CMV-positive and -negative patients. 
3.6 Discussions  
The FACS analysis of the stored PBMC samples of patients have revealed elevated 
quantities of subtypes of end-stage terminally differentiated (TEMRA) T cells from 
both the CD4+ and CD8+ T cell compartments as well as NKT cells in the CMV-
positive patients compared to the CMV- negative group. In details, these data show 
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that pre-effector-2 (pE2) (CD45RA+CD27+CCR7-CD28-), effector 
(CD45RA+CD27-CCR7-CD28-) and effector memory-3 (EM3) (CD45RO+CD27-
CCR7-CD28-) subtypes of  the CD4+ T cell compartment, as well as effector 
(CD45RA+CD27-CCR7-CD28-) and effector memory-3 (EM3) (CD45RO+CD27-
CCR7-CD28-) phenotypes of the CD8+ T cell compartment  accumulated more in the 
CMV-positive patients. Phenotypically, the terminally nonproliferating effector T cell 
subsets usually lack the costimulatory receptors CD27 and CD28 as well as lymph 
node homing receptors CCR7 and CD62L on the cells surface,  and are variously 
referred to as TEMRA, CD45RA+ memory, terminally differentiated (TTD) or end-
stage or persisting effector T cells (Pawelec et al., 2005). As a result, these cells are 
characterised by diminished long-term memory potential, limited effector function 
and poor cytokine production resulting in impaired immune functions capable of 
causing increased vulnerability to infections (Wherry, 2011, Rothe et al., 2016).  
CD4+ and CD8+T cells constitute the majority of the T-lymphocytes in the peripheral 
blood. Both of which possesses specific T cell receptors for efficient adaptive 
immunological responses. The high accumulation of nonproliferating versions of 
these cells portends immune deficits for the patients. Moreover, effector T cells that 
display TEMRA phenotypes have been reported to demonstrate senescence and end-
stage differentiation and are found eminently increased in both CD4+ and CD8+ T 
cell arms, especially in association with ageing and CMV infection (Derhovanessian 
et al., 2011, Koch et al., 2008a). A close look at the differentiation phases of T cells in 
Figure 3-11 identifies terminal effector T cells (TEMRA) as the most differentiated 
subtype of memory T cells, which are known to be extremely susceptible to apoptosis 
and display high levels of perforin and Fas ligand (cytotoxic molecules) (Woodbury, 
1996).  
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Figure 3-11: Illustrations of distinct and developmental phases of effector and 
memory T‑cells.  
Reproduced with permission from (Seder et al., 2008) and copyright clearance center. 
 
Although higher proportion of NKT cells is observed in the CMV-positive FL 
patients, a functional analysis of these cells would be required to help in assessing the 
functional potential of the high frequency cells in FL. However, NKT cells are known 
to share properties of both NK cells and T cells. They act rapidly to stimuli, a 
characteristic of the innate arm of the immunity, and can produce cytokines such as 
IL-2, IFN-γ, TNF-α, and IL-4 typical of adaptive immunity to promote or suppress 
different immune responses (Liao et al., 2013). Of interest, the NKT cells have been 
shown to play a role in tumour immunity. Particularly, it has been demonstrated that 
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poor IFN-γ production due to defective NKT cells was observed in patients with 
progressive malignant multiple myeloma but not in non-progressive myeloma or 
premalignant gammopathy (Terabe and Berzofsky, 2008, Dhodapkar et al., 2003). 
Furthermore, an analysis of peripheral blood has reported a statistically significant 
reduction in the quantities of NKT cells in patients with some solid tumours in 
relation to healthy persons (Terabe and Berzofsky, 2008, Giaccone et al., 2002).  
Also, decreased production of  IFN-γ or proliferation by type I NKT cells associated 
with cancer patients, and low circulating levels of type I NKT cells was an 
independent predictor of poor O/S and DFS in patients with head and neck squamous 
cell carcinoma (Molling et al., 2007). Conversely, the type II NKT cells mediates a 
regulatory opposite role in tumour immunity, for instance, activation of type II NKT 
cells by sulfatide enhanced tumour burden. But because we did not stratify the NKT 
cells into its subtypes, it is not possible to conclude which subtype of NKT cells is 
elevated in the CMV-positive FL patients and what impact of such increase on 
clinical outcome of these patients.  However, drawing from the functional profile of 
NKT cells, it is also sensible to infer that the CMV-positive FL will either suffer more 
recurrent infections and AEs as well as poor response to therapies. It is also suggested 
that the increase in NKT cells in CMV- positive cases might be a compensatory 
response to the reduction in adaptive immunity resulting from reduced CD4+ T cells 
and accumulation of exhausted T cells reported in Table 3-3. 
Conversely, although marginally significant, CMV-positive patients are associated 
with decreased CD4+T cells (p=0.051, Table 3-3) were associated with CMV-
negative FL patients compared to the CMV-positive group. Of note, CD4+ T helper 
(TH) and cytotoxic CD8+ T lymphocytes (CTL) constitute the bulk of T-lymphocytes. 
Importantly, CD4+ T cells which comprise of different lineages elicit immune 
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responses via the production of distinct cytokines and are capable of performing 
multiple functions including activation of a host of immune and non-immune cells 
such as B-lymphocytes and cytotoxic CD8+ T cells. In this regard, the CMV- 
negative FL patients possibly have some immunologic advantage over the CMV-
positive patients. Furthermore, although there is no significant difference in the 
quantities of the Naïve-CD4+ and -CD8+ T cell phenotypes due to CMV status, the 
CMV- negative patient have shown a trend of higher median values for both naïve 
CD4+ and CD8+ T cells compared to the CMV- positive group (Table 3-3). It is 
important to mention that having sufficient quantities of naïve T cells provide a more 
virile response and protection against infections by novel pathogens (Pennock et al., 
2013).  
The multicolour flow cytometric analysis employed by the current study seems to 
demonstrate for the first time an analysis of a large number of subpopulations of T 
cells in FL, especially in relation to CMV infection. However, to secure a clear-cut 
interpretation of flow cytometric analysis of circulating lymphocyte subtypes, a 
functional analysis of the various T cell subsets is suggested. In the meantime, an 
exploratory analysis relating the quantities of the cell types to clinical data, involving 
treatment response status and toxicities records of the trial patients will help in 
providing a further understanding of the clinical implications of findings (see Chapter 
7). Also, it is well known fact that in a deliberate effort to keep the CMV under 
checks, the immune profile of a latent CMV-infected individual is adversely affected, 
particularly leading to an expanded population of CMV-specific memory CD8+ T 
cells, in a memory inflation phenomenon (Klenerman and Oxenius, 2016). 
Unfortunately, it was not within the scope of this study to investigate this important 
116 
 
hallmark of CMV infection by evaluating for CMV-specific T cells and functional 
study to provide further support to findings.  
Although not much has been reported on CD4 TEMRA cells, the phenomenon of 
expanded end stage T cells in the peripheral blood has been reported by researchers in 
relation to other clinical conditions. For instance, a study by Reinke et al has reported 
a significant correlation between elevated levels of end stage CD8 (+) effector 
memory T (TEMRA) cells in peripheral blood with delayed fracture healing (Reinke 
et al., 2013). Their study has provided a clear illustration of the role of T cells in 
modulating endogenous bone fracture repair even in the absence of infection. Another 
study that employed Cox regression model reported a 2-fold higher risk of late graft 
dysfunction among kidney transplant recipients who had increased levels of 
differentiated TEMRA CD8+ T cells before transplantation (Yap et al., 2014). Also, 
an increased accumulation of terminally differentiated CD8 T cells (TEMRA) has 
been reported in chronic graft-versus-host disease (cGVHD) as a consequence of 
continuous differentiation from naïve/central memory T cells to TEMRA cells 
following prolonged alloantigen exposure (D'Asaro et al., 2006). However, a study 
that also determined the frequency of subtypes of peripheral T-cells including CD8 
TEMRA cells before kidney transplantation showed that advanced end-stage renal 
disease (ESRD) related with T-cell dysregulation is associated with a relative 
expansion of CD8 TEMRA cells guards against the acute rejection of kidney 
allografts (Betjes et al., 2012). Elevated percentages and absolute numbers of 
TEMRA cells in the subsets of CD4 and CD8 T that express CD26 were observed in 
type 1 diabetes and the number of TEMRA cells associated positively with indices of 
intermediate and long-term glycaemic control (Matteucci et al., 2011). The significant 
accumulation of TEMRA T cells in type 1 diabetes patients is thought to be caused by 
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a long-term and sustained antigenic stimulation consequent to a prolonged 
presentation of viral or other antigenic particles or could be a homeostatic deficit in 
the regulation/contraction of immunological responses. 
Judging from the significant accumulation of end-stage T cells and high amount of 
senescence and exhausted T cells in the CMV-positive patients, one may speculate 
that the presence of CMV infection in FL patients is capable of altering the immune 
dynamics of patients. These findings support the hypothesis that CMV infection 
results in perturbation of the immune system in FL in a way that might increase the 
risk of infection, and this question is examined directly in Chapter 6. 
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Chapter 4 : Effect of CMV infection on Serum cytokines 
4.1 Introduction 
Immune cells in both the tumour microenvironment and in the peripheral circulation 
are known to secrete cytokines that perform critical roles in the control of 
fundamental pathways of the immune system (Labidi et al., 2010).  The cytokine 
types and quantities may reveal some fundamental biological developments involving 
tumour–host interplays (Pedersen et al., 2005). Cytokines are incriminated in the 
pathogenesis of various lymphomas. For instance, elevated frequencies of several 
cytokines and angiogenic factors have been documented as biomarkers for utility in 
the diagnosis and prognosis of Hodgkin and NHLs (Casasnovas et al., 2007, Pedersen 
et al., 2005, Salven et al., 2000).  
In this perspective,  high serum quantities of VEGF and FGF-basic at diagnosis have 
been associated with poor outcome in NHL (Salven et al., 1997). Also, low baseline 
serum IL-6 and VEGF levels have been related to a good response rate and overall 
survival in NHL patients (Pedersen et al., 2005). This has been further echoed by a 
significant reduction  of the serum IL-6 and VEGF in NHL patients that achieved CR 
following CHOP treatment(Pedersen et al., 2005). 
Since CMV infection has been shown to elevate end-stage T cell subtypes in patients 
with FL as found in Chapter 3, cytokines produced by those cells or other cell types 
may reflect functions and regulations of those T cells in FL.  CMV infection, 
therefore, may alter the cytokine profiles in the serum of patients with this disease.   
However, there is still a lack of sufficient experimental evidence for such a 
hypothesis.   Thus, this chapter aimed to address this hypothesis with the analysis of 
27 serum cytokines secreted mainly by T cells and other cells in patients with and 
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without CMV infection before the commencement of trial treatment. To achieve this, 
I applied the Luminex technique to measure those cytokines quantitatively. This 
technique was used because a profoundly sensitive readout of the bulk of cytokines is 
achievable with a tiny amount of the sample.  Also, Luminex technology allows for 
simultaneous measurement of multiple proteins (cytokines), thereby reduce sample 
handling, for instance, the freezing/thawing cycles as well as decreased processing 
time (Ellington et al., 2009). Although Multiplex assay is comparable with other 
immunoassays (Dias et al., 2005, Wang et al., 2005), some of the problems that may 
be encountered with introducing multiplex assays in routine clinical use in 
comparison with the single-plex platforms such as sELISA may include the 
determination of the optimum working sample dilution that can cut across the 
spectrum of all analytes being measured and the freezing-thawing stability across 
analytes (Jani et al., 2016). As these challenges further increase the complexity of 
validating the performance of the Multiplex assay for its intended use, this study was 
planned to examine the agreement between Luminex assay and sELISA technique in 
order to examine the quality of the cytokine data generated from Luminex as well as 
to evaluate the impact of freeze-thaw cycles on the sELISA results of serum 
cytokines. The outcomes of these experiments will inform whether results of cytokine 
data generated using either of the techniques can be reliably used for cytokine 
analysis in the routine clinical patient care. 
4.2 Laboratory Approaches & Reagents 
As stated above, the Bio-Plex Pro Human Cytokine 27-plex Assay (Luminex, Bio-
Rad Laboratories Ltd, Hertfordshire, UK)) platform was used to measure the 
expression levels of serum cytokines of the FL patients used in the FACS analysis in 
Chapter 3. The 27 cytokines determined before the treatment in serum samples of 42 
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FL patients comprising of 21 CMV- positive and 21 CMV- negative are listed in 
Table 4-1. The choice of the 27-plex was based on the availability of commercial kits 
for the evaluation of the right blend of cytokines and mediators that spans across TH1 
(IL-12, IL-15, INF-γ, TGF-β) and TH2 (IL-4, IL-5, IL-10, IL-13) cytokine types based 
on their sources (Ellyard et al., 2007, Cui and Florholmen, 2008, Kantola et al., 2012). 
By function, the test kit has proinflammatory cytokines such as IL-6, IL-8, IL-17, and 
GM-CSF, anti-inflammatory for instance IL-4, IL-10, IL-13, IL-1ra; as well as 
haematopoietic growth factors (GM-CSF, G-CSF) and chemoattractants (IL-8, MIP-
1α, and MIP-1β).  Included in the assay kits are 96-well microplates, coupled 
magnetic beads, detection antibodies, standards, Bio-Plex Pro™ Streptavidin-PE 
reagents, and diluents for the detection of 27 human cytokines (refer to section 2.1). 
The two patient groups were carefully selected to ensure that any difference observed 
in the results between CMV- negative and CMV- positive groups would be not 
attributable to differences in their baseline clinical and pathological characteristics. 
Experiments were performed in the GCLP Facility owing to the legal requirement for 
trial samples to be processed and analysed to stringent criteria. To adjust the cytokine 
concentrations in samples within the range required for the test, 50μl of each serum 
sample were diluted with 150μl of sample diluent according to pre-optimised working 
condition in the GCLP laboratory. For the validation exercise, PeproTech sandwich 
ELISA Development Kits (EDK) containing essential components for the quantitative 
measurement of human cytokines in a sandwich ELISA format was used (refer to 
section 2.6.2). To evaluate the impact of freezing and thawing on serum sample 
sELISA results, we undertook sELISA analyses of IL-4, IL-6, IL-8 and IL-9 using 
respective serum samples from healthy volunteers that were previously subjected to a 
planned thawing and freezing cycles 1 to 3. Furthermore, to evaluate the agreement 
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between Luminex and sELISA techniques for the quantification cytokine levels in 
serum samples, serum IL-9 concentrations of the 42 trial tested with Luminex assay 
were analysed with sELISA and evaluated using Pearson's correlation coefficient (r). 
4.3 The results  
In this section, the serum cytokine data generated from the Multiplex assay, the data 
on the impact of thawing and freezing of serum samples using sELISA and the results 
of correlational analysis between serum IL-9 values determined by Luminex and 
sELISA are presented.  The median and the interquartile range (IQR) values of serum 
cytokines (in pg/ml) are presented according to CMV status as shown in Table 4-1. 
Boxplots in Figures 4-1 and the heat map representations in Figures 4-2 to Figure 4-5 
are displayed with p-values and hierarchical clustering respectively to enhance the 
visibility of the data. Also, a statistical Table 4-2 that demonstrates the relationship 
between groups expressing high and low levels of cytokines taken from the heat map 
and the baseline clinical features is presented. 
The data on the thawing and freezing of serum samples on the results of sELISA is 
presented in section 4.3.2 (Bar charts in Figure 4-6) while the data on the correlation 
between serum IL-9 reports determined by Luminex method and sELISA technique is 
presented in Section 4.3.3 (Figure 4-7). 
4.3.1The cytokine expression profiles in CMV- negative and CMV- positive patients with 
FL 
Levels of the 27 cytokines were measured in baseline serum samples from 21 CMV- 
negative and 21 CMV- positive patients. The clinical and pathological characteristics 
of patients selected for the study are outlined in Table 3-1 of Chapter 3, and showed 
no statistical differences between the two cohorts.   
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To understand whether the differences between the two cohorts presented in Table 4-1 
were statistically significant, Mann-Whitney U-test using SPSS version 20.0 (SPSS, 
Inc., Chicago, IL, USA) was used for comparison. Overall, the serum levels of 10 out 
of the 27 cytokines appeared to be different between CMV- negative and CMV- 
positive FL patients. Among them, IL-17A, IL-9, IL-8, IL-6, MIP-1α, MIP-1β and 
FGF-basic were significantly different with a two-sided P value ranging from 0.01 to 
0.04. The remaining IL-4, GM-CSF and IL-1β also showed a trend of difference 
although the P values (0.06  0.07) were slightly bigger than the pre-set  level.  
Interestingly, levels of all of the 10 cytokines decreased in the CMV- positive cohort 
compared to those from the CMV- negative population as shown in Figure 4-1. To 
show a general picture of relative levels of the 27 cytokines studied, we compared the 
mean rank of each cytokine level in CMV-positive group to that of the CMV-
negative.  Surprisingly, as shown in Figure 4.2, the levels of all cytokines except IP-
10 reduced (by 4 – 40%) in the former cohort, with the most profound reduction (by 
31% to 40%) observed in the 7 with statistical significance following by that in the 3 
borderline different cytokines (by around 28%).   
This negative association is easily visualised even in an unsupervised cluster analysis 
shown in Figure 4-4. We undertook a hierarchical clustering analysis of the cytokine 
data. Firstly, the unsupervised clustering analysis of the data revealed a variable 
cytokine expression among these 42 patients (data not shown).  In a subsequent 
supervised clustering analysis, the differences in the cytokine expression profile 
between the two cohorts of patients became clear as presented in the heat map shown 
in Figure 4-3. In a further analysis of this unsupervised data, the proportion of CMV- 
positive patients was found much higher than those with CMV- negative in patient 
group showing low levels of the 10 cytokines. This was statistically confirmed in 2 
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test, no matter the comparison was performed between cases with the lowest and 
highest cytokine levels (p = 0.008) when all the 42 cases were equally divided into 
three groups, or with low and high levels (p = 0.031) when they were equally divided 
into two groups according to the expression levels (Figure 4-5). Importantly, such a 
difference was not associated with clinical and laboratory characteristics (including 
age, Hb level, level of blood LDH and number of enlarged lymph nodes) of patients 
as summarised in Table 4-2.  
Regarding expression level of individual cytokines, the median serum IL-9 in the 
CMV- positive  cohort was decreased from 42.6pg/ml to 22.2pg/ml (p = 0.006), IL-
17A from 43.9pg/ml to 23.0pg/ml (p = 0.020), FGF-basic from 72.3pg/ml to 
55.9pg/ml (p = 0.028), MIP-1α from 10.1pg/ml to 7.4pg/ml (p = 0.039), MIP-1β from 
294.4pg/ml to 225.0pg/ml (p = 0.029), IL-6 from 19.6pg/ml to 11.5pg/ml (p = 0.029) 
and IL-8 from 534.2pg/ml to 168.9pg/ml (p = 0.037) as compared to the other cohort.  
Also, decreases in the levels of IL-1β from 4.0pg/ml to 3.3pg/ml (p = 0.068), IL-4 
from 5.1pg/ml to 4.2pg/ml (p = 0.066) and GM-CSF from 72.9pg/ml to 37.6pg/ml (p 
= 0.070) were also observed among those exposed to CMV infection compared the 
CMV- negative population, despite of the marginal significance.  There were no 
statistical differences in levels of other 17 cytokines, although all of them except  IP-
10, IL-12 and MCP-1(MCAF) showed the same changes as the 10 with or nearly with 
statistical significance in CMV- positive patients (Table 4-1).  
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Table 4-1: Cytokine levels (pg/ml) in serum samples of FL patients in CMV- 
positive and negative patients with FL  
 
Comparison of median cytokine levels of CMV- positive and CMV-negative groups. 
P< 0.05 is considered statistically significant.  
IQ R = Interquartile Range 
125 
 
 
 
Figure 4-1: The box plot/whiskers graphs of concentrations of 10 cytokines 
measured using the Luminex method that shows significant difference between 
CMV- positive (n=21) and CMV- negative (n=21) FL patients.  
The P-values were from the two-sided Mann-Whitley U test. 
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Figure 4-2: The relative changes in cytokine levels in patients with CMV 
infection as compared to those without infection by this virus.  
The mean rank of concentration of each of the 27 serum cytokines in the 21 CMV- 
positive patients are compared to that in the 21 CMV-negative cases (set as 0).  The 
expression of cytokines marked by * was significantly different (P<0.05), and those 
by ** board-line different (P=0.0660.070) between the two groups of patients.     
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Figure 4-3: The unsupervised heat maps showing expression levels of the 10 
cytokines with statistically differential expression between the two groups in 42 
patients. 
In the heat map in Figure 4-3, cytokine data was log transformed to 0.01 and cytokine 
expression was scaled from the minimum level (-3.90) in green and maximum level 
(3.90) in red. Patients were coded red for CMV- positive and blue for CMV- negative.  
The hierarchical clustering of the ten cytokines of interest versus the 42 FL patients 
has grouped cytokines according to their functional combinations of chemokines (IL-
8, MIP-1α, & MIP-1β) and IL-1β, TH2 cytokines (IL-4, IL-6 and IL-9), TH17 (IL-
17A) and Vascular remodelling (FGF-basic & GM-CSF). 
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Figure 4-4: The supervised heat map showing levels of the 27 cytokines 
measured using the Luminex method between CMV- positive and CMV- 
negative groups in the 42 patients. 
Cytokine data was log transformed to 0.01 and cytokine expression was scaled from 
the minimum level in green and maximum level in red. The CMV- positive and 
CMV- negative patients are under the red and blue bars, respectively.  
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Figure 4-5: The heat maps of 42 patients versus 10 cytokines grouped patients 
according to expression levels of cytokines.  
The middle line on the unsupervised heat map in Figure 4-5 separates patients into 
two halves of 21 each. The left half can be seen to be dominated by red map, 
signifying high levels of cytokine expression and comprises of 7 CMV- positive 
patients against 14 CMV-negative. Green map for low levels of cytokines dominates 
the right half and consists of 14 CMV- positive and 7 CMV- negative patients. The 
Chi-square test revealed a difference (p =0.031)) in the cytokine expression between 
the left (high expression) and right (low expression) halves. Also, Chi-square test 
comparing the first 14 and the last 14 patients on the heat map revealed a statistical 
difference (p = 0.008). This finding shows that there is a statistical difference between 
the levels of cytokine expressed by 14 patients on the extreme left and the 14 on the 
right-wing extreme of the heat map. 
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Table 4-2: Cytokines in heat map and clinical features 
  
 
4.3.2 The effect of Sample Thawing/Freezing Cycles on sELISA Results  
In order to validate results from the Luminex test with an alternative method sELISA, 
some of these 42 serum samples had to be repeatedly frozen and thawed as no 
aliquots were stored initially.  To learn whether the number of cycles of such 
thawing/freezing affect results of the cytokine measurement, we collected serum 
samples from four healthy donors and stored them in 3 aliquots at -80
o
C for 3 days 
per cycle of thawing/freezing.  After experiencing 1, 2 and 3 cycles, the serum 
aliquots from donors 1, 2, 3 and 4 were used for testing concentrations of IL-4, IL-6, 
IL-8 and IL-9, respectively.   Surprisingly, the results changed with the cycle number 
of thawing/freezing increased. The concentration measured for IL-4 and IL-9 became 
higher after each cycle.  Thus, after the 3
rd
 cycle, it was 4.6 and 1.5 folds in samples 
measured for IL-4 and IL-9, respectively, as compared to that in the sample 
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experienced only one cycle (Figure 4-6: A and D). The value of IL-8 was also bigger 
after 2 cycles (1.3 folds), but with no further increase after the 3
rd
 cycle (Figure 4-6: 
C). However, the concentration of IL-6 was reduced by 16% from 3438pg/ml to 
2904pg/ml (Figure 4-6: B). These results suggested that the repeated thawing and 
freezing for serum samples changed measurement values of these cytokines, with an 
increase in most cases. The reasons for increased in the values of these cytokines 
following repeated thawing and freezing have not been investigated. 
 
Figure 4-6:  Cytokine levels measured with sELISA in serum samples after 
different cycles of thawing/ freezing.  
Aliquots of serum samples from 4 healthy donors were subjected to experience of 1, 
2, and 3 cycles cryopreserving storage.  Each aliquot of donors 1, 2, 3, and 4 were 
then used for detecting IL-4 (A), IL-6 (B), IL-8 (C) and IL-9 (D), respectively, in 
sELISA experiments. 
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4.3.3 A positive correlation between IL-9 concentrations measured with Luminex and 
sELISA 
The alternations of cytokine measurement by sELISA in serum samples experienced 
different cycles of thawing and freezing hampered the use of such type of samples for 
validation of cytokine results from the Luminex experiment.  However, the results 
shown in Figure 4-6D suggested that such changes for IL-9 were relatively small and 
consistent with increase in the cycle number.  This implied a possible correlation 
existing between concentrations of this cytokine measured by the two methods, if the 
Luminex results were reliable.  We therefore used the serum samples from all of the 
42 patients after the 3
rd
 cycle of storage to measure IL-9 with sELISA and then 
compared the results with those previously measured with the Luminex.  
As shown in Figure 4-7, the Pearson’s correlation analysis revealed a positive linear 
correlation existing between the two methods, although not perfect (r = 0.374, p = 
0.015).  Expectedly, the average concentration of the cytokine measured by sELISA 
was over 7 folds of that as measured by the Luminex (280pg/ml versus 36pg/ml).  
This might partially be explained by the effects of repeated sample freezing and 
thawing as noticed in our previous experiment (Section 4.3.2).  Those results 
suggested that the relative cytokine levels in patients of this cohort as presented in 
Table 4-4 were consistent with the results of the sELISA experiment, and therefore 
reliable.  
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Figure 4-7: A positive correlation between the Luminex and sELISA in 
measuring IL-9 concentrations in patient serum samples. 
The concentrations of IL-9 measured with the Luminex (Y axis) and sELISA (X axis) 
in all of the 42 patients studied in this chapter are compared in the two-sided 
Pearson’s correlation analysis.  Note that the serum samples used for the sELISA test 
experienced two more cycles of thawing/freezing than those for the Luminex test.   
4.4 Correlation Analysis of cytokines and cell subtypes 
This section presents a correlational analysis of results of the lymphocytes obtained in 
Chapter 3 and cytokines detected with the Luminex in this Chapter. The analysis was 
expected to provide an indirect approach to assessing the functional potential of the 
quantitative T and NKT cells data in Chapter 3 with regards to cytokine production. It 
is also hoped that the correlation analysis will provide an insight into the relationship 
between the lymphocyte subtypes and specific cytokines. In addition, the 
measurement of both lymphocytes and cytokines provides an opportunity for cross-
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validation between the two Chapters to increase confidence that the results of both 
Chapters are trustworthy. 
The graphical representation of Spearman’s correlation coefficient matrix for 
cytokines and FACS data is presented in Figure 4-8. The legend on the right side 
summarises the colour meaning: the blue shades are used for positive correlation and 
the red shades for the negative correlation. The more the variables are correlated; the 
more is the intensity of the colour. The results do not show a high correlation between 
cytokines and the T and NKT cells. However, all the 10 cytokines seem to be 
positively correlated among themselves, especially between FGF-basic with IL-17A (r 
= 0.969, p < 0.001) and between IL-9 with IL-17A (r = 0.916, p < 0.001). 
Furthermore, positive correlations exists among some cell types, especially between 
E-CD4 with EM3-CD4   (r = 0.872, p < 0.001) and between E-CD8 with EM3-CD8 (r 
= 0.899, p < 0.001) cell subtypes. Differently from the cytokines, that show only 
positive correlation among themselves, some cell types seem to correlate negatively 
with others, as between CD4 with EM3-CD8 (r = -0.672, p=0.003) and between CD4 
with E-CD8 (r = -0.631, p=0.009). 
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Figure 4-8: A matrix of correlation coefficients between cell types and cytokines.  
Correlation coefficients were calculated in the Spearman’s correlation analysis and 
presented in heating colours.   
4.5 Discussions 
Being that T cells are known to be the major source of cytokines, a quantitative 
analysis of pre-treatment serum cytokine levels of the PACIFICO trial patient samples 
was carried out as a strategy to evaluate the functional potential of the elevated 
terminally differentiated T cell subtypes observed in the CMV- positive FL patients in 
Chapter 3.  
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Strikingly, Luminex data reveal decreased levels of all the 27 serum cytokines studied 
among the CMV- positive FL patients compared to the CMV- negative patients, 
except for IP-10, IL-12 and MCP-1(MCAF). As depicted in Figure 4-1, significantly 
diminished levels of serum IL-9, IL-17A, FGF-basic, MIP-1α, MIP-1β, IL-6 and IL-8 
were observed in the CMV- positive group compared to the CMV- negative 
counterparts (P < 0.05). Also, marginally significant inferior median quantities of IL-
1β, IL-4 and GM-CSF are seen in the CMV-positive compared to the CMV- negative 
(P = 0.066  0.070) (Table 4-1). Moreover, there were no significant variations in 
clinicopathological features among patients with different status of cytokine 
production (Table 4-2). The reduced cytokine levels observed among the CMV- 
positive FL patients could be attributed to the marginally decreased numbers of CD4+ 
T cells in addition to the significant increase in the quantities of end stage T cells 
among patients reported in Chapter 3. T cells being the primary source of cytokines, 
one of the characteristics of the terminally differentiated T cell phenotypes is the poor 
cytokine production potential (Wherry, 2011, Rothe et al., 2016). Meanwhile, the 
reduced CD4+ T cells can further compound this deficiency since CD4+ T cells are 
needed to support the activity of other immune cells including the production of 
cytokines to suppress or regulate immune responses. These observations could 
suggest that the presence of CMV infection in FL may portend some functional 
immune deficit for the patients’ subject patients to heightened vulnerability to other 
infections and increased AEs as captured in our hypothesis. 
Furthermore, the categorisation of patients into low, medium and high (Figure 4-5) 
according to the median cytokine values has revealed a significant difference between 
patients with CMV- positive and negative status. However, there were no significant 
disparities in pre-treatment clinicopathological features among patients with different 
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status of cytokine production.  These features include age, Ann Arbor staging, Hb 
values, LDH, FLIPI score, CIRS scale, gender, and the number of lymph nodes (LNs) 
involved (Table 4-2). This finding could suggest some degree of homogeneity in the 
participating patients and implies that baseline clinical and pathological 
characteristics of trial patients may not be responsible for the variations in the 
cytokine levels. 
Although Multiplex assay (Luminex technology) has been shown to be comparable 
with other immunoassays (Dias et al., 2005, Wang et al., 2005), this study has 
evaluated the impact of thawing and freezing of serum samples on the results of 
sELISA. This was with the view to validation of the Luminex cytokine data for use in 
the subsequent relevant sections of the thesis. Interestingly, it was observed that 
different cytokines respond differently to the thawing and freezing effects. For 
instance, IL-4 and IL-9 can be seen to maintain an increasing trend in the levels of 
expression through 1 cycle of thawing and freezing to 3 cycles (Figure 4-6: A and D) 
while inconsistencies in the levels of IL-6 and IL-8 can be seen in the respective 
cycles of thawing and freezing (Figure 4-6: B and C). This result is in agreement with 
the findings studies by others.  Using Milliplex® MAP (multi-analyte profiling) kit, 
Lee JE and his group assessed the variations in the concentration of some serum 
cytokines following repeated thawing and freezing and found significant increase or 
decrease in the concentrations of IL-15, IL-17A, TNF-a, and VEGF during repeated 
freezing-thawing cycles (Lee et al., 2015).  Another study that used EVIDENCE 180 
Biochip Analyser system and Cytokine Array I kits revealed a 3‑5-fold increase in IL
‑1β, IL‑4 and IL‑10 levels following 1 freeze/thaw cycle but levels were seen to 
stabilise during the additional 9 freeze/thaw cycles (Guo et al., 2013).  In one more 
study, aliquots of the same sample were subjected to multiple freezing - thawing 
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cycles and cytokines were measured with Bio-Rad Multiplex Immunoassay. In the 
report, IL-6 and IL-10 were found to be stable throughout the multiple freeze-thawing 
cycles, but IL-4, IL-13, IL-15, IL-17, TNF, IFN and CXCL8 levels were found to 
either increase (IL-4 and TNF) or decrease (IL-13, IL-15, IL-17, IFN and CXCL8) 
after one or more freeze - thawing cycles (de Jager et al., 2009). Therefore, our study 
supporting findings by others suggested that for reliable results of cytokines, serum 
samples should avoid repeated freeze - thawing cycles before the tests.  
Undoubtedly, the application of multiplex assays in the routine clinical measurement 
of analytes is not devoid of problems. To resolve them, it requires  to  determine the 
optimum working sample dilution that may cover a broad  spectrum and identify 
effects of the cycles of freezing-thawing serum samples on reliability of results (Jani 
et al., 2016).  Despite of this, the Luminex methods was selected for the cytokine 
studies in this chapter.  This was because the Luminex is a multiplex platform which 
allowed us to measure 27 cytokines simultaneously in one experiment, and also avoid 
result alterations caused by use of samples experienced repeated cycle of storage as 
found in this chapter.  In fact, this method has been successfully applied in other 
cytokine studies. For instance, cytokine data from multiplex assays have been utilised 
in Wei-Lin-Weissfeld regression models to define the relationship between serum 
cytokine concentrations and oral HPV clearance (Lam et al., 2016). Multiplex bead 
assay was employed to analyse archived maternal serum samples that were collected 
at the time of delivery for cytokine levels, and results were used to suggest that 
elevated maternal levels of anti-inflammatory cytokines throughout the perinatal time 
may guard against the psychotic episodes (Allswede et al., 2016). Data of 77 
inflammation markers generated by Luminex bead-platform were subjected to 
weighted Cox models and conditional logistic regression to estimate cumulative risks 
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and odds ratios (ORs) respectively, which revealed that certain levels of circulating 
inflammatory marker are associated with prospective lung cancer risk (Shiels et al., 
2013). In another study, prediagnostic serum cytokine levels of B-cell NHL cases 
were measured by Luminex platform and relevant statistical analysis of data revealed 
an association between a moderately raised risk of all B-cell NHL in women and 
elevated levels of the cytokines (Edlefsen et al., 2014).  
In addition, the Luminex assay had been well established in our GCLP laboratories 
for cytokine studies before this project.  Finally, in this study, a positive linear 
correlation was found between IL-9 concentrations measured using this method and 
sELISA in all of the 42 patients studied   (r = 0.374, p = 0.015).  This result was in 
agreement with other studies.  For instance, Wang et al. revealed perfect correlations 
between Luminex multiplex technology and ELISA platform in measuring levels of 
IL-1β, IL-4, IL-5, IL-6, IL-10, IFN γ, and TNF α (Wang et al., 2005).  Others also 
found the Luminex assay highly reproducible and reliable compared to ELISA in 
quantifying cytokines (Richens et al., 2010, Codorean et al., 2010) 
The results in this chapter therefore provided one more piece of evidence to support 
that both the Luminex and sELISA methods can be used to determine serum cytokine 
levels among patients.  However, due to the limitation to use serum samples without 
experience of repeated storage cycles, cytokine data from the Luminex assay was 
used for subsequent analysis in this thesis.   
Over fifty different chemokines are recognised and classified in humans, and they act 
mainly on neutrophils, monocytes, lymphocytes, and eosinophils and play a crucial 
responsibility in host immune defence mechanisms. It has been suggested that 
chemokines play fundamental roles in the growth, homoeostasis, and functionality of 
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the immune system. The classification of chemokines into four subgroups is based on 
the structural composition of cysteine residues in their amino-terminal portion: CXC, 
CC, CX3C and XC (Springael et al., 2005). Chemokines can also be categorised into 
functional subgroups as the homeostatic and inflammatory categories (Zlotnik and 
Yoshie, 2000, Ben-Baruch, 2002). For instance, the homeostatic chemokines such as 
CCL14, CCL19, CCL20, CCL21, and CCL25 control the directed migration of 
leukocytes in the processes of haematopoiesis and growth of lymphoid organ 
(Sallusto, 2002), on the other hand, inflammatory chemokines such as CXCL-8, 
CCL2, CCL3, CCL4, CCL5, CCL11, CXCL10 facilitate leukocyte infiltration to 
scenes of inflammation and they are induced principally by proinflammatory 
cytokines (Hadden, 1999). 
The hierarchically distinct functional clusters of cytokines in Figure 4-4, revealed 10 
cytokines down-regulated in CMV- positive patients. Among them, MIP-1α (CCL-3), 
MIP-1β (CCL_4) and IL-8 (CCL8) are members of a group of structurally related 
small molecules of about 8–14 kDa involved in the regulation of cell trafficking via 
interactions with a subgroup of transmembrane G-protein–coupled receptors (Zlotnik 
and Yoshie, 2000, Shrivastava et al., 2014). They belong to the inflammatory 
category of chemokines, which have been reported to be produced in high frequencies 
during infection or injury as they regulate the movement of inflammatory cells into 
the site of injury (Graham and Locati, 2013). 
The second distinct cluster shown in Figure 4-4 comprised of IL-6 and IL-9. It is not 
surprising that IL-6 and IL-9 clustered together since both cytokines tend to perform 
similar functions and were originally grouped as TH2 cytokines. The TH2 cells secrete 
several cytokines such as IL-4, IL-6 and IL-9 to activate and sustain humoral 
immunity mainly targeted at extracellular bacterial and parasitic challenges, plus 
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allergens and toxins. Aside from being TH2 cytokines, both IL-6 and IL-9 are 
described as pleiotropic and further identified as proinflammatory cytokines 
(Kishimoto, 2010). The IL-6 and IL-9 as pleiotropic cytokines have the capacity to 
influence the activities of multiple cell types leading to a broad spectrum of biological 
functions in oncogenesis, inflammation and autoimmunity, immune regulation and 
haematopoiesis (Kishimoto, 2010). The deficit observed in the frequencies of IL-6 
and IL-9 among the CMV- positive FL patients could be thought to cause suppressed 
humoral immune responses among others; thereby causing heightened vulnerability to 
infections and illnesses. 
The third cytokine cluster identified on the heat map in Figure 4-4 is the one including 
IL-4, IL-17A and FGF-basic. IL-4 is an autocrine cytokine that is marginally reduced 
among CMV- positive FL patients compared to the CMV- negative group.  This is an 
essential cytokine for TH2 priming and maturation; and high concentrations can 
prevent the production of TH1 cells from the immature T cells. IL-4 is also vital in 
stimulating B cell proliferation and maturation of plasma cells and regulates the class 
switching of antibodies. The IL-17A is a proinflammatory cytokine and a member of 
the IL-17 cytokine family in addition to IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and 
IL-17F (McAllister et al., 2005).  It provides a strong defence against extracellular 
microbes and bacterial and fungal infections and adds to the pathogenesis of several 
autoimmune disorders (Yao et al., 1995, Kolls et al., 2003). It also regulates the 
formation and recruitment of neutrophils to the sites of inflammation due to its ability 
to cause the release of CXC chemokines (Moseley et al., 2003) and coordinating the 
expression of G-CSF (Jones and Chan, 2002). The FGF-basic and GM-CSF can be 
grouped under vascular remodelling cytokines. In a situation where there is no signal, 
FGF-basic is known to remain in basement membranes of the subendothelial 
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extracellular matrix of blood vessels. It is assumed that during both normal wound 
healing process and in tumour development, FGF-basic is activated by the action of 
heparan sulphate degrading enzymes and triggers angiogenesis (Kühn et al., 2012). 
Additionally, studies have demonstrated that FGF-basic protects the heart from injury 
connected to heart attack, reduction of tissue death and encouraging enhanced 
function following reperfusion (House et al., 2003). Also, low levels of FGF-basic has 
been reported to play a vital role in the occurrence of extreme anxiety (Perez et al., 
2009). A monomeric glycoprotein, GM-CSF operates as a cytokine by activating stem 
cells to produce granulocytes and monocytes (Francisco-Cruz et al., 2014). The 
polymorphs are known to play pivotal roles, especially in the innate arm of the 
immunity, while the monocytes egress the circulation and relocate into tissues where 
they develop into macrophages and dendritic cells and participate in the characteristic 
immunological processes of defending the body and combating infections (Gasson, 
1991). GM-CSF can, therefore, be said to promote the development of the immune 
system. 
The weak negative correlation observed between levels of almost all cytokines and 
numbers of NKT and CD8+ E and EM3 cells is in keeping with the idea that these 
cells are (a) not the main source of the cytokines, (b) are not very good at making 
cytokines (supporting the idea that they are exhausted), and (c) in the case of NKT 
cells, their accumulation may be compensatory and secondary to depletion of 
competent T cells. Also, the weak positive correlation between E-CD4+ and EM3-
CD4+ cells and IL-6, IL-8 and IL-1β suggest that these cells make pro-inflammatory 
cytokines, albeit not very effectively.  
Therefore, it is logical to speculate that the ability of the end-stage effector T cells 
seen among the CMV-positive patients to produce cytokine is poor. By removing all 
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other confounders, the reduced cytokine levels in the serum of the CMV-infected FL 
patients can be attributed to the disruptive influence of the virus on T cell repertoires 
being the primary cellular source of cytokines. In another way, it is also rational to 
observe higher levels of end-stage (TEMRA) T cells in the circulating blood of CMV-
positive FL patients due to the sustained antigenic stimulations of T cells over time 
and induction of premature immune senescence by the virus. Inferring from the above 
outlook, cytokine data can be said to portray danger for the CMV- positive FL 
patients as compared the CMV- negative. By implication, the lower expression levels 
of cytokines in this study can impact on both innate and adaptive arms of the immune 
system and possess a grave danger to patients exposed to CMV, and can be 
attributable to reduced secretions by relevant cells that produce them.  The generally 
lower cytokine levels observed in the CMV- positive patients may potentially make 
them more vulnerable to adverse events and recurrent infection in the course of 
therapy compared to the CMV- negative. It is speculated that a functional study on T-
cell subtypes, especially the end-stage T cell types may provide a further 
understanding of T cell plasticity and open the open the mystery of re-engineering and 
reverting end stage T cells to functional subtypes. To further unravel the impact of 
CMV infection in FL lymphoma biology, probing into the FL microenvironment to 
evaluate quantitative intensities of accessory cells according to the CMV infection 
status is thought to be complimentary. Hence, Chapter 5 is devoted to studying 
surface protein markers of key accessory infiltrating cells in the FL 
microenvironment. Besides, as part of this study, an evaluation of the relationship of 
the levels of cytokine expression and clinical data of trial patients, including toxicities 
and response status is explored in Chapter 7. Therefore, Chapter 7 of this thesis is 
144 
 
aimed at providing further illumination on the wider clinical relevance of the reduced 
cytokine levels in FL as seen in CMV- positive patients.  
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Chapter 5 : Effect of CMV on accessory cells in tissues 
5.1 Introduction  
This chapter is designed to examine key markers of cellular infiltrates in the FL 
microenvironment and to relate the findings to data from the FACS analysis in 
Chapter 3 and the serum cytokine data in Chapter 4 of this thesis. The result of the 
intensities of accessory cell markers in the tissues according to CMV status is related 
to patients’ efficacy and toxicity data. It is anticipated that by associating laboratory 
findings to treatment response status and AEs experienced by the trial cohort, 
laboratory data can provide a useful pointer for better understanding of the clinical 
and biological relevance of the presence and frequencies of cellular markers within 
the follicular microenvironment.  
The tumour microenvironment (TME) is comprised of normal cells, molecules, and 
blood vessels that surround and feed the tumour cell. A tumour can change its 
microenvironment, and the microenvironment can affect the growth and spread of 
tumours. The abundance of immune cells in the secondary lymphoid organs in TME 
of haematologic malignancies makes it distinctly different from solid tumours that 
exhibit decreased numbers of immune cells. Similarly, the number and function of 
immune cells vary greatly among patients with the identical type of tumour and has 
been proven to influence patient outcomes (Yang and Ansell, 2012a).  
This study is aimed to unravel and evaluate the effect of CMV infection on the 
intensities and colocalization of non-malignant immune cells in the FL 
microenvironment. Most immunological assays including IF and IHC adopt the 
fundamental principle of antigen binding to its specific antibody for the detection and 
quantification of small quantities of antigenic molecules of biological interest such as 
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proteins, peptides, hormones, or antibody in fluid samples. Therefore, IHC was used 
as a platform to determine the optimal working concentrations (dilutions) of the 
primary antibodies before moving on to use IF to stain for more than one marker on 
each slide. 
5.2 Experimental approaches 
After determining the working dilutions of the primary antibodies based on the degree 
of positivity and distribution of targets of interest as outlined in sections 2.6.10.1- 2, 
Table 2-4 and illustrated in Figure 2-6, the working dilutions of the fluorochrome-
conjugated secondary antibodies were determined. Three different dilutions around 
the manufacturers' recommended working dilutions for Alexa Fluor 488 (AF488) -
Donkey anti-Mouse, and Alexa Fluor 647 (AF647)-Donkey anti-Rabbit antibodies 
were used to stain for sections of defined dilutions of Mouse anti-human CD56 
(1:100) and Rabbit anti-human CD8 (1:500). Following a thorough assessment of the 
staining characteristics, optimal working dilutions of 1:2000 for AF488-Donkey anti-
Mouse antibody and 1:100 for AF647-Donkey anti-Rabbit antibody were determined. 
These dilutions were used for the immunofluorescence staining of the PACIFICO 
FFPE tissue sections. Nine cell markers were evaluated per patient. Four sections 
were stained for markers expressing CD4/CD8, CD56/CD16, CD68/CD163 and 
PD1/FOXP3. However, a section was stained for cells expressing CD21. Although 
forkhead box protein P3 (FOXP3) is also expressed in recently activated human T 
cells (Magg et al., 2012), it is used to quantitate regulatory T (Tregs) cells. 
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5.3 The Results  
5.3.1 Patients and materials 
FFPE tissue biopsies from PACIFICO FL patients for this chapter comprised of 20 
CMV positive and 22 CMV-negative patients. The selection of patient samples was 
based on the size and availability of lymph node biopsy material and not 
clinicopathological characteristics. A summary of demographic and baseline 
characteristics of this study cohort are described in Table 5-1. Patients' risk factors 
and the prognosis are stratified according to the Follicular Lymphoma International 
Prognostic Index (FLIPI) score into three risk categories: good (0 or 1), Intermediate 
(2) and poor (3-4). The FLIPI score is determined using five adverse prognostic 
factors including Ann Arbor stage (III-IV vs. I-II), age (> 60 years vs. ≤ 60 years),  
haemoglobin level (< 120 g/L vs. ≥ 120 g/L), number of nodal areas (> 4 vs. ≤ 4), and 
serum LDH level (above normal vs normal or below) (Solal-Céligny et al., 2004). A 
slightly higher proportion of CMV positive patients are on the high risk FLIPI grade 
compared to the CMV negative (65.0% vs. 59.1%). The Cumulative Illness Rating 
Scale (CIRS) is used to predict survival in lymphoma patients under 13 near 
independent areas.  It is a 5-point rating of the degree of severity scale that ranges 
from none (1) to extremely severe (5) (Linn et al., 1968). There is no significant 
difference in the proportion of patients in Table 5-1 due to CMV status. 
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Table 5-1: Demographic and baseline characteristics of study cohort according 
to CMV status 
 
*For continuous variables this refers to the Mean (SD) or Median (IQR). **P value 
for 2 test or Fisher’s exact test for the difference between categorical variables or t - 
test for the   difference between two means.  
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5.3.2 Evaluating of crossreactivity  
The primary antibodies used in this double labelling study are Mouse anti-human in 
combination with Rabbit anti-human on a section and Donkey anti-Mouse secondary 
antibody conjugated to AF488 and mixed with Donkey anti-Rabbit secondary 
antibodies conjugated to AF647. Consequently, this study evaluates the cross-
reactivity of a rabbit anti-human IgG and Mouse anti-human IgG1  as a representative 
of the antibodies used for the IF analysis of cellular markers on FFPE of FL patients. 
The aim of this experiment is to define if there is any cross-reactivity between the two 
secondary antibodies to exclude non-specific binding from interfering with the 
analysis.  
To rule out the effect of crossreactivity, we undertook a crossreactivity assessment of 
the Mouse anti-human CD4 and Rabbit anti-human CD8. As shown in the cross-
reactivity appraisal illustrated in Figure 5-1, 3-micron tonsil sections were stained 
thus: Sections A and D were stained with Mouse anti-CD4, while sections B and C 
were stained with Rabbit anti-CD8. Then sections A and B were counterstained with 
Donkey anti-Mouse secondary antibody conjugated to AF488 (for section B to be 
negative) and sections C and D were counterstained with Donkey anti-Rabbit 
conjugated to AF647 (making D a negative control).From the images in Figure 5-1, 
CD4+ (Figure 5-1A) and CD8+ (Figure 5-1C) cells are well defined with blue nuclear 
staining and surrounding red and green stains. Minimal cross reactivity was seen in 
Figure 5-1B and D for both secondary antibodies.  
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Figure 5-1: Images from the crossreactivity assessment.  
Section A was stained with Mouse anti-CD4 and section B stained with Rabbit anti-
CD8, and both sections were counterstained with Donkey anti-Mouse-AL488 
(Green). Sections C and D were stained with Rabbit anti-CD8 and Mouse anti-CD4 
respectively, and both were counterstained with Donkey anti-Rabbit-AF647 (Red). 
FFPE tonsil sections were used for the evaluation. (Original magnification: x40).  
5.3.3 Evaluating simultaneous and sequential double IF  
With the understanding that there was minimal crossreactivity in our design and as 
part of optimising the immunofluorescence protocol, an experiment to assess whether 
to use simultaneous or sequential double immunofluorescence staining was 
undertaken using an Autostainer. FFPE tonsil sections were stained for CD4 and CD8 
markers and detected using fluorochrome-conjugated secondary antibodies, Donkey 
anti-Mouse-AF488 and Donkey anti-Rabbit-AF647 using the Dako AutostainerPLUS. 
The images from both methods are displayed in Figure 5-2 as composites, A and D 
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(CD4/CD8/DAPI), and single antibody fluorochromes with DAPI (CD4/DAPI and 
CD8/DAPI).  No pronounced difference between the qualities of images from the two 
staining methods was observed. However, being that the simultaneous staining 
method reduces the chances of tissue detachment (as fewer steps), as well as the 
exposure to ambient light, this method was chosen for analysing the patients’ tissue 
samples. 
 
Figure 5-2: Evaluating Immunofluorescence staining methods.  
Images of double stained of FFPE tonsil sections with antibodies directed against 
CD4 (green) and CD8 (red) by sequential (upper panel) and simultaneously (lower 
panel) methods. (Original magnification: x40). 
This project adopts a simultaneous double labelling IF technique of targets on FFPE 
tissue sections to analyse for the expression levels of CD4+ and CD8+ (T cells), 
CD68+ and CD163+ (macrophages), FOXP3+ (regulatory T cells), CD21+ (primarily 
FDCs) PD1+ (exhausted T cells), CD16+ and CD56+ (NK cells) populations in FFPE 
tissue biopsies from FL patients. 
To answer our hypothesis that CMV infection modulates FL microenvironment with 
the possibility of influencing rituximab-chemotherapy, we quantified and compared 
the expression of cellular markers between CMV- positive and negative patients. 
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After staining the 3-micron sections from the PACICIFO FFPE tissue biopsies the 
coverslips were sealed to the slide with nail varnish and stored in the fridge until 
ready for image capturing and analysis. A total of 8 images were captured per section 
using an Olympus BX63 motorised upright microscope with a 40× objective, 
equipped with a Photometrics CoolSnap camera and MicroManager acquisition 
software (Edelstein et al., 2014). Images were analysed with ImageJ (Schneider et al., 
2012) using in-house written macros and Java plugins. The representative images of 
the antibody staining of five different tissue sections are displayed in Figures 5-3 to 5-
7.  
In Fig 5-3, higher intensities of CD8 (cytotoxic) expressing T cells compared to CD4  
(helper) expressing T cells seen in A & C. Figures 5-4 shows PD1+ cells (a surface 
protein marker) stained with  FOXP3+ cells (a nuclear protein). In this study, PD1 
expression is used as a marker to assess for exhausted T cells in the FL 
microenvironment. Higher expression of FOXP3 can be seen in C & E. The 
expression of CD21, a FDC marker in FFPE sections, revealed a meshwork pattern of 
CD21+ staining Figure 5-5as commonly demonstrated by FDC in lymphoid tissue 
(Alio et al., 2015). Sections were stained for CD56/CD16 and CD68/CD163 
expressing cells in the FFPE to quantitate for intratumoral NK cells and macrophages. 
Weak colocalization was demonstrated in CD68 and CD163 in Figures 5-7 and as 
evaluated in section 5.3.4: 
153 
 
 
Figure 5-3: Double labelled immunofluorescent image for CD4/CD8 expression. 
Immunofluorescent images of CD4/DAPI (A), CD8/DAPI (C) and a merged image of 
CD4/CD8/DAPI (E) alongside corresponding Isotype controls (B, D & F). The 
secondary antibodies comprised a mixture of Donkey anti-Mouse-AF488 dye (green) 
and Donkey anti-Rabbit-AF647 (a bright and photostable far-red dye). (Original 
magnification: x40). 
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Figure 5-4: Double labelled immunofluorescent image for PD1/FOXP3 
expression.  
Immunofluorescent images of PD1/DAPI (A), FOXP3/DAPI (C) and a merged image 
of PD1/FOXP3/DAPI (E) alongside corresponding Isotype controls (B, D & F). The 
secondary antibodies comprised a mixture of Donkey anti-Mouse-AF488 dye (green) 
and Donkey anti-Rabbit-AF647 (a bright and photostable far-red dye. (Original 
magnification: x40). 
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Figure 5-5:  A single labelled immunofluorescent image for CD21 expression. 
Immunofluorescent image for CD21/DAPI (A) and Isotype control (B). The 
secondary antibody used is Donkey anti-Rabbit-AF647 (a bright and photostable far-
red dye). (Original magnification: x40). 
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Figure 5-6: Double labelled immunofluorescent images for CD56/CD16 
expression.  
Immunofluorescent images of CD56/DAPI (A), CD16/DAPI (C) and a merged image 
of CD56/CD16/DAPI (E) alongside corresponding Isotype controls (B, D & F). The 
secondary antibodies comprised a mixture of Donkey anti-Mouse-AF488 dye (green) 
and Donkey anti-Rabbit-AF647 (a bright and photostable far-red dye). (Original 
magnification: x40). 
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Figure 5-7: Double labelled immunofluorescent images for CD68/CD163 
expression.  
Immunofluorescent images of CD68/DAPI (A), CD163/DAPI (C) and a merged 
image of CD68/CD163/DAPI (E) alongside corresponding Isotype controls (B, D & 
F). The secondary antibodies comprised a mixture of Donkey anti-Mouse-AF488 dye 
(green) and Donkey anti-Rabbit-AF647 (a bright and photostable far-red dye). Arrow 
points at Colocalization (E; yellow). (Original magnification: x40). 
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5.3.4 Evaluating colocalization  
The distribution of fluorescent signals between the paired markers per section 
(CD4/CD8, CD68/CD163 and CD56/CD16) was analysed quantitatively and 
statistically using the chi-squared (2) test to determine the correlation coefficient (r) 
between pairs. This analysis revealed whether two markers associate with the same 
structures (not the same cell). This information is anticipated to provide an insight 
into possible co-expression of two markers on a cell. 
 
Figure 5-8: Spearman Rank Order Correlation for paired markers.  
Figure summarises colocalisation of CD56/CD16, CD4/CD8 & CD68/CD163 
according to CMV status. CMV- depicts CMV- negative while CMV+ represents 
CMV- positive. 
5.3.5 Median intensities of markers of accessory in FL 
The median expression levels of the accessory cell markers according to CMV 
infection status are as displayed in Table 5-2. The Mann-Whitney U test was used to 
analyse the intensities of markers of accessory cells in the FL microenvironment. 
Figure 5-9 revealed a statistically significant elevated median intensity of CD21 
expression among CMV- positive (432.59) compared to the CMV- negative cohort 
(340.97) with a p-value of 0.043. Also, the sections from CMV- positive patients 
show marginally increased intensities of FOXP3 (p-values=0.069) and PD1 (p-
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0.0
0.2
0.4
0.6
0.8
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p=0.288
p=0.266
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value=0.097) expression compared to CMV- negative. No other markers demonstrate 
a significant difference due to CMV status. However, from the table the CMV- 
negative group has shown a trend of increased median values of CD4+, CD8+, 
CD16+, CD56+, CD68+ and CD163+ expression.  
Table 5-2: Descriptive table of intensities of cellular infiltrates in the FL 
microenvironment determined by immunofluorescence 
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Figure 5-9: Median intensities of accessory cell markers in the FL 
microenvironment.  
The p-values are determined by Mann-Whitney U-test.  
5.4 Discussions   
Cellular composition and quantities of infiltrating accessory cells in the FL 
microenvironment are imperative in determining the overall outcome of the disease. 
This Chapter has evaluated the intensities of essential cell markers of the FL 
microenvironment with a view to identify any conceivable differences in the tumour 
microenvironment due to CMV infection. Analysis of the median intensities of cell 
markers in the FL microenvironment revealed a statistically significant elevation in 
the level of CD21 (markers of FDCs) among CMV- positive FL patients compared to 
the CMV- negative group (p=0.043). Also, marginal increase in the expression of 
FOXP3 and PD1 were observed in CMV- positive than negative (p=0.069 & p=0.097 
respectively). 
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By morphology, the FL is described as a proliferation of malignant GCBs surrounded 
by a variety of nonmalignant cells such as follicular helper T (TFH) cells, follicular 
dendritic cells (FDCs), follicular reticular cells (FRCs) and macrophages, as 
illustrated in Figure 5-10 that can potentially affect the fate of tumour (Kridel et al., 
2012). On the other hand, a 2-fold role of the FL microenvironment has been 
described to include supporting tumour growth/survival and suppressing the 
antitumoral immune response.  
 
Figure 5-10: A model of the FL microenvironment. 
This figure is reproduced with permission from (Kridel et al., 2012) and copyright 
clearance.  
CD21 is a marker for FDCs that forms a complex with CD19, CD225 and CD81 in 
the membrane of mature B cells; which results in a considerably enhanced B cell 
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response to the antigen. FDCs are not a subtype of normal dendritic cells (DCs) as 
they are stromal in origin and develop from vascular mural cells, while the traditional 
DCs are haematopoietic (Aguzzi et al., 2014). While DCs activate naïve T cells by 
presentation of processed antigen via major MHC molecules, FDCs appear to present 
unprocessed antigen in the form of trapped immune complexes (Krautler et al., 2012). 
This attribute, along with the availability of chemokines, adhesion molecules, and 
trophic factors, enables FDCs to shape B cell responses and fashion the local 
microenvironment (Kridel et al., 2012).  
Furthermore, FDC links innate and adaptive (B cell) responses. The ability of the 
FDCs to perceive innate stimuli through Toll-like receptors elaborates specific 
immune responses (Krautler et al., 2012). Also, FDCs control the elimination of 
apoptotic GC B cells. Though, FDCs can also contribute to autoimmune diseases, the 
FDC-mediated ingestion of dying B cells plays a crucial role in preventing 
autoimmunity. An immunohistological study has demonstrated that the dense mesh-
like networks of follicular dendritic cells (CD21+) that contain growing neoplastic B-
cells in low-grade B-cell lymphomas disappear in high-grade lymphomas (Shiozawa 
et al., 2003). The prognosis was found to be statistically better for patients with low-
grade tumour than for those with high-grade tumour (p = 0.026), and there was a 
pattern of poorer survival among CD21-negative cases (p = 0.186). Along these lines, 
the presence of CD21-positive follicular dendritic cells in neoplastic follicles may 
predict the capability of FL to change to DLBCL (Shiozawa et al., 2003). 
The model in Figure 5-10 also illustrates the variety of accessory infiltrating cells in a 
typical FL microenvironment, although quantities and types of cells in the 
microenvironment vary from one case to another and their clinical relevance. FL 
growth and survival signals may include IL-4 and IL-21. These supporting factors can 
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bind to the interleukin receptors on FL cells such as IL-4R/IL-21R or CXCL12 and 
CXCL13 secreted by the stromal cell subtypes. FDCs being professional antigen 
presenters can mediate BCR signalling, which can also take place via the action of an 
innate immune system (Janeway et al., 1997). As illustrated in Figure 5-10, it can be 
seen that tumour cells are capable of suppressing the immune responses against them 
from macrophages, CTLs and T helper cells (Kridel et al., 2012). 
FL cells can survive the cytotoxic effects of CTLs by causing a T-cell immune 
dysfunction and induction of T cell exhaustion by secreting IL-12 (Kridel et al., 
2012). Also, Tregs and M2 polarised macrophages have been reported to suppress an 
efficient immunological response against FL cells (Mantovani et al., 2017, Chung et 
al., 2011, Ha, 2009). The enhanced Tregs in the FL microenvironment weakens the T 
cell response.  
FL contributes to the preferential conversion of T helper cells into Tregs by proteins 
such as TGF-β or CCL22 (Ha, 2009). Whereas classically activated TAMs, the M1 
polarised CD68+ control malignant growth by inducing a TH1 response; M2-polarized 
TAMs exerts a tumour-promoting function through angiogenesis and induction of an 
immunosuppressive TH2 response (Quatromoni and Eruslanov, 2012). 
There are well-documented pieces of evidence that point to the fact that the malignant 
B cells depress the function of the various T cell subtypes in the FL 
microenvironment so that they can escape immunosurveillance (Kridel et al., 2012). 
Studies have also revealed that elevated quantities of CD68+ -TAMS correlated with 
inferior prognosis and poor outcome in FL. (Clear et al., 2010, Taskinen et al., 2007). 
Although no statistical difference is observed due to CMV status, the CMV- negative 
FL patients had higher expression intensities for CD68 and may lead to a poor 
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outcome compared to the CMV- positive patients. It was also demonstrated that IL-12 
secretion by malignant B cells induces T cell exhaustion (Yang et al., 2012).  
Elevated numbers of tumour infiltrating FOXP3 (regulatory T cells) have been shown 
to associate with enhanced overall survival in FL (Carreras et al., 2006). This may 
suggest that CMV- positive patients are likely to fare better than the CMV- negative 
FL patients. It has also been reported that FL cells effect the transformation of 
effector T cells into FOXP3-expressing Tregs, which suppress the proliferation and 
action of both CD4+ and CD8+ T cells (Kridel et al., 2012, Ai et al., 2009).  FDCs are 
professional APCs and increased frequencies in the microenvironment of FL patients 
with chronic CMV infection may be logical in enhancing BCR signalling, which is 
achievable either via the innate immune system, provoking BCR through N-glycans, 
or via antigen processing and presentation by FDCs (Kridel et al., 2012). Furthermore, 
it has also been reported that FL cells affect the transformation of effector T cells into 
FOXP3 (Tregs), which suppress the proliferation and action of both CD4+ and CD8+ 
T cells.  
Our data may be vaguely interpreted as enhanced antigen presentation activity due to 
CMV, increased T cell regulation and raised T cell exhaustion following chronic and 
sustained antigenic stimulation. 
The present study has not been able to characterise the various cell types in the FL 
microenvironment that express PD-1, however, two subcategories of T-cells are 
known to express PD-1 based on the expression levels of the marker. The PD-
1
high
CXCR5+ TFH cells phenotype which are exclusively expressed by the CD4+ T 
cells have been reported to promote the survival of B cells. On the other hand, the PD-
1
low
TIM-3+ exhausted T cells category can be expressed on both CD4+ and CD8+ T 
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cells, and this subtype has lost the ability to secrete cytokines and to convey cell 
signalling (Yang et al., 2015). Therefore, there is no clear understanding of the 
functional or clinical relevance of the marginally elevated median intensities of PD-1 
in the CMV- positive FL patients compared the CMV- negative counterparts.    
Taking together, FL patients with CMV infection can be seen to express higher 
intensities of markers for FDCs (CD21+), regulatory T cells (FOXP3+) and exhausted 
T cells (PD1+) in the tumour microenvironment.  
A Longitudinal study will further illuminate the relevance of findings. Also, a study 
that incorporates other differentiating markers for instance, TIM-3 can offer more 
information regarding the significance of the elevated intensities of CD21, PD-1 and 
FOXP3 markers in the FL microenvironment due to CMV infection. In the meantime, 
the explorative analysis of the relationship between clinical data (treatment efficacy 
and toxicity) and CMV status (Chapter 6) as well as laboratory data (Chapter 7) will 
provide an insightful perspective on the clinical relevance of the laboratory data. 
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Chapter 6 : Effect of CMV on treatment efficacy and toxicity 
6.1 Introduction 
The overall hypothesis for this thesis was that CMV infection in FL alters immune 
function in two ways: (1) altering the lymphoma microenvironment in a way that 
could modulate the behaviour of the disease as well as its response to therapy; and (2) 
accelerating immune senescence and thereby increasing the risk of infection following 
immunosuppressive chemo-immunotherapy. By showing that CMV infection was 
associated with the accumulation of exhausted T cells, reduction of some cytokines in 
the blood, and expansion of follicular dendritic cells in affected lymph nodes, the 
laboratory data presented in Chapters 3-5 support both components of this hypothesis. 
The aim of the present Chapter was to explore the potential impact of CMV infection 
in patients with FL at the clinical level by relating CMV infection status to therapy 
response and toxicity, especially infection. 
6.2 Approach 
Clinical data were related to CMV status using explorative statistics in 3 separate 
cohorts of patients: those whose samples were used for the FACS/cytokine analysis 
(n=42), those whose samples were used for the immunofluorescence study (n=42 
including 6 in FACS/cytokine cohort), and all patients of known CMV serostatus who 
were recruited into the PACIFICO trial (n=269). As previously explained, samples 
used for lymphocyte/cytokine profiling and tissue staining were specifically selected 
(a) to provide an equal number of CMV-positive and CMV-negative cases and (b) to 
be well balanced in other respects. It was considered important to examine the effect 
of CMV status in the overall trial cohort in order to increase statistical power and 
therefore the chances of finding significant differences between the CMV-positive 
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and CMV-negative groups. On the other hand, there was a risk that CMV-positive and 
CMV-negative patients might not be balanced in other respects, potentially 
introducing bias. At the point of data lock, 360 patients had been randomised into the 
PACIFICO study.  Of these, 269 (75%) were informative for CMV status and 
constituted the overall trial cohort. 191 patients were only in the overall cohort 
whereas the rest were also in FACS/cytokine cohort and/or IF cohort. Figure 6.1 
shows the relationship between FACS/cytokine, IF and overall trial cohorts.   
 
Figure 6-1: Venn diagram showing the number of patients and relationship 
between the three cohorts analysed.   
The proportion of CMV-positive cases in FACS/cytokine, IF and overall trial cohorts 
was 50%, 48% and 40.5%, respectively, the remainder being CMV-negative.  
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The two main clinical events of interest were treatment response and toxicity. Long-
term outcomes such as PFS and OS were not available as the trial is still in follow-up. 
Treatment response after 4 and 8 cycles of treatment was captured through CRFs 
provided by local sites and collated by the Clinical Trials Unit (CTU). The patients' 
response to treatment was evaluated based on Revised Standardised Response Criteria 
for Malignant Lymphoma (Cheson et al., 2007). In this criteria, an anatomical 
response is assessed by contrast-enhanced computed tomography (CT), which defines 
the degree of shrinkage of the affected lymph nodes and essentially classifies response 
into  Complete Remission (CR), Partial Remission (PR), Stable Disease (SD) and  
Progressive Disease (PD) (Subramaniam, 2015, Cheson et al., 2007).  As the name 
implies, CR is reported when there is no evidence of disease confirmed by the 
disappearance of palpable nodules in spleen and liver. PR, on the other hand, denotes 
regression of measurable disease and no new sites involvement. This is defined by a ≥ 
50% reduction in the sum of the product of the diameters of up to 6 largest dominant 
nodal masses (Subramaniam, 2015, Cheson et al., 2007). Meanwhile, a failure to 
achieve CR, PR or a PD during therapy is described as SD. In this situation, no new 
locations identified on CT; with no change in the dimension of early lesions on CT. 
Finally, PD refers to a treatment response status characterised by the appearance of a 
new lesion(s) > 1.5 cm in any axis or increase by ≥ 50% of previously involved sites 
from nadir. Toxicity was captured via Adverse Event (AE) and Serious Adverse 
Event (SAE) reports submitted by local sites and collated by the CTU, and 
categorised in accordance with version 4 of the universally applied National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Since 
CMV infection can accelerate immune senescence, the study focused on infection. 
However, to take into account the possibility that infections might arise in the context 
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of chemotherapy-induced neutropenia, the rate of febrile neutropenia (reported by 
some local sites as “neutropenic fever” or “neutropenic sepsis”) was also examined.   
Summary statistics and independence hypothesis tests were conducted to explore any 
differences in treatment efficacy and toxicity due to CMV status. Toxicity was 
quantified in two different ways: either as the proportion of patients who experienced 
the event of interest, or as the total number of events of interest (thereby taking into 
account that one patient may experience multiple infections). To minimise bias due to 
differences between CMV-positive and CMV-negative patients that could affect the 
reporting of Adverse Events (AEs)/Severe Adverse Events (SAEs) (e.g. duration of 
treatment exposure), the rate of infection and febrile neutropenia was expressed as a 
proportion of all reported toxicity within each group being analysed.   
The results of the analyses are presented under 3 main sections: baseline 
characteristics of the 3 cohorts used for the study; effect of CMV on treatment 
efficacy; and impact of CMV on infection and febrile neutropenia.  
6.3 The baseline characteristics of study cohorts 
The baseline characteristics of patients in the FACS/cytokine and 
immunofluorescence (IF) cohorts used for lymphocyte profiling/cytokine analysis and 
tissue studies respectively have already been presented in Table 3-1 (Chapter 3) and 
Table 5-1 (Chapter 5).  In both cohorts, there was no difference between CMV-
positive or CMV-negative groups in a range of variables with the potential to impact 
on treatment efficacy and/or toxicity. These variables included age, stage, Hb, LDH, 
number of affected lymph node groups and FLIPI score. Table 6-1 shows baseline 
characteristics of the overall trial cohort broken down by CMV status. Of the 269 
patients, 160 (59%) were CMV- negative, and 109 (41%) were CMV- positive. FL 
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Patients' risk factors and the prognosis are stratified by the Follicular Lymphoma 
International Prognostic Index (FLIPI) score into three risk categories: good (0 or 1), 
Intermediate (2) and poor (3-4). The FLIPI score is determined using five adverse 
prognostic factors including Ann Arbor stage (III-IV vs. I-II), age (> 60 years vs. ≤ 60 
years),  haemoglobin level (< 120 g/L vs. ≥ 120 g/L), number of nodal areas (> 4 vs. ≤ 
4), and serum LDH level (above normal vs normal or below) (Solal-Céligny et al., 
2004). The Cumulative Illness Rating Scale (CIRS) is used for the physical 
assessment of impairment of patients under 13 near independent areas.  It is a 5-point 
rating of the degree of severity scale that ranges from none (1) to extremely severe (5) 
(Linn et al., 1968). There is no significant difference in the proportion of patients in 
Table 6-1 due to CIRS. It can be seen that the two groups were mostly well balanced 
for a range of clinical features that have the potential to influence treatment efficacy 
and toxicity, although a higher proportion of patients in the CMV-positive group had 
a high-risk FLIPI score (70% versus 61%), potentially biasing this group towards a 
worse treatment outcome.  
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Table 6-1: Baseline clinicopathological characteristics of the overall trial cohort 
according to CMV status   
 
*For continuous variables this refers to the Mean (SD) or Median (IQR) 
**P value for 2 test or Fisher’s exact test for the difference between categorical 
variables or t - test for the   difference between two means. 
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6.4 Effect of CMV infection on treatment efficacy 
6.4.1 FACS/cytokine Cohort 
Response data was available for 37 of the 42 patients in this cohort. The stacked bar 
chart in Figure 6-2 shows treatment response post cycle 4.  Out of the 18 CMV-
negative FL patients, only 2 (11%) achieved complete remission (CR), and 16 (89%) 
responded partially (PR). On the other hand, out of 19 CMV-positive patients, 9 
(47%) showed CR and 9 (47%) partial remission with 1 (5%) patient showing stable 
disease (SD). Thus the CR rate was significant higher in CMV-positive group than 
that in CMV- negative group after 4 cycles of treatment, as analysed with 2 test (P = 
0.016) or Fisher’s exact test (P = 0.029). As expected, response (CR or PR) was 
recorded in all cases whose treatment lasted for 8 cycles. The CR rate increased in 
both groups after that.  In a total of 35 patients with information available, it was 
achieved by 12 of the 18 CMV-positive (67%), and 9 of the 17 CMV-negative (53%) 
patients (Figure 6.3).  Although the CR rate was still higher in the former group, the 
difference became small and lacked a statistical significance (2 test P = 0.407; 
Fisher’s exact test P = 0.500).  
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Figure 6-2: Stacked bar charts illustrating the proportion percentages of 
patients’ local response after post cycle 4 by CMV status (FACS/cytokine 
Cohort).  
CR= Complete Remission, PR= Partial Remission, SD= Stable Disease. There were 
no patients showing Progressive Disease (PD) response after post cycle 4. 
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Figure 6-3: Stacked bar charts illustrating the proportion percentages of 
patients’ local response after post cycle 8 by CMV status (cytokine/FACS. 
CR= Complete Remission, PR= Partial Remission. There were no patients showing 
Stable Disease response or Progressive Disease response after post cycle 8. 
 
The trend of CR achievement after 4 and 8 cycles of treatment in both groups are 
presented in Figure 6-4, which shows a favourable effect of CMV infection on the 
quick response.  
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Figure 6-4: The line graph shows the proportion of CMV-positive and CMV-
negative patients who achieved a CR at both time points (FACS/cytokine 
cohort). 
6.4.2 Immunofluorescence cohort 
Response data was available for 38 of the 42 patients in this cohort. The stacked bar 
chart in Figure 6-5 shows treatment response at post cycle 4. Out of the 20 CMV- 
negative FL patients, only 3 (15%) responded completely (CR) to therapy, 16 (80%) 
responded partially (PR) and 1 had a stable disease (SD). While among the CMV- 
positive patients, 4 (22%) achieved CR, 12 reached PR, and 1 (6%) each showed SD 
and PD, respectively.  Although the CR rate in the CMV-positive group was bigger 
than that in the negative group, the difference did not reach a statistical significance (p 
= 0.687, Fisher’s exact test).  This was the same when the rate of CR+PR was 
compared between the two groups (p = 0.595). 
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Figure 6-5: Stacked bar charts illustrating the proportion percentages of 
patients’ local response to therapy after post cycle 4 by CMV status 
(Immunofluorescence).  
CR= Complete Remission, PR= Partial Remission, SD= Stable Disease, Progressive 
Disease (PD). 
177 
 
 
Figure 6-6: Stacked bar charts illustrating the proportion percentages of 
patients’ local response to therapy after post cycle 8 by CMV status 
(Immunofluorescence). 
CR= Complete Remission, PR= Partial Remission, SD= Stable Disease, Progressive 
Disease (PD). 
Similar to what was found in the FACS/cytokine cohort, the CR rate increased when 
the treatment lasted for 8 cycles in both CMV-positive and negative groups.  
However, such increase was less profound in the negative group, leading to a bigger 
difference from the positive groups (38% versus 71%, p = 0.085, 2 test) (Figure 6-6).  
Thus, more patients in the positive group are likely to achieve CR.  As summarised in 
Figure 6-7, the CR rates recorded at the two time points post treatment were generally 
in agreement with that found in the previous cohort, suggesting CMV infection is 
associated with good response to the treatment in the trial (detailed in 6.4.1).  
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However, compared the previous cohort, CR rate increased slower in patients with 
CMV negativity and did not reach to the same level at 8 cycle post treatment in this 
cohort.  The reason for the difference was not clear, but might be due to the 
differences in patients between the two cohorts.  (For example, more male patients 
were CMV-negative in this cohort (68.2% versus 38.1%, p = 0.069, Fisher’s exact 
test). 
 
Figure 6-7: The line graph shows the proportion of CMV+ve and CMV-ve 
patients who achieved a CR at both time points (IF cohort).  
CMV-ve denotes CMV- negative, while CMV+ve denotes CMV- positive. 
Furthermore, the logistic regression analysis of contributors to the higher CR rate not 
only further confirmed the role of the prolonged treatment (p = 0.003), but also 
revealed a likely relationship with CMV infection (p = 0.103), as shown in Figure 6-7. 
6.4.3 The PACIFICO overall trial cohort 
Response data was available for 223 of the 269 patients in this cohort. Figures 6-8 and 
6-9 give graphical summaries of the relationship between CMV status of patients and 
response to therapy at post cycles 4 and 8 respectively. The stacked bar chart in 
Figure 6-8 shows that after 4 cycles of therapy, among the 134 CMV- negative FL 
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patients, 21 (28%) had a complete response (CR), 102 (76%) had a partial response 
(PR) and 4 (3%) had stable disease (SD), whereas among the 89 CMV- positive, 20 
(22%) had a CR, 66 (74%) a PR, 2 (2%) SD and 1 (1%) PD. In summary, there was 
no association between CMV status and response post cycle 4. 
 
Figure 6-8: Barplot to show relationship between CMV status and post cycle 4 
(overall trial cohort).  
CR= Complete Remission, PR= Partial Remission, SD= Stable Disease, Progressive 
Disease (PD).  
The stacked bar chart in Figure 6-9 shows that after 8 cycles of therapy, among the 
115 CMV- negative FL patients, 49 (43%) had a (CR), 64 (56%) a PR and 2 (2%) PD, 
whereas among the 69 CMV- positive, 36 (52%) had a CR, 31 (45%) a PR and 2 (3%) 
PD.  
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Figure 6-9: Barplot to show relationship between CMV status and post cycle 8 
(overall trial cohort).  
CR= Complete Remission, PR= Partial Remission, and Progressive Disease (PD). 
From the summary line graph in Figure 6-10, there may be a small trend towards 
higher CR rates after 8 cycles of therapy in the CMV-positive group but the effect is 
much less striking than in the other 2 cohorts.   
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Figure 6-10: The line graph shows the proportion of CMV+ve and CMV-ve 
patients who achieved a CR at both time points (Overall trial cohort).  
CMV-ve denotes CMV- negative, while CMV+ve denotes CMV- positive. 
The discrepancy between results obtained in FACS/cytokine, IF and overall trial 
cohorts can potentially be explained by the fact that a higher proportion of CMV-
positive patients in the overall trial cohort have high-risk FLIPI scores compared to 
the CMV-negative group in the overall Cohort (70% vs 61%). This could bias the 
CMV-positive group towards worse treatment outcome and potentially negate any 
favourable effect on treatment outcome associated with CMV positivity. In contrast, 
FLIPI scores in in FACS/cytokine and IF cohorts were well balanced between CMV-
positive versus CMV-negative groups.  
Overall, in a logistic regression models for the probability of having a Complete 
Response, both the time of assessment (post cycle 4 and 8) and the patient's CMV 
status are included as covariates in the model. There is a significant difference 
between post cycles 4 and 8 (p=0.002871).  The probability of being CR increases 
from post cycle 4 to post cycle 8.  Also, there is some evidence that being CMV- 
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positive increases the chances of a CR but this is not statistically significant 
(p=0.103). 
6.5 Effect of CMV status on infection and febrile neutropenia 
Following correlating CMV infection status with the response to treatment, we 
investigated relationship of such infection to the treatment toxicities in each of the 
two cohorts presented above and the entire cohort of patients recruited into the 
PACIFICO trial with clinical information available. CMV-positive and CMV-
negative patients who experienced any form of toxicity were compared for the 
occurrence of infections and febrile neutropenia (reported as “neutropenic fever” or 
“neutropenic sepsis”). Toxicity was analysed as the percentage of affected patients, or 
the total number of infection or febrile neutropenia episodes reported within each 
group. 
 6.5.1 The number of patients experiencing AEs/SAEs 
6.5.1.1 In the FACS/cytokine cohort 
40 of the 42 patients in this cohort with information about toxicity available were 
included in this analysis. 20 of these patients were CMV-negative whereas 20 were 
CMV-positive.  
Figures 6-11A-E show the proportion of patients in each of these groups who 
experienced infection and/or febrile neutropenia. There was no observed difference 
between CMV-negative and CMV-positive groups in the percentage of patients 
experiencing infection (Fig 6-11A), grade 3+ infection (Fig 6-11B), febrile 
neutropenia (Fig 6-11C), infection and/or febrile neutropenia (Fig 6-11D), or grade 3+ 
infection and/or febrile neutropenia (Fig 6-11E). 
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Figure 6-11: Comparison of incidence of infection and/or febrile neutropenia 
between CMV-positive and negative patients in the FACS/cytokine cohort.   
Bar plot illustrating the proportion of patients in the FACS/cytokine cohort with 
infection and/or febrile neutropenia that were statistically compared between these 
two groups. The figure in each bar represents the % of cases. 
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6.5.1.2 In the IF cohort 
In this cohort, the relevant information was not available from 9 of the 42 patients by 
the time of analysis.  Therefore, results from 33 patients with 17 being CMV-negative 
and 16 CMV-positive are reported here.  
Figure 6-12 shows the proportion of patients in each of these groups who experienced 
infection and/or febrile neutropenia. Similar to the findings above, there was no 
observed difference between the two groups in the percentage of patients 
experiencing infection (Fig 6-12A), grade 3+ infection (Fig 6-12B), febrile 
neutropenia (Fig 6-12C), infection and/or febrile neutropenia (Fig 6-12D), or grade 3+ 
infection and/or febrile neutropenia (Fig 6-12E). 
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Figure 6-12: Comparison of incidence of infection and/or febrile neutropenia 
between CMV-positive and negative patients in the IF cohort.   
The bar plot illustrates the proportion of patients in the IF cohort with infection and/or 
febrile neutropenia that were statistically compared between these two groups. The 
figure in each bar represents the % of cases. 
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6.5.1.3 In the overall trial cohort 
209 of the 269 patients in the overall trial cohort experienced some form of toxicity. 
128 of these patients were CMV-negative whereas 81 were CMV-positive.  
Figure 6-13A-E shows the proportion of the number of AEs/SAEs in each of these 
groups that were due to infection and/or febrile neutropenia. A significantly higher 
proportion of CMV-positive patients experienced infections compared to CMV-
negative patients (74% vs 59%, P=0.033, see Fig 13A). The same was true of 
infections and/or febrile neutropenia (78% vs 62%, P=0.031, see Fig 6-13D). There 
was no observed difference between CMV-negative and CMV-positive groups in the 
percentage of patients experiencing grade 3+ infection (Fig 6-13B), febrile 
neutropenia (Fig 6-13C or grade 3+ infection and/or febrile neutropenia (Fig 6-13E). 
The summary of the percentage of patients who experienced specific toxicities in the 
three patient cohorts is presented in Table 6-2. 
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Figure 6-13: Comparison of incidence of infection and/or febrile neutropenia 
between CMV-positive and negative patients in the overall trial cohort.   
The bar plot illustrates the proportion of patients in the overall trial cohort with 
infection and/or febrile neutropenia that were statistically compared between these 
two groups. The figure in each bar represents the % of cases. 
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Table 6-2: A summary of percentage of patients who experienced specific 
toxicities in the three cohorts 
 
*including neutropenic fever and neutropenic sepsis 
** Febrile neutropenia is by definition grade 3+ 
6.5.2 Analysis of the number of reported AEs/SAEs 
With the findings made above, we further compared the adverse effects quantified as 
the number of episodes experienced by the patients.  
6.5.2.1In FACS/cytokine cohort 
A total of 532 AEs/SAEs were recorded in the FACS/cytokine cohort. Among them, 
342 occurred in CMV-negative and 190 in CMV-positive patients.  
Figure 6-14 shows the percentage of the total number of AEs/SAEs in each of the two 
groups, including infection and/or febrile neutropenia. There was no observed 
difference between CMV-negative and CMV-positive groups in the percentage of 
AEs/SAEs that resulted from infection (Fig 6-14A), grade 3+ infection (Fig 6-14B), 
febrile neutropenia (Fig 6-14C), infection and/or febrile neutropenia (Fig 6-14D), or 
grade 3+ infection and/or febrile neutropenia (Fig 6-14E). 
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Figure 6-14: Comparing AE/SAE episodes between CMV-positive and –negative 
patients in the FACS/cytokine cohort.  
Figures in each bar represent the % of the episodes.   
6.5.2.2 The immunofluorescence (IF) cohort 
A total of 486 AEs/SAEs were reported in the IF cohort. Amongst these, 323 occurred 
in CMV-negative patients and 163 in CMV-positive patients.  
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Figures 6-15A-E show the proportion of the number of AEs/SAEs in each of these 
groups that were due to infection and/or febrile neutropenia. Figure 6-15A and Figure 
6-15D show that CMV-positive FL patients experienced statistically more episodes of 
infection (P=0.017) and infection and/or febrile neutropenia (P=0.037) compared to 
the CMV- negative group. No difference was observed between CMV-negative and 
CMV-positive groups in the percentage of AEs/SAEs that resulted from grade 3+ 
infection (Fig 6-15B), febrile neutropenia (Fig 6-15C) or grade 3+ infection and/or 
febrile neutropenia (Fig 6-15E). 
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Figure 6-15: Comparing AE/SAE episodes between CMV-positive and –negative 
patients in the IF cohort.  
Figures in each bar represent the % of the episodes.  
6.5.2.3 The overall trial cohort 
A total of 2544 AEs/SAEs were reported in the overall cohort. Out of this, 1690 
occurred in CMV-negative patients and 854 in CMV-positive patients.  
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The CMV-positive patients experienced a significantly higher percentage of reported 
number of infections compared to CMV-negative patients (17% vs 12%, P=0.001, see 
Fig 6-16A). Also, CMV- positive had a significantly higher proportion of the 
percentage number of infections and/or febrile neutropenia AEs compared to CMV- 
negative patients (19% vs 13%, P=0.001, see Fig 6-16D). In addition, a significantly 
higher proportion of grade 3+ infection and/or febrile neutropenia was recorded by the 
CMV- positive FL patients compared to CMV-negative patients (6% vs 4%, P=0.021, 
see Fig 6-16E). 
There was no observed difference between CMV-negative and CMV-positive groups 
in the percentage of patients experiencing grade 3+ infection (Fig 6-16B) or febrile 
neutropenia (Fig 6-16C). 
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Figure 6-16: Comparing AE/SAE episodes between CMV-positive and –negative 
patients in the overall PACIFICO trial cohort.  
Figures in each bar represent the % of the episodes. 
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Table 6-3: A summary of percentage episodes of specific toxicities reported in the 
three cohorts. 
 
*includes “neutropenic fever” and “neutropenic sepsis” 
** Febrile neutropenia is by definition grade 3+ 
6.6 Discussions 
This Chapter focuses on the evaluation of the relationship between the available 
clinical endpoint data of the trial patients and CMV status. Results of the two cohorts 
studied suggests that CMV infection in FL associates with better and more rapid 
response to rituximab-containing chemo-immunotherapy in the FACS/cytokine and IF 
cohorts. This association will be tested in the entire trial cohort when data of clinical 
response of all patients is verified. Regarding toxicities of the treatment, the clinical 
data of all patients in the trial were verified and available.  The proportion of patients 
experiencing infection or (infection and/or febrile neutropenia) was significantly 
higher in the CMV-positive group in the whole trial cohort, despite similar between 
the two groups in the two small cohorts studied for FACS/cytokine and IF profiles. 
Also, the percentage of the total number of AEs/SAEs episodes due to infection or 
(infection and/or febrile neutropenia) was significantly higher in the CMV-positive 
group in the overall trial cohort and IF cohort. In the overall trial cohort, the effect is 
particularly striking and extends to grade 3+ infection and/or febrile neutropenia. 
These observations suggest that CMV infection in FL associated with increased 
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episodes of infection and adverse events in the course of rituximab-containing chemo-
immunotherapy, especially as observed in overall PACIFICO trial cohort. 
By implication, the elevated end-stage effector T cell types observed in Chapter 3 and 
the reduced serum cytokine levels seen in Chapter 4 can be said to contribute to the 
increased infection episodes observed among the CMV- positive FL patients. 
Similarly, the more impressive chemo-immunotherapy response rate reported among 
CMV-positive patients compared to the CMV- negative can be attributed to the high 
expression levels of CD21 and FOXP3 reported in the tumour microenvironment 
(Chapter 5). Undoubtedly, leucocytes constitute the primary cellular source of 
cytokines, and since end stage  T cells are poor secretors of cytokines (Rothe et al., 
2016), then the presence of CMV infection can grossly impair immune responses to 
antigenic challenge leading to increased infection rate among the CMV- positive 
patients.  These data, therefore, support the hypothesis that CMV infection alters 
immune function in two ways: (1) Alteration of lymphoma microenvironment with 
modulation of therapy response (opposed by worse FLIPI score in the overall trial 
cohort). The findings are in keeping with enhanced  antibody-dependent cell mediated 
cytotoxicity (ADCC) (mechanism of action of rituximab) due to the increased FDCs 
demonstrated in CMV- positive cases of Chapter 5 (2) Acceleration of immune 
senescence and T cell exhaustion with increased susceptibility to infection. 
The treatment regimens for both arms of the PACIFICO trial (R-FC & R-CVP) 
contain human anti-CD20-IgG1 monoclonal antibody, rituximab, in combination with 
the chemotherapy regimens, and afterwards, it is given as a single agent for 
maintenance therapy to avoid or slow the return of cancer following CR (Witkowska 
and Smolewski, 2016). The mechanisms by which rituximab function to cause the 
destruction of pan-B-cell (more than 90% of B-cell NHL) including the FL cells is by 
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the immune antibody-antigen binding that leads to cell-mediated cytotoxicity, direct 
signalling of apoptosis and complement activation (Smith, 2003). Therefore, some of 
the most notable explanations for the actions of rituximab may include antibody-
dependent cell mediated cytotoxicity (ADCC), complement dependent cytotoxicity 
(CDC) as well as induction of apoptosis and direct growth arrest (Seyfizadeh et al., 
2016, Weiner, 2010, Witkowska and Smolewski, 2016, Zhou et al., 2008). 
In the ADCC pathway, the target (FL) cells are coated with the anti-CD20 antibodies 
which trigger the accessory effector immune cells in the FL microenvironment to 
induce ADCC process that facilitate the lysing of the rituximab-coated target cells 
(Hogarth and Pietersz, 2012, Weiner, 2010). Consequently, the result suggests that the 
significantly elevated FDCs (as identified by CD21+ marker) observed in the FFPE 
tissue sections of the CMV-positive patients could be responsible for potentiating the 
action of rituximab and resulting to the higher proportion of CR rate compared to the 
CMV- negative patients. Although FDCs are known to play a promoting role in 
lymphomagenesis, growth, histologic transformation and survival of FL B cells 
(Lossos and Gascoyne, 2011), FDCs help in shaping immune responses and are 
crucial for the removal of cell debris from GCs and in preventing autoimmunity 
(Aguzzi et al., 2014). Also, the binding of rituximab to FL cells will activate the 
activities of regulatory T cells (FOXP3+ cells) which happen to be elevated at 
borderline significance in CMV-positive patients compared to CMV- negative.  
Although it is not clear whether FOXP3 is an anti- or pro- tumourigenic molecule, 
functional evidence strongly suggest that FOXP3 serves as tumour suppressive 
transcription factor in cancer development (Zuo et al., 2007, Tao et al., 2012). 
Therefore, by the ADCC pathway, the potential anticancer activity of FOXP3 will 
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confer a superior response advantage to the CMV- positive FL patients on rituximab –
chemotherapy regime than the negative. 
Even through some authors have reported that FDCs (CD21+) can block apoptosis 
and enhance cell survival (Mongini et al., 2003), rituximab can act through the 
activities of FOXP3 that represses cell proliferation and induces apoptosis by 
activating the apoptotic signalling pathway to enhance response to treatment (Ma et 
al., 2013, Darmochwal-Kolarz et al., 2012). 
The increased incidence and episodes of infection AEs reported among the CMV-
positive FL patients (in the overall PACIFICO trial cohort) can be attributed to the 
predominance of exhausted T cells over functionally competent T cells reported in 
Chapter 3 of the thesis. This is due to the decreased long-lasting memory potential, 
limited effector function and poor cytokine production capacity of the terminally 
differentiated T cells, which can cause a profound impairment of the immune 
functions and thereby increasing patients susceptibility to infections (Rothe et al., 
2016, Wherry, 2011). Furthermore, the low levels of circulating cytokines across pro- 
and anti-inflammatory categories, as well as chemokines and haematopoietic growth 
factors among the CMV-positive patients, may account for the heighten proportion 
and rate of infection AEs among the patients.  Other reasons for the increased risk of 
infection among CMV- positive FL patients may include, though not statistically 
significant, low levels of naïve and central memory T to fight novel infections and 
mount strong response against secondary infections compared to CMV- negative 
population.  
It is anticipated that understanding the mechanisms by which CMV modulates the 
activity of rituximab-containing chemotherapy in FL treatment might provide 
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headway to researching into drug discovery and improved quality of life of FL 
patients. Furthermore, if data is confirmed by a prospective study, routine CMV 
serostatus of FL patients may be recommended. This step will help in promoting 
precision medicine and to checkmate incidences and rates of toxicities in FL patients, 
especially during immuno-chemotherapy. In this case, the CMV- positive FL patients 
might benefit from enhanced clinical monitoring against AEs/SAEs in the course of 
therapy and for inclusion on other protocols aimed at slowing down the rate of T cell 
exhaustion and immune senescence among patients. Furthermore, it is believed that 
carrying out a survival analysis at the close of the trial relating primary endpoints data 
with CMV infection status may reveal a clearer picture of the role of CMV infection 
in FL biology.  
In conclusion, CMV infection among FL patients has is associated with elevated 
frequencies of circulating end-stage T cell types and NK cells, decreased serum 
cytokine levels and high expression of CD21+ cells in the FL microenvironment. 
Also, CMV infection associated with more episodes of infection AEs but higher CR 
rate. The next chapter (Chapter 7) focuses on exploring the relationship between 
CMV status and the proportion of end stage T cells, median serum cytokine levels and 
intensities of surface markers in the FL microenvironment versus AEs and response 
status. This approach will give ideas on how increased or decreased values of these 
parameters relate to AEs and response status. 
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Chapter 7 : Relating laboratory findings with treatment efficacy 
7.1 Introduction 
The data presented in Chapters 3-5 indicate that CMV infection is associated with an 
altered profile of blood lymphocytes (reduced CD4: CD8 ratio, increased effector and 
effector memory-3 cells within the CD4+ and CD8+ populations, increased NKT 
cells, decreased CD4+ and increased LAG3-CD4 cells), reduced serum cytokines (IL-
1β, IL-4, IL-6, IL-8, IL-9, IL-17, FGF-basic, GM-CSF, MIP1α, MIP1β) and increased 
accessory cells expressing PD-1, FOXP3 and CD21 in affected lymph nodes. 
Furthermore, in Chapter 6, I showed that CMV infection is associated with increased 
infections and possibly an improved response to chemo-immunotherapy. In this 
Chapter, I sought to establish the relationship between the CMV-dependent biological 
variables listed above and the clinical associations of CMV. In doing so, I hoped to be 
able to shed light on the mechanisms through which CMV exerts its clinical effects in 
FL. Unfortunately, it was not possible within the time frame available to relate CMV-
dependent biological variables to infection or febrile neutropenia. Since these were 
the only toxicities associated with CMV, the analysis was confined to elucidating the 
relationship between CMV and treatment efficacy (CR rates after 4 and 8 cycles).    
7.2 Approaches  
To achieve the aim of this chapter, we planned to compare the clinical outcomes 
(response to treatment)  between patients with different levels of those laboratory 
variables differentially expressed between CMV-positive and -negative patients, 
including the 10 cytokines identified in Chapter 4, the 3 microenvironmental markers 
presented in Chapter 5, and the 8 cell types elucidated in Chapter 3.  However, for 
each of these variables the data was continuously distributed rather than categorical 
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and it was not possible to identify a natural cut-off separating “high-level” from “low-
level” cases.  The median level of each laboratory variable of the 42 patients studied 
was therefore applied to divide cases into two groups. Figure 7-1 provides an example 
of how this approach was applied to serum cytokine levels.  For each variable, patient 
groups defined as “high level” (greater than the median value) or “low-level” (lower 
than the median value) were compared for clinical endpoints using the statistical 
analyses described in Chapter 2.  
Although data on treatment response after 4 and 8 cycles was available for most 
patients, it was missing in 5 and 7 patients, respectively, among the cohort of 42 
patients used to examine lymphocyte subsets (Figures 7-2 & 7-3) and serum cytokines 
(Figure 7-6 & 7-7), and in 4 and 15 patients, respectively, among the cohort of 42 
patients used to examine accessory cells in affected lymph nodes (Figures 7-10 & 7-
11).  To validate the results and avoid underestimation of any difference between 
patients due to the limited sample size, a reciprocal statistical analysis was performed 
in which patients were grouped by whether or not they achieved a CR and compared 
across groups for levels of the CMV-dependent laboratory variables. 
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Figure 7-1: Expression levels of cytokines in the studied cohort of patients with 
FL.  
The y-axis represents the levels of cytokines (pg/ml) found to be differentially 
expressed in CMV-positive versus CMV-negative cases. For each cytokine, the data 
have been arranged in rank order. The horizontal line in each chart represents the 
median level of individual cytokines.  
7.3 Results 
7.3.1 Relationship between treatment response and blood lymphocyte subsets 
Following the approaches outlined above, patients were divided into high- and low-
level groups for each lymphocyte subset found to be differentially expressed between 
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CMV-positive and CMV-negative patients (NKT, pE2.CD4, E.CD4, E.CD8, 
EM3.CD8, CD4 & LAG3-CD4). Interestingly, patients with high proportion of 
E.CD4 cells (CD4+CD45RA+CCR7-CD27-CD28-) had a higher CR rate after 8 
cycles of treatment compared to those with a low proportion (77.78% versus 41.18%, 
p = 0.041, Figure 7-3C), although no significant difference was found after 4 cycles. 
Also, patients expressing a high proportion of E.CD8 cells tended to have a higher CR 
rate after 8 cycles of treatment compared to patients that had low E.CD8 cells, 
although this observation failed to reach statistical significance (p=0.094, Figure 7-
3G). No difference in CR rates was observed between patient groups defined by high 
versus low proportions of other lymphocyte subsets.   
Consistent with the finding above, patients who achieved a CR after 8 cycles had a 
higher proportion of E.CD4 cells compared to those who did not achieve a CR at this 
time point (Figure 7-5). Similarly patients who achieved a CR after 4 cycles tended to 
have a higher proportion of pE2.CD4 cells, although this observation just failed to 
reach statistical significance (Figure 7-4). 
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Figure 7-2: Comparison of treatment response post cycle 4 between patients 
expressing low and high frequencies of lymphocyte subsets.  
Patients were grouped based whether they expressed low or high frequency of 
lymphocyte subsets. The y-axis of the stacked bar charts depicts the percentage of 
patients that achieved CR and non CR at post treatment cycle 4. 
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Figure 7-3: Comparison of treatment response post cycle 8 between patients 
expressing low and high frequencies of lymphocyte subsets.  
Patients were grouped based whether they expressed low or high frequency of 
lymphocyte subsets. The y-axis of the stacked bar charts depicts the percentage of 
patients that achieved CR and non CR at post treatment cycle 8.  
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Figure 7-4: Comparison of lymphocyte subsets between patients achieving and 
not achieving CR after 4 cycles of treatment.  
The y-axis on the boxplots represents the percent of the cell subtypes analysed. The 
response status represented by complete remission (CR) and non-complete remission 
(non CR) are presented on the x-axis. 
206 
 
 
Figure 7-5: Comparison of lymphocyte subsets between patients achieving and 
not achieving CR after 8 cycles of treatment.  
The y-axis on the boxplots represents the percent of the cell subtypes analysed. The 
response status represented by complete remission (CR) and non-complete remission 
(non CR) are presented on the x-axis.  
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7.3.2 Relationship between treatment response and serum cytokines 
Next, we divided the cohort of patients into two groups using the median level of each 
of the 10 cytokines identified in Chapter 4. As shown in Figures 7-6 & 7-7, Chi 
square test or Fisher’s exact test found no significant difference in CR rates between 
patients with low versus high levels of any of these 10 cytokines.  
The patients were then grouped by outcome, and cytokine levels were compared 
between patients who did or did not achieve a CR after 4 cycles (Figure 7-8) or 8 
cycles (Figure 7-9) of treatment using the Mann-Whitney U test. Again, no significant 
difference was observed.  
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Figure 7-6: Comparison of treatment response post cycle 4 between patients 
expressing low and high levels of cytokines.  
Patients were grouped based on whether they expressed low or high levels of serum 
cytokines. The y-axis of the stacked bar charts depicts the percentage of patients that 
achieved CR and non CR at post treatment cycle 4.  
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Figure 7-7: Comparison of treatment response post cycle 8 between patients 
expressing low and high levels of cytokines.  
Patients were grouped based whether they express low or high levels of serum 
cytokines. The y-axis of the stacked bar charts depicts the percentage of patients that 
achieved CR and non CR at post treatment cycle 8.  
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Figure 7-8: The cytokine levels in patients with and without CR after 4 cycles of 
treatment.  
Patients were grouped based on whether or not they achieved a CR after completion 
of 4-cycle treatment. The y-axis of the boxplots depicts expression levels of cytokines 
(pg/ml). 
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Figure 7-9: The cytokine levels in patients with and without CR after 8 cycles of 
treatment.  
Patients were grouped based on whether or not they achieved a CR after completion 
of 8-cycle treatment. The y-axis of the boxplots depicts expression levels of cytokines 
(pg/ml). 
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7.3.3 Relationship between treatment response and accessory cells 
Next, we used the median intensity of the 3 differentially expressed 
microenvironmental protein markers (PD1, FOXP3 and CD21) to divide the patients 
into two groups.  The Chi-square test or Fisher’s exact test did not reveal any 
significant difference between the groups in the CR rate after either 4 or 8 cycles of 
treatment (Figures 7-10 & 7-11).   Similarly, no significant difference in intensity of 
any of the three markers was found between cases achieving and not achieving CR 
(Figures 7-12 and 7-13). 
 
Figure 7-10: Treatment response post cycle 4 between patients expressing low 
and high intensities of immune cell markers in the FL microenvironment. 
Patients were grouped based whether they express low or high frequencies of cell 
markers in the FL microenvironment. The y-axis of the stacked bar charts depicts the 
percentage of patients that achieved CR and non CR at post treatment cycle 4. 
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Figure 7-11: Comparison of treatment response post cycle 8 between patients 
expressing low and high intensities of immune cell markers in the FL 
microenvironment.  
Patients were grouped based whether they express low or high frequencies of cell 
markers in the FL microenvironment. The y-axis of the stacked bar charts depicts the 
percentage of patients that achieved CR and non CR at post treatment cycle 8. 
 
214 
 
 
Figure 7-12: Comparison of intensity of protein markers in microenvironment 
between cases with and without CR post cycle 4 of treatment.  
The y-axis on the boxplots represents the fluorescence intensities of the protein 
markers in the FL microenvironment. 
 
Figure 7-13: Comparison of intensity of protein markers in microenvironment 
between cases with and without CR post cycle 8 of treatment.  
The y-axis on the boxplots represents the intensity of the protein markers in the FL 
microenvironment. A summary of the relationship between CMV-dependent 
biological variables and treatment efficacy is presented in Table 7-1. 
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Table 7-1: Summary of the relationship between CMV-dependent biological 
variables and treatment efficacy 
 
Analysis 1 compares CR rates in groups of patients with high or low expression of 
CMV-dependent biological variables (using median values as a cut-off). Analysis 2 
compares the expression of CMV-dependent biological variables in groups of patients 
who achieve or do not achieve a CR. NS = Not significant (P>0.1). 
 
7.4 Discussions 
The aim of this Chapter was to relate treatment responses to CMV-dependent 
biological variables with the aim of shedding further light on the mechanisms 
underlying the possible beneficial effect of CMV infection on response to 
chemoimmunotherapy as reported in Chapter 6. The key positive finding was that 
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patients with a high proportion of E.CD4+ T cells in the blood (> median value) were 
significantly more likely to achieve a CR after 8 cycles of treatment (~80% vs. 
~40%). The reciprocal was also true, i.e. patients achieving a CR after 8 cycles of 
treatment had significantly higher numbers of E.CD4+ T cells in the blood compared 
to those who did not achieve a CR. Patients with a high number of E.CD8+ T cells in 
the blood also tended to have higher CR rates after 8 cycles of treatment, but this 
observation failed to reach statistical significance. There was also a non-significant 
trend for patients with high PE2.CD4+ T cells in the blood to have higher CR rates 
after 4 cycles of treatment. In contrast, patients with a low total number of CD4+ T 
cells (as seen in CMV positive) tended to have higher CR rates after 8 cycles of 
treatment, but again, this observation failed to attain statistical significance (p=0.094). 
No association was observed between CR rates after 4 of 8 cycles of treatment and 
levels of individual cytokines in the serum or number of accessory cells in affected 
lymph nodes expressing PD-1, FOXP3 or CD21. 
Our data reveal that patients with higher proportions of PE2.CD4 (p=0.070), E.CD4 
(p=0.041 & p=0.035) and E.CD8 (p=0.094) as well as low proportion of CD4+ T cells 
(p=0.094) responded better to the rituximab-chemotherapy. In the case of E.CD4 
cells, these differences were identified in a two-way statistical approach that involved 
firstly grouping the patients based on the quantity of each of the laboratory variables 
and then on the basis of clinical outcome (CR).  This reciprocal approach to statistical 
analysis should increase the level of confidence that the findings are real rather than 
spurious.  
The intriguing observation is that similar elevated levels of these T cell subtypes were 
reported among the CMV-positive patients (Chapter 3), and that this group of patients 
also showed greater sensitivity to rituximab-containing chemotherapy compared with 
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the CMV negative group (Chapter 6). Taken together, these observations are in 
keeping with the idea that E.CD4 and E.CD8 cells might mediate some of the 
cytotoxicity of chemo-immunotherapy in FL, and that the superior CR rates observed 
in CMV-positive patients is due to the greater number of E.CD4 and E.CD8 cells that 
accumulate in these patients.  
My results provide the first triangulation between CMV infections, accumulation of 
effector T cells and enhanced sensitivity to rituximab-containing therapy in FL. Thus, 
although CMV infection is known to promote the accumulation of these circulating 
effector and pre-effector T cells in healthy individuals, this phenomenon has not been 
previously documented in FL. Furthermore, although effector cells have been shown 
to promote the antitumor activity of antibody-based therapy in FL (Golubovskaya and 
Wu, 2016, Chames et al., 2009), there are no prior reports of CMV enhancing the 
effectiveness of such treatment.   
Rituximab, the therapeutic mAb which forms part of the treatment regimen for FL and 
a broad variety of other B-cell malignancies, targets the CD20 antigen on B cells 
(Kosmas et al., 2002, Weiner, 2010). Mechanisms by which rituximab exerts its 
therapeutic effects include complement (C1q) binding, induction of B-cell (follicular 
lymphoma cell) depletion via FcR-mediated antibody-dependent cell-mediated 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), inhibition of 
cell proliferation, direct induction of apoptosis, and disruption of anti-apoptotic 
pathways with sensitisation of malignant B cells to chemotherapy (Kosmas et al., 
2002, Boross and Leusen, 2012).  
The killing of FL cells (antibody‐coated target cell) through ADCC mechanism 
requires effector cells, especially the cytotoxic effector cells expressing particular Fc 
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receptors (FcRs) that will release cytotoxic granules or by the expression of cell 
death‐inducing molecules (Romána et al., 2013).  Although it is argued that resting 
CD4+ T-cells lack low-affinity FcRs, however, activated CD4+ T-cells express 
substantial amounts of FcγRIIIa, which were initially observed in small numbers in 
circulating T cells (Chauhan, 2016, Sandor and Lynch, 1993). Therefore, one may 
argue that the high effector CD4+ and CD8+ T cell types reported among the CMV-
positive patients (Chapter 3) might contribute to the CR rate observed in Chapter 6 
which is further confirmed in this Chapter (Chapter 7). Following massive depletion 
of FL (B) cells in the course of rituximab -chemotherapy regimen, effector T cells, 
though short-lived, are capable of homing to opsonized antigens (FL cells) and 
eliminating them at a rate that correlates with the number of effector T cells 
(Golubovskaya and Wu, 2016). This phenomenon should theoretically lead to a better 
CR rate among patients with higher numbers of effector T cells prior to 
commencement of the treatment, as is seen in the CMV-positive cohort. 
Regarding the potential value of passive immunotherapy through ADCC and CDC, 
studies have suggested that because the maximum clinical benefit of rituximab is 
achieved months after the commencement of therapy, the adaptive arm of immunity is 
involved in the overall realisation of an enduring benefit of rituximab therapy 
(Cartron et al., 2004, Weiner et al., 2010). Evidence suggests that induction of 
adaptive immune responses in the course of antibody therapy is achieved when DCs 
present peptides from engulfed apoptotic cells on MHC class I molecules to elicit 
antigen-specific CD8+ T cell responses (Weiner et al., 2010). These understandings 
provide a possible explanation for the higher CR rates observed post cycle 8 
compared to post cycle 4 (see Table 7.1) and the impact of the effector CD4 and CD8 
T cell functions in clearing FL cells. 
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To understand the mechanism by which rituximab can influence the functional 
properties of T cells, a group reported that rituximab efficiently depletes all the CD20 
expressing T cells (CD20 T cells), which account for about 1.6% to 2.4% of all T 
cells (Wilk et al., 2009). The study concluded that CD20 T-cell population contributes 
largely to disease severity, and that depletion of this T-cell subset can serve an 
additional mechanism by which the monoclonal CD20 antibodies therapy can 
effectively work in the treatment of other diseases such as RA. 
Of course, mechanisms other than ADCC and CDC might explain the better treatment 
responses observed among patients with elevated PE2.CD4+, E.CD4+ and E.CD8+ T 
cells, as seen in the CMV-positive group, although it is difficult to speculate on what 
these mechanisms might be. 
No association was found between CR rates and serum cytokines or number of 
accessory cells expressing PD-1, FOXP3 or CD21. This negative finding may reflect 
physiological variation in serum cytokine levels. Thus, even in healthy individuals, 
levels of serum cytokines have been reported to vary widely, with even more variation 
seen in pathological conditions (Kleiner et al., 2013). For instance, some studies have 
linked higher levels of pro-inflammatory cytokines (e.g. IL-1 or TNF-α) to worse 
disease outcomes, and curtailing the biological activities of these cytokines can reduce 
the impact of illness (Dinarello, 2000, Fitzgerald et al., 2005).  Alternatively, the lack 
of association between serum cytokine levels and CR rate may simply reflect the 
small sample size. This speculation also applies to the lack of association observed 
between CR rates and PD-1, FOXP3 or CD21-expressing accessory cells in the 
tumour microenvironment. Thus, others have shown that T-cell subtypes, proteins and 
cells in the tumour microenvironment are associated with survival in FL and may 
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influence response to treatment and the risk of transformation in this disease (Yang 
and Ansell, 2012a).  
Finally, my findings are likely to be confounded by other variables that I have not 
studied but which might modulate response to treatment in FL such as the genetic and 
cellular factors (KIR genotyping, HLA genotyping, and KIR ligand assignment) that 
drive immune responses in mAb therapy (Du et al., 2014). Also, genetic 
polymorphisms in the gene for C1q have been linked to variations in rituximab 
efficacy in humans, single-nucleotide polymorphisms (SNP) and copy number 
variations of the FCGR2A and FCGR3A genes that play roles in the efficacy of 
rituximab therapy (Moriya et al., 2014, Rezvani and Maloney, 2011) may impact on 
response. Such variables could dilute and potentially mask any effects due to the 
variables of interest. The identification of laboratory variables that may associate with 
clinical outcome but were not studied in this Chapter could form the basis for a future 
research project.  
In summary, the data presented in this Chapter suggest that CMV increases sensitivity 
to chemo-immunotherapy in FL due to the secondary accumulation of effector T cells 
which mediate the therapeutic effects of rituximab. 
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Chapter 8 General Discussion & Conclusions 
The hypothesis addressed in this thesis is that CMV infection alters the immune 
system in FL in two ways: first, by expediting immune senescence, thereby leading to 
increased susceptibility to heterologous infection; and second, by altering the 
lymphoma microenvironment in such a way as to alter the response to 
chemoimmunotherapy. My experimental approach involved comparing CMV-positive 
and CMV-negative patients with FL who entered the PACIFICO trial for circulating 
lymphocyte subsets (Chapter 3), blood cytokine levels (Chapter 4), accessory cells at 
sites of tissue involvement (Chapter 5), and clinical outcome (Chapter 6). 
Furthermore, in an attempt to elucidate pathogenetic mechanisms responsible for the 
effects of CMV on clinical outcome, the latter was related to laboratory variables 
found to be associated with CMV serostatus. The present Chapter attempts to 
integrate my experimental findings and, in doing so, provide a unifying explanation 
for the effects of CMV infection in FL. 
In considering the extent to which my findings support the hypothesis underlying my 
thesis, the first point to make is that CMV status was indeed associated with a number 
of the biological variables examined. These include blood lymphocyte subsets, serum 
cytokine profile, and the number of specific accessory cells at sites of tissue 
involvement. The existence of such differences indicates that hypothesis has the 
potential to be correct. 
The salient findings were as follows: Flow cytometric analysis of stored PBMCs of 
FL patients in Chapter 3 revealed higher percentages of end-stage T cell subtypes 
(pE2.CD4 (p=0.048), E.CD4 (p=0.030), EM3.CD4 (p=0.019), E.CD8 (p=0.035) & 
EM3.CD8 (p=0.005)), as well as NKT cells (p=032), in CMV-positive patients 
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compared to the CMV-negative counterparts. In Chapter 4, the Luminex assay show 
significantly decreased levels of multiple cytokines in the serum of CMV-positive 
patients compared to the CMV-negative group. These included IL-6 (p=0.029), IL-8 
(p=0.037), IL-9 (p=0.006), IL-17A (p=0.020), FGF-basic (0.028), MIP-1α (p=0.039) 
and MIP-1β (p=0.029). Furthermore, there were more accessory cells expressing 
CD21 (p=0.043), FOXP3 (p=0.069) and PD-1 (0.097) in the lymphoma 
microenvironment of CMV-positive cases compared to CMV-negative patients, 
suggesting an accumulation of FDCs, Tregs and exhausted T cells, respectively. At 
the clinical level, I showed in Chapter 6 that CMV infection was associated with a 
better response to chemo-immunotherapy in the cohort used for flow 
cytometry/cytokine profiling (p= 0.019), and with an increased risk of infection in the 
cohort used for tissue immunofluorescence (p=0.017), as well in the much larger 
overall patient cohort (p<0.001). In Chapter 7, I showed that response to 
chemoimmunotherapy was associated with increased circulating end-stage T cells 
(p=0.041 for E.CD4; p=0.094 for E.CD8) but not with any of the other CMV-
dependent biological variables examined. Figure 8-1 summarises these associations. 
In summary, I have produced evidence that CMV infection in FL results in (1) the 
accumulation of circulating end-stage T cells, (2) a reduction in multiple serum 
cytokines, (3) increased FDCs, Tregs and exhausted T cells in the lymphoma 
microenvironment, (4) increased infection and (5) better therapeutic response to 
chemo-immunotherapy, the latter being associated with increased circulating end-
stage T cells but not with reduced serum cytokines or increased FDCs, Tregs and 
exhausted T cells in tissues. 
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Figure 8-1:  Associations observed between CMV infection, alterations in the 
immune system and clinical outcome in patients with FL 
The observed association between CMV positivity and the accumulation of 
circulating end-stage T cells strongly supports the hypothesis that, in patients with FL, 
CMV accelerates the general process of immune senescence as has been suggested in 
healthy individuals (Solana et al., 2012, Tsoukas, 2012).  
Since many cytokines are produced by T cells, and since one of the features of end-
stage T cells is their inability to produce cytokines, it is reasonable to assume that the 
reduction in serum cytokines observed in CMV-positive FL patients is secondary to 
alterations in lymphocyte subsets. The observed association between CMV positivity 
and infection following chemoimmunotherapy indicates that CMV infection is 
immunosuppressive in this context and implicates accelerated immune senescence as 
an underlying mechanism. Unfortunately it was not possible within the time frame 
available to look for a direct relationship between infection and either blood 
lymphocyte subsets or serum cytokines to confirm the relationship between 
accelerated immune senescence and susceptibility to infection. 
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As outlined above, CMV status was also associated with alterations in the number of 
accessory cells in the lymph node microenvironment with increased numbers of FDCs 
(CD21+), Tregs (FOXP3+) and exhausted T cells (PD-1+) detected in CMV-positive 
patients. The functional relationship between these CMV-dependent tissue alterations 
and CMV-dependent alterations in blood lymphocyte subsets is unclear as it was not 
possible to apply the same level of cellular characterisation to FFPE biopsy material 
as was possible for cryopreserved PBMCs. Nevertheless, it is noteworthy that one of 
the histological associations of CMV in FL tissues was an increase in exhausted (PD-
1+) T cells. Although these cells are phenotypically distinct from the TEMRA (T 
effector memory re-expressing CD45RA) cells that accumulate in the circulating 
blood of CMV-positive FL patients, they resemble TEMRA cells in being 
functionally incompetent. Consequently, it appears that CMV infection in FL results 
in the accumulation of a multiple types of functionally incompetent T cells both in the 
blood and also at sites of tissue involvement.  
 
The FL microenvironment in CMV-positive patients was associated not only with an 
increase in exhausted T cells but also with higher numbers of Tregs and FDCs which, 
in the case of FDCs, reached statistical significance. It is therefore logical to speculate 
that one or more of these cell types might be responsible for the better response to 
chemoimmunotherapy that was observed in CMV-positive patients. The latter 
observation was apparent in both of the smaller patient cohorts (where other variables 
that could confound outcome were well balanced between CMV-positive and CMV-
negative cases) and reached statistical significance in the FACS/cytokine cohort.  
Given the effect of CMV on both therapy response and accessory cells at sites of 
tissue involvement, it was surprising that no association was detected between the 
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latter two variables. Specifically, response to chemo-immunotherapy was not 
associated with the number of exhausted T cells, Tregs or FDCs in the FL 
microenvironment. This could indicate that these cells were not responsible for the 
effect of CMV on therapy response, or that one or more of these cell types was 
responsible for the effect of CMV on therapy response but that a statistically 
significant association was overlooked due to small sample size. Interestingly, the 
only CMV-dependent biological variable found to be statistically associated with 
therapy response was the proportion of circulating end-stage T cells. Thus, twice as 
many patients with a high (greater than the median) E.CD4/E.CD8 count achieved a 
CR after 8 cycles of chemoimmunotherapy compared to patients with a low 
E.CD4/E.CD8 count (p=0.041 and p=0.094, respectively).  The explanation for this 
observation is unclear. One possibility is that the accumulation of circulating TEMRA 
cells is simply a marker of CMV infection and that these cells do not mediate the 
effect of CMV on therapy response. This model is supported by the fact that TEMRA 
cells lack homing receptors such as CCR7 and CD62L (Willinger et al., 2005) and 
should therefore be poorly equipped to migrate into the FL microenvironment. 
Alternatively, it is possible that TEMRA cells do accumulate in the FL 
microenvironment and modulate therapy response but were undetected by the 
immunofluorescence staining for CD4 and CD8 that was reported in Chapter 5 as 
their accumulation does not affect the total number of CD4+ or CD8+ T cells in 
affected tissues. 
The above conclusions and deductions are based on data which (as is the case with all 
datasets) has both strengths and limitations. The fact that all the data generated in this 
thesis is derived from samples obtained as part of a clinical trial should be regarded as 
a major strength. In fact, due to the relatively low incidence of FL, it would be 
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difficult for a single treatment centre to accumulate a sufficient number of samples for 
the studies performed in this thesis. Under these circumstances, centralised sample 
collection performed as part of a multicentre trial provides the only realistic 
opportunity to perform such research. Furthermore, since trial entry is tightly 
governed by strict entry criteria, and since clinical data collection is performed to a 
high standard, patients recruited into trials are extremely well defined in terms of pre-
treatment characteristics, treatment administered and treatment outcome. On the 
negative side, trial populations may not be entirely representative of the overall 
population with a given disease in terms of age (older patients are typically under-
represented) and co-morbidity (less fit patients are typically unrepresented). An 
additional problem with trial samples is that clinical outcome data cannot be released 
until the primary results of the trial are published, as there is a risk that the primary 
results might be deduced from the released data. For this reason, it was not possible to 
analyse the two treatment arms of the PACIFICO trial separately. This is unfortunate 
as the R-FC arm is likely to be more T cell-immunosuppressive than R-CVP. It 
therefore follows that patients who received R-FC are likely to be more sensitive to 
the effects of CMV compared to those who received R-CVP. Furthermore, it was not 
possible to relate pre-treatment characteristics (including CMV status) to long-term 
therapy response (progression-free survival) as the number of deaths/progressions is 
currently too small for analysis to be meaningful. Consequently, the analysis was 
confined to short-term response (CR rate).  
Another limitation in the data was the need, for practical reasons, to confine the 
FACS/cytokine and IF analysis to a cohort compromising 42 patients. The actual 
number of samples for which a complete dataset was available was even smaller as 
trial data collection is ongoing. These two factors reduced the statistical power of 
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comparisons between different patients groups within these cohorts and in doing so 
increased the risk of overlooking true associations between the variables examined. 
On the other hand, the process of selecting samples for the FACS/cytokine and IF 
cohorts ensured that CMV-positive and CMV-negative patients were well balanced 
for prognostic factors that could bias the results. Such patient selection should 
increase the reliability of comparisons made between CMV-positive and CMV-
negative patients. However, despite showing that CMV seropositivity is associated 
with a better therapy response in the two smaller, well-balanced cohorts, failure to 
show any association between CMV status and therapy response in the larger, 
unselected cohort means that CMV serostatus is unsuitable as a clinically useful 
predictive biomarker for therapy response. In contrast, the strong association observed 
between CMV serostatus and infection in the larger, unselected cohort means that 
CMV serostatus has potential value as a clinically useful predictive biomarker for 
infection. 
The sophistication of the analytical techniques employed and the large amount of data 
produced by these techniques should be regarded as one of the strengths of this thesis. 
Furthermore, the data should be reliable since all assays were validated before being 
applied to the trial samples. Indirect validation of the assays is provided by the fact 
that some of the observed differences between CMV-positive and CMV-negative 
cases include some previously reported effects of CMV in healthy individuals. It 
would have been interesting to quantify CMV-specific T cells using CMV-specific 
tetramers and assess lymphocyte function by measuring activation following 
stimulation with recall antigens (Gratama et al., 2001, Gratama and Kern, 2004), and 
the lack of such data should be regarded as a limitation. A further limitation is the 
lack of longitudinal data to show the combined effect of CMV and 
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chemoimmunotherapy on circulating lymphocytes and serum cytokines. Although 
sequential samples were available for some patients, it was simply not possible to 
perform these analyses within the time frame available. 
Although some of the associations that I have demonstrated between biological 
variables are strong, others are weaker – just bordering on statistical significance. 
Furthermore, causal relationships have not been proven between any of the variables, 
although many can be strongly inferred from the application of existing knowledge 
and basic principles. Although factors other than CMV such as age, gender, and other 
pathophysiological conditions may cause variation in the numbers and types of 
circulating immune cells  (Koch et al., 2008b), the differences between CMV-positive 
and CMV-negative patients observed in my study are likely to be due to CMV itself 
since these other factors were well balanced between the CMV-positive and CMV-
negative groups that were compared with one another. 
One important limitation of my study is that it did not formally establish whether the 
end-stage lymphocytes that accumulated in CMV-positive patients with FL were 
exclusively CMV-reactive or whether they included non-CMV-reactive lymphocytes. 
In the absence of co-staining with CMV-specific tetramers, it was not possible to 
formally address this question. However, the average proportion of CMV-reactive 
circulating memory T cells in healthy CMV-seropositive individuals is ~10% (Naeger 
et al., 2010). In contrast, in my study, circulating end-stage T cells were 2-3 folds 
higher in CMV-positive cases (Table 3-3). Consequently, it seems very likely that the 
end-stage T cells that accumulate in CMV-positive patients with FL include not only 
CMV-specific T cells but also T cells with other specificity. 
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Having considered the strengths and limitations of the data presented in this thesis, it 
is important to discuss the extent to which my data support or contradict the existing 
literature and suggest possible explanations for any discrepancies.  
The concept that CMV infection results in the accumulation of terminally 
differentiated lymphocyte subtypes in the blood is in agreement with previous reports 
of both healthy individuals (Welzl et al., 2014, Ohlin and Söderberg-Nauclér, 2015) 
and cancer patients (P Chou and B Effros, 2013, Myklebust et al., 2013). The end-
stage lymphocytes found to accumulate in CMV-positive individuals in these studies 
included T cells lacking the costimulatory receptors CD27 and CD28 as well as the 
lymph node-homing receptors CCR7 and CD62L (Pawelec et al., 2005) (Moro-
García, Alonso-Arias et al. 2015). Other studies  that used  blood and bone marrow 
samples spanning from young (mean age, 29 years; range, 20–39 years) to old (mean 
age, 80 years; range, 71–91 years) healthy donors  demonstrated a correlation between 
CMV infection and increased end-stage (short-lived) CD45RA+ CD27− CD4+ and 
CD8+ T cells  (Libri et al., 2011, Smith et al., 2016). By using multiple linear 
regression analysis, these authors demonstrated that increases in CD45RA⁻ CD27⁻ 
(effector memory) and CD45RA+ CD27⁻ CD4+ (effector) T cell phenotypes are due 
mainly to CMV infection. Furthermore, Griffiths in his PhD thesis linked CMV 
seropositivity in healthy blood donors to increased CD45RA+ memory T cells in the 
peripheral blood (Griffiths, 2011). These cellular phenotypes are all features of 
immune senescence and are indicative of repeated antigenic stimulation and impaired 
immune functionality that can potentially lead to increased susceptibility to recurrent 
infections (Pawelec et al., 2005, Alonso Arias et al., 2013, Smith et al., 2016).   The 
concept that the end-stage T cells that accumulate in CMV-positive patients are 
functionally incompetent is further supported by a study reporting a significant 
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correlation between accumulated end stage T lymphocytes, especially enriched CD8+ 
TEMRA cells, and delayed bone fracture healing (Reinke et al., 2013).  
My study also showed a significant increase in circulating NKT cells amongst CMV-
positive patients compared to those who were CMV negative. NKT cells are known to 
exhibit either protective or injurious effects through the secretion of cytokines that 
promote either immune tolerance or inflammation (Savage et al., 2016). Although the 
exact mechanisms are not clear, the increase in the NKT cells in CMV-positive cases 
might reflect a compensatory response of the innate immune system to heterologous 
infections caused by the reduction in the number of CD4+ T cells and the skewing of 
T cells towards a senescent phenotype.  
In a study of healthy individuals, Schrier et al found an association between CMV 
infection and circulating T cells expressing PD-1, a marker of T-cell “exhaustion” 
(Schrier et al., 1986). In my study, CMV infection was associated with increased PD-
1 expression in affected lymph nodes but not in circulating T cells. Since PD-1 
influences the apoptosis of stimulated T-cells and minimises their capacity to produce 
cytokines (Sester et al., 2008). Thus may help to explain the reduced serum cytokine 
levels observed among CMV-positive FL patients.  
Surprisingly, my study appears to be the first to directly demonstrate that CMV 
seropositivity is associated with a significant increase in infections. That this 
phenomenon has not been previously reported suggests that the effect may only be 
evident in the presence of additional immunosuppression such as that induced by 
chemo-immunotherapy. This key observation provides crucial new evidence to 
support the idea that CMV infection can cause clinically significant 
immunodeficiency by inducing the accumulation of terminally differentiated T cells.  
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On the other hand, my demonstration that CMV infection may enhance sensitivity to 
chemo-immunotherapy in FL (Chapter 6) via the accumulation of terminally 
differentiated E.CD4 and E.CD8 T cells (Chapter 7) suggests that the T cells that 
accumulate in CMV-positive patients are functionally active and capable of 
modulating the cytotoxicity of chemotherapy drugs or, more likely, rituximab via 
enhanced ADCC. This concept is in keeping with the report of Libri et al, which 
demonstrated the multifunctional capability of the CD45RA+ CD27⁻ T-cell subtype 
(Libri et al., 2011).  These latter cells possess cytotoxic function similar to those of 
CD45RA⁻ CD27+ T-cell subsets, indicating that end-stage T cells are not completely 
functionally incompetent. A report by Henson et al also described CMV infection as 
one of the leading causes of elevated end-stage T cells (Henson et al., 2012). In their 
article, end-stage T cells were characterised by increased activation of senescence 
signalling pathways, decreased proliferative capacity, and higher sensitivity to 
apoptosis, yet were capable of multiple effector functions. The latter characteristic is 
in agreement with the report of Libri et al and potentially explains my own 
observations regarding CMV serostatus and therapy response.  
The notion that the end-stage T cells that accumulate in CMV-positive indivuals are 
functionally active need to be reconciled with my observation that CMV sero-
positivity is associated with increased infection following chemo-immunotherapy, 
which implies loss of T-cell function. The likely explanation for this apparent 
contradiction is that the effector T cells that accumulate in CMV-positive patients are 
mainly pathogen-specific and show poor response to novel pathogens (Pennock et al., 
2013, Briceño et al., 2016).  
We have reported significantly decreased levels of 7 serum cytokines in the CMV-
positive patients in Chapter 4 as summarised in Table 8-1. 
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Table 8-1: Serum cytokines differentially expressed due to CMV infection 
 
A brief summary of cytokines that are differentially expressed in CMV positive FL 
compared to the CMV negative (Kaplan et al., 2015, Rouvier et al., 1993) and 
providing summary sources, targets and actions. DCs= dendritic cells, NKT cells = 
Natural Killer T cells, MIP-1α = Macrophage Inflammatory Proteins-1 α, MIP-1β = 
Macrophage inflammatory protein-1-β. 
Interestingly, serum levels of most cytokines and chemokines are generally low in 
healthy persons, although some variation has been observed due to ageing (Kleiner et 
al., 2013, Kim et al., 2011). By inference, one may be tempted to think that the lower 
levels of serum cytokines reported among CMV-positive patients confer some benefit 
to this group of patients. However, such an assumption would be overly simplistic 
owing to the considerable functional heterogeneity of cytokines.  
The significantly reduced levels of serum cytokine observed in the CMV-positive 
patients in Chapter 4 was not unexpected, given that T cells are the primary source of  
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these cytokines and that the T cells that accumulate in CMV-positive patients are 
terminally differentiated and therefore poorly equipped to produce cytokines. 
Contrary to our data,  other studies have reported elevated levels of serum cytokines 
(IL-6, IL-8 & TNF-α) among CMV-positive bone marrow transplant recipients 
(Humar et al., 1999). Unlike in our study cohort, the bone marrow transplant patients 
experienced CMV reactivation and severe inflammatory CMV disease which likely 
accounts for the increased serum cytokine levels. In contrast, a recent study that 
evaluated hand-grip strength in older subjects did not observe any strong correlations 
between CMV serostatus and serum cytokine (IL-1β, IL-6 or TNF) levels (Goldeck et 
al., 2016). From these observations, one may argue that in the absence of an acute 
inflammatory response, CMV infection does not increase cytokine levels but rather 
results in a reduced capacity for cytokine production in chronic diseases such as FL. It 
is also likely that reduced capacity for cytokine production is partly responsible for 
the increased infection that is observed among CMV-positive patients with FL 
following chemo-immunotherapy. Unfortunately, the mechanisms deployed by CMV 
in concert with relevant cellular sources of cytokines to downregulate the productions 
of these cytokines are not well studied. Due to the limited time frame, no experiments 
were conducted to understand the exact mechanisms.  
The immunofluorescence Chapter reveals that CMV-positive patients show higher 
intensities of CD21+ (FDCs), FOXP3 (regulatory T cells) and PD1+ (exhausted T 
cells) expressing cells in the FL microenvironment compared to CMV negative 
patients. The significantly higher intensity of CD21-expressing cells among CMV-
positive patients is interpreted as indicating a higher number of FDCs as the staining 
showed distinctive meshwork in most cases. FDCs are mainly found in the primary 
and secondary follicles of the B cell areas where they play a vital role in organising 
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lymphoid microarchitecture, antigen capturing, memory B-cell support, debris 
removal and prevention of autoimmunity (Kranich et al., 2008, Aguzzi and Krautler, 
2010, Cyster, 2010). However, the elevated level of CD21-expressing cells and well 
as those of FOXP3 and PD1 in the CMV-positive patients did not show any 
association with the rituximab treatment efficacy. Going by the efficacy data in 
Chapter 7, it can be deduced that CD21, FOXP3 and PD1 expressing cells as seen in 
the FL microenvironment of CMV-positive patients might not hold any role in 
potentiating treatment efficacy in FL therapy. This implies that their activities may 
not have a direct beneficial impact on the actions of Rituximab such as ADCC, CDC 
as well as in the induction of apoptosis and direct growth arrest of cell circle.  
Intriguingly, CMV infection and elevated end stage T cells (E.CD4 and E.CD8) have 
shown an association with enhanced response to rituximab-chemotherapy, especially 
at the post cycle 8. Ordinarily, with the increased number of senescent, exhausted and 
end-stage T cell subtypes, the higher CR rate seen among the CMV-positive patients 
seemed contradictory to expectation. The mechanism by which CMV infection 
modulates rituximab therapy resulting to enhance response in FL is not known. 
However, its activity has been linked to the accumulation of effector (E.CD4 and 
E.CD8) T cells which as a recent study investigating effector functional potentials of 
CMV-pp65-reactive T-cells including IL-2, TNF-α, IFN-γ, perforin, and CD107a 
expression revealed that CMV-specific CD4 + and CD8 + T cells manifest 
polyfunctionality including cytotoxic functions (Chiu et al., 2016). However, the 
mechanism by which these T cell subtypes accentuate response to rituximab 
chemotherapy is not known and will require investigation. Using a univariate 
analysis, a study that evaluated the impact of CMV infection on the clinical outcome 
of a prospective cohort of B‐CLL patients reported a poor OS in the CMV-positive 
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group compared to the CMV negative, although in a multivariate modelling, no 
significant survival difference was observed between the groups (Parry et al., 2016a). 
Despite patients were recruited into PACIFICO trial based on stringent inclusion and 
exclusion criteria and those selected into this study were well balanced  based on 
equal distribution of their clinical and laboratory features, a multivariate analysis will 
further confirm whether above cellular changes were independently or interrelated 
with each other and/or with other clinical and laboratory variables to contribute to the 
clinical outcome. Similar to our data, increased incidence infections have been 
reported in patients with lymphomas being treated with rituximab (Kelesidis et al., 
2011, Looney et al., 2008). The significantly increased incidence and episodes of 
infections among the CMV-positive FL patients on rituximab –chemotherapy seen in 
our data suggests that the end stage T cells reported in Chapter 3 and the low cytokine 
levels in Chapter 4 is not able to provide a robust immunity against infection. This 
observation is in agreement with several reports that linked CMV infection with 
immune senescence that results in phenotypic alterations and functional decline in the 
T cell repertoire, culminating in increased vulnerability to infections (P Chou and B 
Effros, 2013).  
Regarding the originality of this study, this is the first report of accumulated end-stage 
T cell types, significantly decreased serum cytokine levels and high intensities of 
CD21 expressing cells tumour microenvironment of CMV positive FL patients. Our 
data has demonstrated a perceived favourable role of CMV infection in rituximab-
containing chemotherapy among FL patients. Furthermore, the study has observed a 
potential relationship between high frequencies of effector CD4+ and CD8+ T cells 
and CR in the course of FL immunochemotherapy. A prospective study on a large 
cohort of patients to elucidate the impacts of CMV infection on the clinical outcome 
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of patients with chronic lymphocytic leukaemia (B-CLL) showed that CMV-positive 
patients had significantly worse overall survival than the negative patients in the 
univariate analysis (Parry et al., 2016b). However, no evidence that CMV infection 
impacts on the clinical outcome of patients with B-CLL was observed in a 
multivariate analysis of the same cohort. Another study using seasonal influenza 
vaccination expectedly showed weak responses to the vaccine and an overall 
decreased immune response in the elderly regardless of CMV serostatus (Furman et 
al., 2015). Conversely, CMV-positive young adults showed an enhanced response to 
influenza vaccine, enhanced CD8+ T cell sensitivity, and raised levels of circulating 
IFN-γ compared to CMV negative (Furman et al., 2015). This perceived beneficial 
effect of CMV infection supports our data which shows enhanced response to 
rituximab therapy in the CMV positive patients. It is even speculated that the high 
global prevalence of latent CMV infection may be due to the beneficial effect it has 
on the host immunity (Furman et al., 2015).  Although several researchers have 
demonstrated correlations between CMV serostatus and heterologous infection, we 
have shown increased incidence and episodes of specific infection AEs among CMV 
positive FL patients compared to CMV negative. 
In conclusion, this study has demonstrated strong associations between CMV 
seropositivity and the following: increased circulating end-stage T cells, decreased 
levels of serum cytokines, increased FDCs in the FL microenvironment as well as 
increased incidence and episodes of infections/neutropenia AEs and better/more rapid 
response to rituximab-containing chemo-immunotherapy. These results support our 
hypothesis which states that CMV infection alters immune function in two ways: (1) 
Acceleration of immune senescence with increased vulnerability to heterologous 
infection and (2) Alteration of lymphoma microenvironment with the possibility of 
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modulating FL therapy response. These understandings can ultimately improve on the 
therapeutic strategies in FL management toward a combinatorial approach for direct 
cytotoxic and indirect immunomodulatory treatment regimens. 
With these associations observed in this retrospective study using pre-trial (baseline) 
samples from FL patients , the next would be to prospectively assess the predictive 
value of CMV infection status in this disease.  Also, repeating this study using post –
therapy samples from the PACIFICO trial patients may provide additional insights 
into the impact of CMV infection in FL. The plan of future development, including 
study design and technical approaches, is presented in Chapter 9. 
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Chapter 9 Future Research 
9.1 Introduction  
As presented in previous chapters, the hypothesis of this study has been largely 
addressed by comparison of profiles of T cell subtypes, cytokine expression and tissue 
protein markers between CMV-positive and –negative patients with FL, and 
correlation of  clinical outcomes with CMV infection and the study variables.  
However, due to limitations described in Chapter 8, the quality of this study can be 
further improved with the following work proposed for future.  
9.2 Future work 
9.2.1 Confirmation of results in an independent cohort of patients with a sample size 
estimated based on observations in this study 
Validation of results is the first task in the future work. For this purpose, it is 
necessary to recalculate the sample size.  Despite having been calculated in section 
2.5, the samples size of 42 used in most comparisons in this study was based on 
results of a pilot experiment of cytokine expression in the two groups of patients.  It 
might not be big enough to find all of real differences due to the  error. For example, 
an estimated difference of one was used in the calculation.  But the actual difference 
for most of these cytokines was smaller than that (Table 4.1.). This might result in the 
statistical power smaller than the estimated 80%.  As the initial analysis was 
exploratory in nature and covered a wide range of endpoints, a sample size on any 
single outcome is not possible.  To replicate the finding of the analyses presented 
(FACS, Luminex, and IF) in the future, we would consider it clinically significance if 
the odds of an outcome was twice as likely in one CMV cohort compared to the other.  
Using an odds ratio 2, a power of 80% and an alpha level of 0.001 to account for the 
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multiple testing required, a sample size of 206 patients would be sufficient.  This 
assumes a binomial distribution with outcomes assumed to occur around the centre of 
the distribution as this is the scenario that gives the maximum variance.  Outcomes 
measured using a continuous scale or which are observed to be more/less likely will 
increase the power.  In addition to a reliable validation of results, it is also important 
for increasing chances to identify real differences that were underestimated, e.g. those 
borderline differences recorded in the current study.   Those borderline differences 
existed in T cell subtypes (e.g. CD4+ T cells (p=0.051), LAG3-CD4 (p=0.074), CD4: 
CD8 ratio (p=0.054)), cytokines (e.g. IL-1β (p=0.068), IL-4 (p=0.066) and GM-CSF 
(p=0.070)) and tissue markers (e.g. FOXP3 (p=0.069)). 
9.2.2 Validation of cytokine data using an alternative method and stable serum samples 
In Chapter 4, I found the levels of 7 out of the 27 cytokines significantly lower in 
CMV-positive patients in experiments with LUMINEX. Those should have been 
confirmed either using an alternative method or repeating with the same technique. 
But only IL-9 was confirmed using sELISA (see section 4.3.3). Confirmation of 
others was hampered by a lack of stabilised serum samples (see section 4.3.2).  In a 
future study, therefore, the serum sample from each of individual patients will be 
stored at -80
o
C in multiple aliquots after phlebotomy, so that each aliquot can be used 
only once in each of subsequent experiments.  This can minimise the sample 
instability caused by repeated thawing and freezing, as found in section 4.3.2.  Once 
the stable samples are available, the standard sELISA will be applied in the validation 
given its cost efficiency as compared to LUMINEX and other available 
methodologies, such as V-PLEX and multiplex immunoassay technologies for 
profiling the expression of multiple proteins from minute sample volumes (Jones et 
al., 2016, Sandberg et al., 2016).  
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9.2.3 Investigating the impact of CMV infection on the outcome of the two arms of 
therapies in PACIFICO trial 
As noted in section 2.2, although the patient recruitment has been closed, the 
PACIFICO trial is still ongoing.  The full treatment outcome will be not available 
untill2018. In Chapter 6, I found an increased treatment response rate together with a 
trend of higher incidence of adverse events in CMV-positive patients regardless of the 
treatment regimen designed for the trial.  Once the trial is completed within two years, 
these clinical outcomes will be further compared with CMV infection status between 
patients treated with R-VCP and R-FC.  This may address whether or not the impact 
of CMV infection is the same in patients treated with the two regimens.  Furthermore, 
with the follow-up extended, a further analysis of the impact of CMV infection status 
on overall survival (OS) and progression-free survival (PFS) will be performed for the 
entire trial cohort and patients treated in each of the two therapy arms. 
9.2.4 Evaluating the potential predictive value of CMV infection status in FL  
In the current retrospective study, CMV infection has been demonstrated to associate 
with elevated end-stage T cell subtypes (Chapter 3), decreased serum cytokine 
(Chapter 4), and increased intensity of FDCs in the FL microenvironment (Chapter 5). 
It has also been shown to associate with high incidence and episodes of infection 
AEs/SAEs and a beneficially enhanced response to rituximab-containing 
chemotherapy (Chapter 6). We have also reported an association between effector 
CD4 and CD8 cell types with better response to rituximab-chemotherapy (Chapter 7).  
We have also planned future work to strengthen most of above findings FL. Once the 
future work is completed, the next is to test the most possible biomarker candidates in 
prospective studies.  That will eventually confirm the clinical usefulness of these 
biomarkers in management of FL. To do so, the total number of patients to be 
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recruited will be determined by a calculation the frequency of CMV infection in FL 
and the level of each biomarker expressed in CMV-positive and negative groups as 
observed in the current study.  If necessary, the prospective study will include 
multiple centres to shorten the study duration.   
9.2.5 Analysis of PD-L1 in FFPE tissue biopsies 
As reported in Table 5-2 and Figure 5-9, my study has revealed a marginal increase in 
the intensity of cells expressing PD1 in the FL microenvironment of the CMV-
positive patients compared to the negative (median: 291.3 versus 187.9, p=0.097). It 
is worthy to recall that the prevalence, location and subtypes of intratumoral T cells 
can influence tumour immunity either negatively or positively (Yang et al., 2015). 
Meanwhile, aside from its involvement in the induction of T cell exhaustion, PD-1 
has been shown to associate with negative regulation of T-cell receptor signalling, 
decrease proliferation as well as reduce cytokine secretion in T cells (Riella et al., 
2012, Day et al., 2006). Diverse subsets of intratumoral T cells have shown to express 
PD1 in FL, for instance, exhausted T effector cells and follicular helper T (TFH) cells 
(Yang et al., 2014, Yang et al., 2012, Schaerli et al., 2000). The PD1/PD-L1 pathway 
has been explored for cancer immunotherapy due to the importance of this checkpoint 
to ensures that the immune system is only activated appropriately (Topalian et al., 
2012, Chen and Mellman, 2013). This pathway is also susceptible to exploitation by 
tumour cells to elude detection and repress the immune response (Topalian et al., 
2012). Considering the importance of PDL-1 in facilitating PD1 immune response, 
the determination of the intensity of PDL-1 in the FFPE tissue section from the 
PACIFICO trial patients by immunofluorescence technique may reveal a potential 
immune biomarker in FL management. 
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9.2.6 A study of post-treatment sequential samples 
The PACIFICO clinical trial requires clinical follow-up of recruited patients and 
sequential sample collection. This trial  design will support additional investigation of 
the interrelationships between exposure to the two arms of therapies in the presence or 
absence of CMV infection and subsequent outcome measures, including treatment 
efficacy and toxicities(Grossmann et al., 2006, Fraley and Hudson, 2014). This could 
potentially provide additional data on the impact of the two arms of immuno-
chemotherapies, the R-VCP and R-FC on the circulating peripheral immune cells, 
serum cytokines and infiltrating cells in the tumour microenvironment of CMV-
positive patients. This would present a clearer picture of the impact of CMV infection 
on the clinical behaviour to treatment of FL. Furthermore, the availability of study 
outcome data will further improve on the analysis of the impact of CMV infection 
(CMV status) and the treatment arm on overall survival (OS) or progression-free 
survival (PFS).   
9.3 Conclusions 
In conclusion, future work has been outlined above.  It is planned based on limitations 
in the current study and possible developments in the near future.  It is expected that 
completion of those plans will further improve the quality of this project and help us 
to better understand the biology and clinical relevance of CMV infection in FL. 
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Appendices 
Appendix 1: Standard Curves for cytokines 
 
Figure 1A: The 8-point Bio-Plex Manager™ software version 6.0 derived 
standard curves used for the analysis of serum cytokine by Luminex assay.  
In performing curve fitting, outliers are considered invalid.  As such they are removed 
to generate a more realistic and accurate standard curve. This may result in an 
extended assay working range and allows quantitation of samples that might 
otherwise be considered out of range (OOR).   
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Figure 1B: The 8-point Bio-Plex Manager™ software version 6.0 derived 
standard curves used for the analysis of serum cytokine by Luminex assay.  
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Figure 1C: The 8-point Bio-Plex Manager™ software version 6.0 derived 
standard curves used for the analysis of serum cytokine by Luminex assay.  
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Figure 1D: The 8-point Bio-Plex Manager™ software version 6.0 derived 
standard curves used for the analysis of serum cytokine by Luminex assay.  
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Appendix 2: Copyright Licence 
 
Figure 2: Copyright licence for Figure 3-11: Illustrations of distinct and 
developmental phases of effector and memory T‑cells. 
The page 1 of 6 pages of copy right licence for reproduction Figure 3-11: Illustrations 
of distinct and developmental phases of effector and memory T‑cells.  
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Figure 3: Copyright licence for Figure 5-10: A model of the FL 
microenvironment. The page 1 of 5 pages of copy right licence for reproduction 
Figure 5-10: A model of the FL microenvironment.  
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Appendix 3A: Uncontrolled copy of the PACIFICO Patient Consent Form-Page1 
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Appendix 3B: Uncontrolled copy of the PACIFICO Patient Consent Form-Page2 
 
